

Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention

JAMA - Journal of the American Medical Association

2012; 308: 2411-2421

DOI: [10.1001/jama.2012.1127](https://doi.org/10.1001/jama.2012.1127)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Authorship for Research Groups. JAMA - Journal of the American Medical Association, 2002, 288, 3166.	3.8	55
3	Clinical use of novel antithrombotic agents in the management of acute coronary syndromes. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2002, 32, 282-288.	0.5	1
4	The Role of Clopidogrel in the Management of Patients with Ischemic Heart Disease. Cardiovascular Drugs and Therapy, 2003, 17, 467-477.	1.3	11
5	Cerebrovascular complications in interventional cardiology. Seminars in Cerebrovascular Diseases and Stroke, 2003, 3, 228-232.	0.1	1
6	Secondary prevention of small subcortical strokes (SPS3). Seminars in Cerebrovascular Diseases and Stroke, 2003, 3, 8-17.	0.1	3
7	A comparison of 1-month and 6-month clopidogrel therapy on clinical and angiographic outcome after stent implantation. Heart and Vessels, 2003, 18, 123-129.	0.5	15
12	Comparison of short- and long-term outcomes of coronary angioplasty in patients with and without diabetes mellitus and with and without hemodialysis. American Journal of Cardiology, 2003, 92, 721-725.	0.7	24
13	Prediction of significant left main coronary artery stenosis by the 12-lead electrocardiogram in patients with rest angina pectoris and the withholding of clopidogrel therapy. American Journal of Cardiology, 2003, 92, 846-848.	0.7	93
14	Late stent thrombosis in the nonbrachytherapy population: A real phenomenon?. Catheterization and Cardiovascular Interventions, 2003, 59, 504-508.	0.7	5
15	Combined Antiplatelet Therapy in Atrial Fibrillation:. Journal of Cardiovascular Electrophysiology, 2003, 14, S60-S63.	0.8	34
16	Scientific and therapeutic advances in antiplatelet therapy. Nature Reviews Drug Discovery, 2003, 2, 15-28.	21.5	346
17	Perspectivas terapéuticas de la doble antiagregación plaquetaria. Revista Clinica Espanola, 2003, 203, 388-390.	0.2	0
18	Risk Stratification and Interventional Cardiology: Robert L. Frye Lecture. Mayo Clinic Proceedings, 2003, 78, 1507-1518.	1.4	3
19	Ensayos clínicos presentados en la 75.ª Sesión Científica Anual de la American Heart Association (Chicago, 17-20 de noviembre de 2002). Revista Espanola De Cardiología, 2003, 56, 89-98.	0.6	0
20	Platelet inhibition strategies in percutaneous coronary intervention. Journal of the American College of Cardiology, 2003, 42, 1196-1198.	1.2	11
21	Aspirin resistance:a new independent predictor of vascular events?***Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology. 2003, 41, 966-968.	1.2	108
22	Clopidogrel versus ticlopidine after the placement of coronary artery stents. Journal of the American College of Cardiology, 2003, 42, 772.	1.2	0
23	Clopidogrel versus ticlopidine after the placement of coronary artery stents: Reply. Journal of the American College of Cardiology, 2003, 42, 772-773.	1.2	1

#	ARTICLE	IF	CITATIONS
24	Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition. <i>Journal of the American College of Cardiology</i> , 2003, 42, 981-988.	1.2	27
25	Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival. <i>Journal of the American College of Cardiology</i> , 2003, 42, 1188-1195.	1.2	111
26	Effects of pretreatment with clopidogrel on platelet and coagulation activation in patients undergoing elective coronary stenting. <i>Thrombosis Research</i> , 2003, 112, 19-24.	0.8	14
27	Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention. <i>American Heart Journal</i> , 2003, 146, 764-774.	1.2	15
28	Reduced thrombus cohesion in an ex vivo human model of arterial thrombosis induced by clopidogrel treatment: kinetics of the effect and influence of single and double loading-dose regimens. <i>Thrombosis Research</i> , 2003, 111, 19-27.	0.8	10
29	Ischemic heart disease in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 6-12.	1.5	15
31	The role of clopidogrel in the management of acute coronary syndromes. <i>Clinical Therapeutics</i> , 2003, 25, 2155-2181.	1.1	9
32	The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: To what extent should the results be generalizable?. <i>American Heart Journal</i> , 2003, 145, 595-601.	1.2	30
33	Management of patients with unstable angina and non-ST-segment elevation myocardial infarction: update ACC/AHA guidelines. <i>American Journal of Emergency Medicine</i> , 2003, 21, 346-351.	0.7	8
35	Angina pectoris: interventional therapies and treatment of restenosis. <i>International Journal of Biochemistry and Cell Biology</i> , 2003, 35, 1399-1406.	1.2	4
36	Aspirin and Clopidogrel in Acute Coronary Syndromes. <i>Archives of Internal Medicine</i> , 2003, 163, 1145.	4.3	79
37	Safety of an Aspirin-Alone Regimen After Intracoronary Stenting With a Heparin-Coated Stent. <i>Circulation</i> , 2003, 108, 1078-1083.	1.6	48
39	Are Antiplatelet Effects of Clopidogrel Inhibited by Atorvastatin?. <i>Circulation</i> , 2003, 107, 1568-1569.	1.6	36
40	Cost-effectiveness of Newer Antiplatelet Drugs? Reply. <i>Archives of Internal Medicine</i> , 2003, 163, 2533.	4.3	1
41	JournalScan. <i>British Heart Journal</i> , 2003, 89, 239-240.	2.2	0
42	Clopidogrel and Percutaneous Coronary Interventions? Reply. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 1925; author reply 1926-7.	3.8	1
43	Platelets as Predictors of Vascular Risk: Is There a Practical Index of Platelet Activity?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003, 9, 177-190.	0.7	253
44	Effects of Statins on Platelet Inhibition by a High Loading Dose of Clopidogrel. <i>Circulation</i> , 2003, 108, 2195-2197.	1.6	131

#	ARTICLE	IF	CITATIONS
45	The effects of GPIIb-IIIa antagonists and a combination of three other antiplatelet agents on platelet-leukocyte interactions. <i>Current Medical Research and Opinion</i> , 2003, 19, 178-186.	0.9	21
46	Lack of Adverse Clopidogrel-Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial. <i>Circulation</i> , 2003, 108, 921-924.	1.6	259
47	Drug-drug interactions involving antiplatelet agents. <i>European Heart Journal</i> , 2003, 24, 1707-1709.	1.0	14
48	Application of Current Guidelines to the Management of Unstable Angina and Non-ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2003, 108, 28III-37.	1.6	52
49	Highlights of the 2002 Update to the 2000 American College of Cardiology/American Heart Association Acute Coronary Syndrome Guidelines. <i>Cardiology in Review</i> , 2003, 11, 113-121.	0.6	11
50	Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis. <i>Current Opinion in Hematology</i> , 2003, 10, 333-338.	1.2	61
51	Title is missing!. <i>Coronary Artery Disease</i> , 2003, 14, 373-380.	0.3	1
52	Clopidogrel in the Management of Ischemic Heart Disease. <i>Heart Disease (Hagerstown, Md)</i> , 2003, 5, 144-152.	1.3	10
53	Contemporary use of antiplatelet therapies in percutaneous coronary interventions. <i>Coronary Artery Disease</i> , 2003, 14, 373-380.	0.3	3
54	10 Most Commonly Asked Questions About Which Antiplatelet Agent To Prescribe. <i>Neurologist</i> , 2003, 9, 318-322.	0.4	0
55	Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) Acute Coronary Syndromes Critical Pathway Toolkit. <i>Critical Pathways in Cardiology</i> , 2003, 2, 153-177.	0.2	3
56	Management of Patients Undergoing Percutaneous Coronary Revascularization. <i>Annals of Internal Medicine</i> , 2003, 139, 123.	2.0	79
57	Long-Term Outcome after Stroke due to Atrial Fibrillation. <i>Cerebrovascular Diseases</i> , 2003, 16, 3-8.	0.8	39
58	Evidence with Antiplatelet Therapy and ADP-Receptor Antagonists. <i>Cerebrovascular Diseases</i> , 2003, 16, 20-26.	0.8	13
59	ADP receptor antagonists as antiplatelet therapeutics. <i>Expert Opinion on Emerging Drugs</i> , 2003, 8, 93-101.	1.0	10
60	Interventional pharmacotherapy. <i>BMJ: British Medical Journal</i> , 2003, 327, 43-46.	2.4	3
61	Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. <i>Thrombosis and Haemostasis</i> , 2003, 89, 783-787.	1.8	534
62	Antiplatelet drugs. <i>Medical Journal of Australia</i> , 2003, 178, 568-574.	0.8	54

#	ARTICLE	IF	CITATIONS
63	Facts and Principles Learned at the 30th Annual Williamsburg Conference on Heart Disease. Baylor University Medical Center Proceedings, 2003, 16, 168-171.	0.2	1
64	Antiplatelet Therapy for Secondary Prevention of the Complications of Atherothrombotic Disease. The Consultant Pharmacist, 2004, 19, 813-823.	0.4	0
66	Prevention of cardiovascular disease: an evidence-based clinical aid 2004. Medical Journal of Australia, 2004, 181, 1-14.	0.8	4
67	Prevention of cardiovascular disease: an evidence-based clinical aid 2004. Medical Journal of Australia, 2004, 181, S1-S14.	0.8	10
68	Late coronary thrombosis after drug-eluting stent: stent vs patient-driven prescription of aspirin-clopidogrel combination. Thrombosis and Haemostasis, 2004, 92, 668-669.	1.8	9
69	Secondary Prevention of Acute Coronary Syndromes. Journal of the American Pharmacists Association: JAPhA, 2004, 44, S28-S36.	0.7	3
70	Catheter-based treatment of atherosclerosis. Postgraduate Medicine, 2004, 115, 14-25.	0.9	3
71	Facts and Principles Learned at the 31st Annual Williamsburg Conference on Heart Disease. Baylor University Medical Center Proceedings, 2004, 17, 106-115.	0.2	0
73	Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. European Heart Journal, 2004, 25, 476-483.	1.0	93
74	Should the MATCH Results Be Extrapolated to All Stroke Patients and Affect Ongoing Trials Evaluating Clopidogrel Plus Aspirin?. Stroke, 2004, 35, 2606-2608.	1.0	28
75	Antithrombotic therapy for prevention of recurrent stroke in the new millenium. Expert Review of Neurotherapeutics, 2004, 4, 145-149.	1.4	0
76	Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. European Heart Journal, 2004, 25, 190-198.	1.0	79
77	Paclitaxel-Eluting Coronary Stents. New England Journal of Medicine, 2004, 350, 2099-2100.	13.9	8
78	Antiplatelet Therapy for Ischemic Heart Disease. New England Journal of Medicine, 2004, 350, 2101-2102.	13.9	5
79	Prevention of Cardiovascular Events after Percutaneous Coronary Intervention. New England Journal of Medicine, 2004, 350, 2708-2710.	13.9	6
80	A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention after Pretreatment with Clopidogrel. New England Journal of Medicine, 2004, 350, 232-238.	13.9	557
81	Antiplatelet Therapy for Ischemic Heart Disease. New England Journal of Medicine, 2004, 350, 277-280.	13.9	97
82	Relationship Between Activated Clotting Time and Ischemic or Hemorrhagic Complications. Circulation, 2004, 110, 994-998.	1.6	163

#	ARTICLE	IF	CITATIONS
83	Summary of recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction. <i>British Heart Journal</i> , 2004, 90, 676-677.	2.2	27
84	Case 3: Acute chest pain. <i>British Heart Journal</i> , 2004, 90, 112-112.	2.2	0
85	If There's Smoke, Is There Fire?. <i>Circulation</i> , 2004, 109, 1442-1444.	1.6	0
86	Acute coronary syndromes: should women receive less antithrombotic medication than men?. <i>British Heart Journal</i> , 2004, 90, 363-366.	2.2	3
87	Prevention of cardiac complications of non-cardiac surgery: stenosis and thrombosis. <i>British Journal of Anaesthesia</i> , 2004, 92, 628-632.	1.5	8
88	Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations. <i>Archives of Internal Medicine</i> , 2004, 164, 2106.	4.3	119
89	A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2004, 350, 221-231.	13.9	2,601
90	Volumetric Analysis of In-Stent Intimal Hyperplasia in Diabetic Patients Treated With or Without Abciximab. <i>Circulation</i> , 2004, 109, 861-866.	1.6	39
91	Antiplatelet Therapy in Non-ST-Segment Elevation Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 1875.	3.8	35
92	Clopidogrel Resistance. <i>Circulation</i> , 2004, 109, 3064-3067.	1.6	190
93	Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction. <i>Circulation</i> , 2004, 109, 3171-3175.	1.6	1,274
94	Propensity Analysis of Long-Term Survival After Surgical or Percutaneous Revascularization in Patients With Multivessel Coronary Artery Disease and High-Risk Features. <i>Circulation</i> , 2004, 109, 2290-2295.	1.6	240
95	Loading With 600 mg Clopidogrel in Patients With Coronary Artery Disease With and Without Chronic Clopidogrel Therapy. <i>Circulation</i> , 2004, 110, 1916-1919.	1.6	191
96	Drug-eluting stents: new era and new concerns. <i>Postgraduate Medical Journal</i> , 2004, 80, 13-18.	0.9	45
97	Aspirin Sensitivity. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 3017.	3.8	143
98	Expert Consensus Document on the Use of Antiplatelet Agents The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 166-181.	1.0	334
99	Radial approach to day case intervention in coronary artery lesions (RADICAL): a single centre safety and feasibility study. <i>Heart</i> , 2004, 90, 1340-1341.	1.2	28
100	Recent Clinical Trial Results with Antiplatelet Therapy: Implications in Stroke Prevention. <i>Cerebrovascular Diseases</i> , 2004, 17, 6-10.	0.8	15

#	ARTICLE	IF	CITATIONS
101	ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary. <i>Circulation</i> , 2004, 110, 588-636.	1.6	3,307
102	Economics of Sirolimus-Eluting Stents. <i>Circulation</i> , 2004, 110, 472-474.	1.6	10
103	Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non-ST-Elevation Acute Coronary Syndrome. <i>Circulation</i> , 2004, 110, 1202-1208.	1.6	778
104	Beyond Restenosis. <i>Circulation</i> , 2004, 110, 1226-1230.	1.6	283
105	Impact of Prior Use or Recent Withdrawal of Oral Antiplatelet Agents on Acute Coronary Syndromes. <i>Circulation</i> , 2004, 110, 2361-2367.	1.6	344
106	Revascularisation in diabetics with multivessel coronary artery disease. <i>Heart</i> , 2004, 90, 999-1002.	1.2	1
107	Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences*1. <i>European Heart Journal</i> , 2004, 25, 1197-1207.	1.0	240
108	Aspirin and Clopidogrel. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 1980-1987.	1.1	395
109	Absence of Interaction Between Atorvastatin or Other Statins and Clopidogrel. <i>Archives of Internal Medicine</i> , 2004, 164, 2051.	4.3	142
110	Antiplatelet therapy in cardiovascular disease. <i>Postgraduate Medical Journal</i> , 2004, 80, 155-164.	0.9	44
111	Antithrombotic and Thrombolytic Therapy for Ischemic Stroke. <i>Chest</i> , 2004, 126, 483S-512S.	0.4	456
112	Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischaemic Attack or Ischaemic Stroke (MATCH): Study Design and Baseline Data. <i>Cerebrovascular Diseases</i> , 2004, 17, 253-261.	0.8	61
113	Oral Antiplatelet Therapy in Cerebrovascular Disease, Coronary Artery Disease, and Peripheral Arterial Disease. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 1867.	3.8	158
114	Are we making efficient use of clopidogrel?. <i>European Heart Journal</i> , 2004, 25, 454-456.	1.0	11
115	Long-term clopidogrel therapy after percutaneous coronary intervention in PCI-CURE and CREDO: the “Emperor's New Clothes” revisited. <i>European Heart Journal</i> , 2004, 25, 720-722.	1.0	45
116	High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. <i>European Heart Journal</i> , 2004, 25, 1903-1910.	1.0	268
117	Risk reduction with long-term clopidogrel following percutaneous coronary intervention. <i>European Heart Journal</i> , 2004, 25, 2169-2170.	1.0	8
118	ADP Receptor P2Y ₁₂ Is Expressed in Vascular Smooth Muscle Cells and Stimulates Contraction in Human Blood Vessels. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 1810-1815.	1.1	166

#	ARTICLE	IF	CITATIONS
119	Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance. <i>Circulation</i> , 2004, 109, 166-171.	1.6	449
120	Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention. <i>Platelets</i> , 2004, 15, 465-474.	1.1	31
121	Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary Stenoses. <i>Circulation</i> , 2004, 110, 508-514.	1.6	212
122	Cost-Effectiveness of Clopidogrel. <i>Pharmacoeconomics</i> , 2004, 22, 1-3.	1.7	2
124	Effects of a Novel Platelet Nitric Oxide Donor (LA816), Aspirin, Clopidogrel, and Combined Therapy in Inhibiting Flow- and Lesion-Dependent Thrombosis in the Porcine Ex Vivo Model. <i>Circulation</i> , 2004, 110, 1686-1693.	1.6	43
125	Lessons Learned From a Clinical Trial. <i>Circulation</i> , 2004, 110, 3610-3614.	1.6	12
126	Antiplatelet and Antithrombin Therapy for Early Management of Acute Coronary Syndromes. <i>Journal of Pharmacy Practice</i> , 2004, 17, 347-369.	0.5	1
127	Diabetes, Coronary Intervention, and Platelet Glycoprotein IIb/IIIa Blockade. <i>Circulation</i> , 2004, 110, 3618-3620.	1.6	7
128	Clopidogrel in the management of cerebrovascular events. <i>International Journal of Clinical Practice</i> , 2004, 58, 402-410.	0.8	3
129	Guidelines on the management of secondary prophylaxis of vascular events in stable patients in primary care. <i>International Journal of Clinical Practice</i> , 2004, 58, 153-168.	0.8	4
130	Concordance between clopidogrel use and prescribing guidelines. <i>Internal Medicine Journal</i> , 2004, 34, 663-667.	0.5	13
131	Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 7-9.	1.9	1
132	Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? No. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 10-12.	1.9	0
133	Polymer-Based Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: A Review of the TAXUS Trials. <i>Journal of Interventional Cardiology</i> , 2004, 17, 271-282.	0.5	49
134	Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2004, 128, 425-431.	0.4	207
135	Warfarin for atrial fibrillation: the end of an era?. <i>Lancet Neurology</i> , The, 2004, 3, 305-308.	4.9	31
136	The results of MATCH: light or heat?. <i>Lancet Neurology</i> , The, 2004, 3, 642.	4.9	1
137	Role of Clopidogrel in Unstable Angina and Non- σ ST-Segment Elevation Myocardial Infarction: From Literature and Guidelines to Practice. <i>Pharmacotherapy</i> , 2004, 24, 1037-1049.	1.2	2

#	ARTICLE	IF	CITATIONS
138	Practical approach to incorporating new studies and guidelines for antiplatelet therapy in the management of patients with non-â€œST-segment elevation acute coronary syndrome. American Journal of Cardiology, 2004, 93, 69-72.	0.7	1
139	Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. American Journal of Cardiology, 2004, 93, 679-684.	0.7	117
140	Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. American Journal of Cardiology, 2004, 94, 358-360.	0.7	100
141	Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention. American Journal of Cardiology, 2004, 94, 623-625.	0.7	33
142	Quelle mÃ©thode d'angiographie pour prÃ©dire le risque coronaire en 2003? Annales De Cardiologie Et D'Angiologie, 2004, 53, 79-90.	0.3	0
144	Modulating Thrombotic Potential in Catheter-Based Percutaneous Coronary and Peripheral Vascular Interventions. Journal of Thrombosis and Thrombolysis, 2004, 17, 11-20.	1.0	1
145	Patient-Specific Antiplatelet Therapy. Journal of Thrombosis and Thrombolysis, 2004, 17, 63-77.	1.0	2
146	Percutaneous Coronary Intervention in Diabetics. Reviews in Endocrine and Metabolic Disorders, 2004, 5, 277-285.	2.6	6
148	Does Clopidogrel Increase the Degree of Platelet Inhibition When a Platelet Glycoprotein IIb/IIIa Inhibitor Has Been Given? Insights From an Optical Platelet Aggregometry Study. Journal of Thrombosis and Thrombolysis, 2004, 18, 25-30.	1.0	2
150	Diabetes and Percutaneous Coronary Revascularization in the Drug-Eluting Stent Era. Herz, 2004, 29, 542-50.	0.4	1
152	Clopidogrel: How good is it and how does it work?. Current Cardiology Reports, 2004, 6, 264-268.	1.3	14
153	Current concepts in the antithrombotic management of non-ST-elevation acute coronary syndromes. Current Cardiology Reports, 2004, 6, 279-286.	1.3	1
154	Early and long-term outcome of elective stenting of the infarct-related artery in patients with viability in the infarct-area: Rationale and design of the Viability-guided Angioplasty after acute Myocardial Infarction-trial (The VIAMI-trial). Current Controlled Trials in Cardiovascular Medicine, 2004, 5, 11.	1.5	7
155	Late stent thrombosis (> 1 year) following clopidogrel withdrawal after brachytherapy treatment: Need to assess aspirin resistance?. Catheterization and Cardiovascular Interventions, 2004, 62, 39-42.	0.7	6
156	SCAI statement on ad hoc versus the separate performance of diagnostic cardiac catheterization and coronary intervention. Catheterization and Cardiovascular Interventions, 2004, 63, 444-451.	0.7	17
157	Building evidence for early initiation of clopidogrel loading in non-â€œST-segment elevation acute coronary syndromes. Annals of Emergency Medicine, 2004, 43, 666-668.	0.3	0
158	Does the use of statins compromise the effectiveness of platelet inhibition by clopidogrel?. Platelets, 2004, 15, 201-205.	1.1	7
159	Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. Platelets, 2004, 15, 95-99.	1.1	43

#	ARTICLE	IF	CITATIONS
160	Clopidogrel and vascular disease prevention. <i>Current Medical Research and Opinion</i> , 2004, 20, 1835-1838.	0.9	6
161	Role of antiplatelet therapy in cardiovascular disease I: acute coronary syndromes. <i>Current Medical Research and Opinion</i> , 2004, 20, 1839-1843.	0.9	6
162	Failure of Aspirin to Prevent Atherothrombosis. <i>American Journal of Cardiovascular Drugs</i> , 2004, 4, 57-67.	1.0	27
163	Antiplatelet Agents for the Prevention of Cardiovascular Disease in Diabetes Mellitus. <i>American Journal of Cardiovascular Drugs</i> , 2004, 4, 87-106.	1.0	27
164	Stent liberador de rapamicina en el tratamiento de lesiones coronarias con alto riesgo de reestenosis. Seguimiento clnico a 6 meses de los primeros 100 pacientes. <i>Revista Espanola De Cardiologia</i> , 2004, 57, 116-122.	0.6	19
166	Aspirin plus clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in patients at high risk patients (MATCH): Randomized double-blind placebo-controlled trial. <i>Journal of Vascular Surgery</i> , 2004, 40, 1259.	0.6	0
167	Antiplaquettaires et anesthsie. <i>Praticien En Anesthesie Reanimation</i> , 2004, 8, 29-34.	0.0	0
168	Sirolimus-Eluting Stents to Treat Lesions With a High Risk of Restenosis. Six-Month Clinical Follow-Up in the First 100 Patients. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2004, 57, 116-122.	0.4	1
169	Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. <i>Journal of the American College of Cardiology</i> , 2004, 43, 979-984.	1.2	130
170	Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. <i>Journal of the American College of Cardiology</i> , 2004, 43, 1982-1988.	1.2	159
171	Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. <i>Journal of the American College of Cardiology</i> , 2004, 43, 1122-1126.	1.2	467
172	For how long should treatment with clopidogrel be continued after coronary stent implantation?. <i>Journal of the American College of Cardiology</i> , 2004, 43, 1331.	1.2	1
175	Lack of efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation. <i>Journal of the American College of Cardiology</i> , 2004, 44, 20-24.	1.2	51
176	Intracoronary Brachytherapy After Stenting De Novo Lesions in Diabetic Patients. <i>Journal of the American College of Cardiology</i> , 2004, 44, 520-527.	1.2	25
177	Diminishing returns and too many choices the saga of pharmacologic therapy to reduce the complications of percutaneous coronary intervention**Editorials published in the <i>Journal of the American College of Cardiology</i> reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. <i>Journal of the American College of Cardiology</i> , 2004, 44, 25-27.	1.2	4
178	Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1194-1199.	1.2	17
179	Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. <i>Journal of the American College of Cardiology</i> , 2004, 44, 2133-2136.	1.2	156
180	Foundation and sites of action of antithrombotic agents. <i>Best Practice and Research in Clinical Haematology</i> , 2004, 17, 3-22.	0.7	8

#	ARTICLE	IF	CITATIONS
181	Platelet ADP receptor antagonists: ticlopidine and clopidogrel. <i>Best Practice and Research in Clinical Haematology</i> , 2004, 17, 55-64.	0.7	41
182	The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. <i>Platelets</i> , 2004, 15, 117-125.	1.1	70
183	Risk Reduction Strategies in Ischaemic Stroke. <i>Clinical Drug Investigation</i> , 2004, 24, 245-254.	1.1	15
184	Quelle méthode d'angiographie pour prédire le risque coronaire en 2003? Aspects réglementaires et pratiques de l'utilisation de la coronarographie, de l'IRM et de l'angioscanner. <i>Annales De Cardiologie Et D'Angéiologie</i> , 2004, 53, 79-90.	0.3	2
185	Commentary Evidence-based Cardiovascular Medicine - Volume 8, Issue 4. Evidence-based Cardiovascular Medicine, 2004, 8, 366-367.	0.0	0
186	A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after coronary stent implantation. <i>American Heart Journal</i> , 2004, 147, 676.	1.2	17
187	Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. <i>American Heart Journal</i> , 2004, 148, 263-268.	1.2	193
188	Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: A meta-analysis of randomized trials. <i>American Heart Journal</i> , 2004, 148, 990-997.	1.2	46
189	Cardiovascular disease and chronic kidney disease: Insights and an update. <i>American Heart Journal</i> , 2004, 148, 230-242.	1.2	66
190	Elective coronary revascularization, an iatrogenic form of acute coronary syndrome: How can clinicians reduce the risks?. <i>American Heart Journal</i> , 2004, 148, 371-377.	1.2	7
191	Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial: Study design and rationale. <i>American Heart Journal</i> , 2004, 148, 764-775.	1.2	231
192	Clinical outcomes of primary stenting versus balloon angioplasty in patients with myocardial infarction: a meta-analysis of randomized controlled trials. <i>American Journal of Medicine</i> , 2004, 116, 253-262.	0.6	100
193	Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes. <i>American Journal of Medicine</i> , 2004, 116, 119-129.	0.6	4
194	ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction Executive Summary. <i>Journal of the American College of Cardiology</i> , 2004, 44, 671-719.	1.2	1,084
195	Pharmacokinetics of clopidogrel after administration of a high loading dose. <i>Thrombosis and Haemostasis</i> , 2004, 92, 311-316.	1.8	215
196	Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2004, 364, 331-337.	6.3	2,110
197	Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. <i>Lancet</i> , The, 2004, 364, 1045-1053.	6.3	361
198	Long-term management of atherothrombosis. <i>British Journal of Hospital Medicine</i> , 2004, 65, 206-209.	0.3	4

#	ARTICLE	IF	CITATIONS
199	Focusing on Inflammation in the Treatment of Atherosclerosis. <i>Cardiology in Review</i> , 2004, 12, 194-200.	0.6	15
200	The effect of long-term clopidogrel use on neointimal formation after percutaneous coronary intervention. <i>Coronary Artery Disease</i> , 2004, 15, 347-352.	0.3	12
201	Risk Stratification and the Management of Non- σ ST-Segment Elevation Acute Coronary Syndromes. <i>Critical Pathways in Cardiology</i> , 2004, 3, 83-86.	0.2	2
202	Diabetes Mellitus: An Imperative for Prevention and Intense Management. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 394-396.	1.0	1
203	Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects. <i>Chest</i> , 2004, 126, 234S-264S.	0.4	578
204	Reply: Long-term clopidogrel following PCI: marginal antithrombotic effects are offset by increased bleeding risks. <i>European Heart Journal</i> , 2004, 25, 2170-2171.	1.0	2
205	The Value of Clopidogrel in Addition to Standard Therapy in Reducing Atherothrombotic Events. <i>Pharmacoeconomics</i> , 2004, 22, 29-41.	1.7	8
206	Antithrombotic Therapy During Percutaneous Coronary Intervention. <i>Chest</i> , 2004, 126, 576S-599S.	0.4	220
207	Progress in Clinical Neurosciences: Pharmacotherapies for the Secondary Prevention of Stroke. <i>Canadian Journal of Neurological Sciences</i> , 2004, 31, 295-303.	0.3	1
208	PLA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. <i>Blood Coagulation and Fibrinolysis</i> , 2004, 15, 89-93.	0.5	88
209	Invasive Management of Patients With ST Elevation Myocardial Infarction With > 12-h Delay in Presentation. <i>Chest</i> , 2004, 126, 2-4.	0.4	2
210	Glycoprotein IIb/IIIa Antagonists in Non-ST Elevation Acute Coronary Syndromes and Percutaneous Interventions: From Pharmacology to Individual Patient's Therapy. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 43, 477-484.	0.8	5
211	Atherothrombosis: Epidemiology, Pathophysiology, and Prevention. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2004, 44, S5-S13.	0.7	56
212	A Practical and Evidence-Based Approach to Cardiovascular Disease Risk Reduction. <i>Archives of Internal Medicine</i> , 2004, 164, 1490.	4.3	54
213	Antithrombotic Therapy for Acute Coronary Syndromes. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2004, 44, S14-S27.	0.7	4
214	Chapter 9 Antithrombotic Therapy for Secondary Prevention of Ischemic Stroke. <i>Blue Books of Practical Neurology</i> , 2004, 29, 175-196.	0.1	0
215	Comparison of Ticlopidine and Aspirin versus Clopidogrel and Aspirin after Percutaneous Coronary Interventions in High-Risk Patients. <i>Cardiology</i> , 2005, 5, 187-192.	0.3	0
216	Emerging Therapies: Clopidogrel and Aspirin. <i>Stroke</i> , 2005, 36, 707-707.	1.0	3

#	ARTICLE	IF	CITATIONS
217	Stroke prevention. <i>Postgraduate Medicine</i> , 2005, 117, 26-30.	0.9	5
218	Aprotinin Decreases Postoperative Bleeding and Number of Transfusions in Patients on Clopidogrel Undergoing Coronary Artery Bypass Graft Surgery. <i>Circulation</i> , 2005, 112, 1276-80.	1.6	77
219	What Is the Optimal Timing of Clopidogrel in Acute Coronary Syndromes?. <i>Critical Pathways in Cardiology</i> , 2005, 4, 46-50.	0.2	7
220	Cellular and molecular biology for intensivists: A primer—Endothelial cells. <i>Critical Care Medicine</i> , 2005, 33, S517-S519.	0.4	29
221	P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 199-204.	0.5	94
222	A Cost-Effectiveness Analysis of Combination Antiplatelet Therapy for High-Risk Acute Coronary Syndromes: Clopidogrel plus Aspirin versus Aspirin Alone. <i>Annals of Internal Medicine</i> , 2005, 142, 251.	2.0	88
223	Efficacy and Safety of Heparinase I versus Protamine in Patients Undergoing Coronary Artery Bypass Grafting with and without Cardiopulmonary Bypass. <i>Anesthesiology</i> , 2005, 103, 229-240.	1.3	58
225	Relationship Between Myocardial Injury and Soluble P-Selectin in Non-ST Elevation Acute Coronary Syndromes. <i>Circulation Journal</i> , 2005, 69, 530-535.	0.7	7
226	Part 5: Acute coronary syndromes. <i>Resuscitation</i> , 2005, 67, 249-269.	1.3	36
227	European Resuscitation Council Guidelines for Resuscitation 2005. <i>Resuscitation</i> , 2005, 67, S87-S96.	1.3	41
228	Are We Putting the Cart Ahead of the Horse: Who Determines the Standard of Care for the Management of Patients in the Emergency Department?. <i>Annals of Emergency Medicine</i> , 2005, 46, 198-200.	0.3	2
231	Prediction of coronary artery disease severity in patients referred for coronary angiography. <i>Clinical Cardiology</i> , 2005, 28, 288-292.	0.7	0
232	Small Molecule Anticoagulant/Antithrombotic Agents. <i>Annual Reports in Medicinal Chemistry</i> , 2005, , 85-101.	0.5	8
233	Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 85-92.	1.9	367
234	Therapeutic approaches in arterial thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1577-1589.	1.9	74
235	Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 2649-2655.	1.9	50
236	Not all statins interfere with clopidogrel during antiplatelet therapy. <i>European Journal of Clinical Investigation</i> , 2005, 35, 476-481.	1.7	40
237	Percutaneous coronary interventions for coronary artery disease: the long and short of optimizing medical therapy. <i>International Journal of Clinical Practice</i> , 2005, 59, 1070-1081.	0.8	2

#	ARTICLE	IF	CITATIONS
238	Existence of a Clinically Relevant Interaction between Clopidogrel and HMG-CoA Reductase Inhibitors? Re-evaluating the Evidence. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2005, 96, 103-110.	1.2	14
239	Long-Term Outcome After Coronary Angioplasty in Renal Transplant and Hemodialysis Patients. <i>Journal of Interventional Cardiology</i> , 2005, 18, 331-337.	0.5	11
240	Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. <i>American Journal of Cardiology</i> , 2005, 95, 509-510.	0.7	114
241	Aspirin resistance and a single gene. <i>American Journal of Cardiology</i> , 2005, 95, 805-808.	0.7	103
242	Analysis of Risk of Bleeding Complications After Different Doses of Aspirin in 192,036 Patients Enrolled in 31 Randomized Controlled Trials. <i>American Journal of Cardiology</i> , 2005, 95, 1218-1222.	0.7	304
243	Prediction of Complications Following Nonemergency Percutaneous Coronary Interventions. <i>American Journal of Cardiology</i> , 2005, 96, 907-912.	0.7	27
244	Treating Patients With Acute Coronary Syndromes With Aggressive Antiplatelet Therapy (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.7	17
246	Actualizaci3n en cardiolog3a intervencionista 2004. <i>Revista Espanola De Cardiologia Suplementos</i> , 2005, 5, 104A-117A.	0.2	0
247	The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. , 2005, 108, 180-192.		96
248	Antiplatelet Drug Resistance: Not Ready for Prime Time. <i>Pharmacotherapy</i> , 2005, 25, 1621-1628.	1.2	9
249	Randomized clinical trial of the antiplatelet effects of aspirin+clopidogrel combination versus aspirin alone after lower limb angioplasty. <i>British Journal of Surgery</i> , 2005, 92, 159-165.	0.1	54
250	Angiographic predictors of femoral access site complications: Implication for planned percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 65, 196-202.	0.7	189
251	Late thrombosis of sirolimus-eluting stents following noncardiac surgery. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 65, 516-519.	0.7	81
252	Late thrombosis following treatment of in-stent restenosis with drug-eluting stents after discontinuation of antiplatelet therapy. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 65, 520-524.	0.7	29
253	Clopidogrel (Plavix) desensitization: A case series. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 65, 525-527.	0.7	39
254	Percutaneous recanalization of chronically occluded coronary arteries: Procedural techniques, devices, and results. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 66, 217-236.	0.7	119
257	Platelet Inhibition in Percutaneous Coronary Interventions. <i>Herz</i> , 2005, 30, 189-196.	0.4	0
258	Clopidogrel in acute coronary syndrome: when, how much, how long?. <i>Clinical Research in Cardiology</i> , 2005, 94, 377-382.	1.2	4

#	ARTICLE	IF	CITATIONS
259	Current treatments in neurology: Stroke. <i>Journal of Neurology</i> , 2005, 252, 260-267.	1.8	9
260	Aspirin and clopidogrel: Efficacy, treatment, and resistance in coronary artery disease. <i>International Journal of Angiology</i> , 2005, 14, 109-114.	0.2	1
261	The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention. <i>European Journal of Health Economics</i> , 2005, 6, 354-362.	1.4	21
263	La prise en charge des patients sous anticoagulants ou sous agents antiplaquettaires avant une endoscopie digestive. <i>Acta Endoscopica</i> , 2005, 35, 351-363.	0.0	1
264	Antiplatelet medications in the secondary prevention of ischemic stroke. <i>Current Neurology and Neuroscience Reports</i> , 2005, 5, 1-3.	2.0	0
265	Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. <i>Thrombosis Journal</i> , 2005, 3, 10.	0.9	77
266	The Variability of Platelet Response to Aspirin and Clopidogrel: Revisiting the Caprie, Cure, Credo, and Match Trials. <i>Baylor University Medical Center Proceedings</i> , 2005, 18, 331-336.	0.2	9
268	The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease. <i>Thrombosis and Haemostasis</i> , 2005, 94, 438-43.	1.8	33
269	The role of clopidogrel in the emergency department. <i>Canadian Journal of Emergency Medicine</i> , 2005, 7, 22-27.	0.5	2
270	Treating non-ST-segment elevation ACS. <i>Postgraduate Medicine</i> , 2005, 118, 23-32.	0.9	0
271	Clopidogrel inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation. <i>Thrombosis and Haemostasis</i> , 2005, 94, 568-577.	1.8	115
272	Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intimal thickening in mice. <i>Thrombosis and Haemostasis</i> , 2005, 93, 535-543.	1.8	40
273	Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. <i>Thrombosis and Haemostasis</i> , 2005, 93, 527-534.	1.8	22
274	Intracranial Atherosclerosis: Incidence, Diagnosis and Treatment. <i>Journal of Clinical Neurology</i>		

#	ARTICLE	IF	CITATIONS
279	Platelet Function Profiles in Patients With Type 2 Diabetes and Coronary Artery Disease on Combined Aspirin and Clopidogrel Treatment. <i>Diabetes</i> , 2005, 54, 2430-2435.	0.3	492
280	Peri-procedural myocardial injury: 2005 update. <i>European Heart Journal</i> , 2005, 26, 2493-2519.	1.0	286
281	Loading, Pretreatment, and Interindividual Variability Issues With Clopidogrel Dosing. <i>Circulation</i> , 2005, 111, 2557-2559.	1.6	36
282	Bleeding Complications Associated With Combinations of Aspirin, Thienopyridine Derivatives, and Warfarin in Elderly Patients Following Acute Myocardial Infarction. <i>Archives of Internal Medicine</i> , 2005, 165, 784.	4.3	166
283	Routine vs Selective Invasive Strategies in Patients With Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 2908.	3.8	717
284	Clopidogrel in non-ST segment elevation acute coronary syndromes: an overview of the submission by the British Cardiac Society and the Royal College of Physicians of London to the National Institute for Clinical Excellence, and beyond. <i>Heart</i> , 2005, 91, 1135-1140.	1.2	6
285	Part 8: Stabilization of the Patient With Acute Coronary Syndromes. <i>Circulation</i> , 2005, 112, IV-89-IV-110.	1.6	9
286	Clopidogrel versus Aspirin and Esomeprazole to Prevent Recurrent Ulcer Bleeding. <i>New England Journal of Medicine</i> , 2005, 352, 238-244.	13.9	567
287	Diabetes and acute coronary syndromes â€” a cardiologist's view. <i>Diabetes and Vascular Disease Research</i> , 2005, 2, 101-102.	0.9	2
288	Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in Women. <i>Circulation</i> , 2005, 111, 940-953.	1.6	214
289	Clopidogrel Pretreatment for Percutaneous Coronary Intervention. <i>Circulation</i> , 2005, 111, 2019-2021.	1.6	8
290	Percutaneous coronary intervention: recommendations for good practice and training. <i>Heart</i> , 2005, 91, vi1-vi27.	1.2	38
291	A Simplified Approach to the Management of Nonâ€”ST-Segment Elevation Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 349.	3.8	54
292	Clopidogrel: cardiologistsâ€™ panacea or neurologistsâ€™ headache?. <i>Future Cardiology</i> , 2005, 1, 579-590.	0.5	1
293	Could clopidogrel's platelet inhibition be enhanced by an increased loading dose and eptifibatide?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 344-345.	3.3	0
294	Treatment of unprotected left main coronary artery stenosis with a drug eluting stent in a heart transplant patient with allograft vasculopathy. <i>Heart</i> , 2005, 91, e11-e11.	1.2	6
295	Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. <i>European Heart Journal</i> , 2005, 26, 1180-1187.	1.0	183
296	Platelet VASP phosphorylation assessment in clopidogrel-treated patients: Lack of agreement between Western blot and flow cytometry. <i>Platelets</i> , 2005, 16, 474-481.	1.1	12

#	ARTICLE	IF	CITATIONS
298	The role of antiplatelet therapy in the management of acute coronary syndromes. Expert Opinion on Drug Safety, 2005, 4, 541-556.	1.0	6
299	Clopidogrel in Acute Coronary Heart Disease. The American Heart Hospital Journal, 2005, 3, 234-242.	0.2	2
300	Does clopidogrel provide additional benefit to aspirin and fibrinolytic therapy in patients after STEMI?. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 500-501.	3.3	1
301	Dual Antiplatelet Therapy for Coronary Stenting. Circulation, 2005, 111, 1097-1099.	1.6	7
302	Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention. Circulation, 2005, 111, 1390-1397.	1.6	113
303	Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention. Heart, 2005, 91, iii16-iii19.	1.2	3
304	Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y ₁₂ Antagonist, With Clopidogrel in Percutaneous Coronary Intervention. Circulation, 2005, 111, 3366-3373.	1.6	392
305	Time Dependence of Platelet Inhibition After a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention. Circulation, 2005, 111, 2560-2564.	1.6	363
306	Medications for the treatment of acute coronary syndromes. Expert Opinion on Pharmacotherapy, 2005, 6, 2843-2854.	0.9	0
307	Clopidogrel for Percutaneous Coronary Revascularization. JAMA - Journal of the American Medical Association, 2005, 294, 1271.	3.8	14
308	Diabetes and percutaneous coronary intervention in the setting of an acute coronary syndrome. Diabetes and Vascular Disease Research, 2005, 2, 128-135.	0.9	6
309	Is the Measurement of Cerebral Microembolic Signals a Good Surrogate Marker for Evaluating the Efficacy of Antiplatelet Agents in the Prevention of Stroke?. European Neurology, 2005, 53, 132-139.	0.6	16
310	Antiplatelets in Stroke Prevention: The MATCH Trial. Cerebrovascular Diseases, 2005, 20, 109-118.	0.8	11
311	Monitoring of Clopidogrel Action: Comparison of Methods. Clinical Chemistry, 2005, 51, 957-965.	1.5	165
312	Controversies in Antiplatelet Therapy for Patients With Cardiovascular Disease. Circulation, 2005, 111, e267-71.	1.6	22
313	Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention. Circulation, 2005, 111, 2099-2106.	1.6	635
314	Initial Appraisal of Acute Coronary Syndromes. Journal of Pharmacy Practice, 2005, 18, 377-393.	0.5	0
315	Prevention of Stroke in Patients with Diabetes mellitus and the Metabolic Syndrome. Cerebrovascular Diseases, 2005, 20, 24-34.	0.8	22

#	ARTICLE	IF	CITATIONS
316	Cryptogenic Stroke, Aortic Arch Atheroma, Patent Foramen Ovale, and the Risk of Stroke. <i>Cerebrovascular Diseases</i> , 2005, 20, 68-74.	0.8	30
317	Guidelines for Percutaneous Coronary Interventions. <i>European Heart Journal</i> , 2005, 26, 804-847.	1.0	1,408
318	High-Dose Clopidogrel Loading in Percutaneous Coronary Intervention. <i>Annals of Pharmacotherapy</i> , 2005, 39, 918-922.	0.9	7
319	Effect of Clopidogrel Pretreatment Before Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction Treated With Fibrinolytics<SUBTITLE>The PCI-CLARITY Study</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 1224.	3.8	644
320	Thrombosis of Sirolimus-Eluting Coronary Stent in the Postanesthesia Care Unit. <i>Anesthesia and Analgesia</i> , 2005, 101, 971-973.	1.1	35
321	Recent advances in endoluminal revascularization for intracranial atherosclerotic disease. <i>Neurological Research</i> , 2005, 27, 89-94.	0.6	4
322	Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosisâ€. <i>European Heart Journal</i> , 2005, 26, 567-575.	1.0	34
323	Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. <i>European Heart Journal</i> , 2005, 26, 1063-1069.	1.0	47
324	One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrelâ€. <i>European Heart Journal</i> , 2005, 26, 1379-1384.	1.0	44
325	Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. <i>European Heart Journal</i> , 2005, 26, 1585-1595.	1.0	230
326	A comparison of dual vs. triple antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndrome: results of the ELISA-2 trial. <i>European Heart Journal</i> , 2005, 27, 1401-1407.	1.0	38
327	Platelets and new antiplatelet drugs. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 465-502.	0.2	8
328	Current status of stroke prevention in patients with atrial fibrillation. <i>Country Review Ukraine</i> , 2005, 7, C12-C18.	0.8	6
329	Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache?. <i>European Heart Journal</i> , 2005, 26, 576-583.	1.0	175
330	Preventing in-hospital cardiac and renal complications in high-risk PCI patients. <i>Country Review Ukraine</i> , 2005, 7, G13-G24.	0.8	2
332	Addition of clopidogrel to aspirin in 45â€852 patients with acute myocardial infarction: randomised placebo-controlled trial. <i>Lancet, The</i> , 2005, 366, 1607-1621.	6.3	1,737
333	ASGE guideline: the management of low-molecular-weight heparin and nonaspirin antiplatelet agents for endoscopic procedures. <i>Gastrointestinal Endoscopy</i> , 2005, 61, 189-194.	0.5	155
334	Case 6â€2005 Thoracotomy After Myocardial Infarction and Intracoronary Stenting: A Balance Between Myocardial Recovery and Procedural Risk. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2005, 19, 794-800.	0.6	0

#	ARTICLE	IF	CITATIONS
335	Cardiac surgery in patients on antiplatelet and antithrombotic agents. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2005, 17, 66-72.	0.4	3
336	Antiplatelet Therapy in Neuroendovascular Therapeutics. <i>Neurosurgery Clinics of North America</i> , 2005, 16, 517-540.	0.8	42
337	Treatment of Acute Coronary Syndromes in Patients Who Have Chronic Kidney Disease. <i>Medical Clinics of North America</i> , 2005, 89, 563-585.	1.1	8
338	Acute Coronary Syndromes: Risk Stratification and Initial Management. <i>Cardiology Clinics</i> , 2005, 23, 401-409.	0.9	14
339	Antiplatelet Agents: Current Drugs and Future Trends. <i>Hematology/Oncology Clinics of North America</i> , 2005, 19, 87-117.	0.9	10
340	Percutaneous coronary intervention versus coronary artery bypass grafting in diabetic patients. <i>Cardiology Clinics</i> , 2005, 23, 185-191.	0.9	2
341	Adding clopidogrel to aspirin improves outcome in ST-elevation myocardial infarction patients receiving fibrinolytic therapy. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005, 5, 751-761.	0.7	3
342	Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel. <i>Circulation</i> , 2005, 112, 2946-2950.	1.6	605
343	Avoiding Central Nervous System Bleeding During Antithrombotic Therapy. <i>Stroke</i> , 2005, 36, 1588-1593.	1.0	336
344	Evolving role of clopidogrel in acute coronary syndromes. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 977-980.	0.6	0
345	Interventional Cardiovascular Pharmacotherapy. <i>American Journal of Cardiovascular Drugs</i> , 2005, 5, 93-102.	1.0	2
346	Antiplatelet Agents in Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiovascular Drugs</i> , 2005, 5, 307-318.	1.0	14
347	Increased long term rates of stent thrombosis and mortality in patients given clopidogrel as compared to ticlopidine following coronary stent implantation. <i>International Journal of Cardiology</i> , 2005, 103, 293-297.	0.8	15
348	The difference between clopidogrel responsiveness and posttreatment platelet reactivity. <i>Thrombosis Research</i> , 2005, 115, 89-94.	0.8	138
349	Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. <i>Thrombosis Research</i> , 2005, 115, 101-108.	0.8	154
350	Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage. <i>Thrombosis Research</i> , 2005, 116, 55-66.	0.8	21
351	Superior efficacy of clopidogrel plus acetylsalicylic acid compared with extended-release dipyridamole plus acetylsalicylic acid in preventing arterial thrombogenesis in healthy volunteers. <i>Thrombosis Research</i> , 2005, 116, 293-300.	0.8	7
352	Balancing the Benefit and Risk of Oral Antiplatelet Agents in Coronary Artery Bypass Surgery. <i>Annals of Thoracic Surgery</i> , 2005, 80, 768-779.	0.7	60

#	ARTICLE	IF	CITATIONS
353	Thrombin, an ideal target for pharmacological inhibition: A review of direct thrombin inhibitors. <i>American Heart Journal</i> , 2005, 149, S43-S53.	1.2	40
354	Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy—Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial. <i>American Heart Journal</i> , 2005, 149, 227-233.	1.2	51
355	Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro study. <i>American Heart Journal</i> , 2005, 150, 796-799.	1.2	7
356	Enhancing reperfusion therapy for myocardial infarction with dual antiplatelet therapy: Breaking the glass ceiling. <i>American Heart Journal</i> , 2005, 149, 947-949.	1.2	1
357	Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: Further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. <i>American Heart Journal</i> , 2005, 150, 1177-1184.	1.2	67
358	A global view of atherothrombosis: Baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. <i>American Heart Journal</i> , 2005, 150, 401.e1-401.e7.	1.2	29
359	A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy. <i>American Heart Journal</i> , 2005, 150, 220.e1-220.e5.	1.2	18
360	Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream Tirofiban, in cath Lab Downstream Abciximab (CLOTILDA) study. <i>American Heart Journal</i> . 2005. 150. 401.e9-401.e14.	1.2	21
361	Cilostazol improves long-term outcomes after coronary stent implantation. <i>American Heart Journal</i> , 2005, 150, 568.e1-568.e5.	1.2	17
362	Design and methodology of the Occluded Artery Trial (OAT). <i>American Heart Journal</i> , 2005, 150, 627-642.	1.2	56
365	Optimal Duration of Antiplatelet Therapy in Recipients of Coronary Drug-Eluting Stents. <i>Drugs</i> , 2005, 65, 725-732.	4.9	38
366	Advances in Adjunctive Pharmacological Therapy for Percutaneous Coronary Interventions. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2005, 58, 729-743.	0.4	0
368	Aspirin Resistance and Atherothrombotic Disease. <i>Journal of the American College of Cardiology</i> , 2005, 46, 986-993.	1.2	179
369	Variability in platelet responsiveness to clopidogrel among 544 individuals. <i>Journal of the American College of Cardiology</i> , 2005, 45, 246-251.	1.2	713
370	Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , 2005, 45, 369-376.	1.2	41
371	Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1165-1171.	1.2	56
372	Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. <i>Journal of the American College of Cardiology</i> , 2005, 45, 838-845.	1.2	103
373	Late Angiographic Stent Thrombosis (LAST) Events With Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2005, 45, 2088-2092.	1.2	611

#	ARTICLE	IF	CITATIONS
374	Long-Term Cost Effectiveness of Early and Sustained Dual Oral Antiplatelet Therapy With Clopidogrel Given for Up to One Year After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2005, 46, 761-769.	1.2	115
375	Economic Effects of Extended Clopidogrel Therapy—A Word of Caution. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1376.	1.2	0
377	Platelet Reactivity in Patients and Recurrent Events Post-Stenting. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1820-1826.	1.2	628
378	Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. <i>New England Journal of Medicine</i> , 2005, 352, 1179-1189.	13.9	1,739
379	Impact of Coaching Patients on Coronary Risk Factors. <i>Disease Management and Health Outcomes</i> , 2005, 13, 225-244.	0.3	13
380	Primary stenting versus primary balloon angioplasty for treating acute myocardial infarction. <i>The Cochrane Library</i> , 2005, , CD005313.	1.5	37
381	Tirofiban in acute coronary syndromes. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 193-206.	0.6	11
382	Regulatory issues facing the development of drug-eluting stents: a US FDA perspective. <i>Expert Review of Medical Devices</i> , 2006, 3, 297-300.	1.4	7
383	Clopidogrel use in coronary artery disease. <i>Expert Review of Cardiovascular Therapy</i> , 2006, 4, 7-15.	0.6	6
384	Clopidogrel. <i>Pharmacoeconomics</i> , 2006, 24, 709-726.	1.7	16
385	The Role of Oral Antiplatelet Agents in Atherothrombotic Disease. <i>American Journal of Cardiovascular Drugs</i> , 2006, 6, 149-157.	1.0	16
386	Cost Effectiveness of the Sirolimus-Eluting Stent in High-Risk Patients in Canada. <i>American Journal of Cardiovascular Drugs</i> , 2006, 6, 159-168.	1.0	22
387	Medical Treatment of Patients with Heart Failure or Left Ventricular Dysfunction Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiovascular Drugs</i> , 2006, 6, 313-325.	1.0	1
388	Intensive Reduction of Low-Density Lipoprotein-Cholesterol. <i>American Journal of Cardiovascular Drugs</i> , 2006, 6, 367-371.	1.0	7
389	Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. <i>BMJ: British Medical Journal</i> , 2006, 333, 726.	2.4	324
390	Effect of combined administration of clopidogrel and lysine acetylsalicylate versus clopidogrel and aspirin on platelet aggregation and activated GPIIb/IIIa expression in healthy volunteers. <i>Platelets</i> , 2006, 17, 105-107.	1.1	12
391	Effects of ad hoc clopidogrel loading versus pre-treatment on P-selectin expression after coronary stent implantation. <i>Platelets</i> , 2006, 17, 344-346.	1.1	4
392	Clopidogrel in the treatment of ischaemic heart disease. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1109-1120.	0.9	3

#	ARTICLE	IF	CITATIONS
394	Coping with new challenges in acute coronary syndromes. Canadian Journal of Cardiology, 2006, 22, 13C-20C.	0.8	0
395	Controversia terapéutica: clopidogrel y estatinas. Clínica E Investigaci3n En Arteriosclerosis, 2006, 18, 34-48.	0.4	0
396	Aspirin resistance. Lancet, The, 2006, 367, 606-617.	6.3	503
397	Good old warfarin for stroke prevention in atrial fibrillation. Lancet, The, 2006, 367, 1877-1878.	6.3	19
398	Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet, The, 2006, 367, 1903-1912.	6.3	1,820
399	Prasugrel. Expert Opinion on Investigational Drugs, 2006, 15, 1627-1633.	1.9	21
400	Percutaneous coronary intervention. Medicine, 2006, 34, 197-202.	0.2	1
401	Present and Future Anticoagulants. Advances in Anesthesia, 2006, 24, 29-66.	0.5	4
402	Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy. Mayo Clinic Proceedings, 2006, 81, 641-652.	1.4	49
403	Aspirin and Clopidogrel Resistance. Mayo Clinic Proceedings, 2006, 81, 518-526.	1.4	88
404	Antithrombotic Therapy for Percutaneous Coronary Intervention. Cardiology Clinics, 2006, 24, 175-199.	0.9	3
405	CLOPIDOGREL DESENSITIZATION. Annals of Allergy, Asthma and Immunology, 2006, 96, 756-757.	0.5	17
406	Antiplatelet Agents and Arterial Thrombosis. Clinics in Geriatric Medicine, 2006, 22, 57-74.	1.0	5
407	Platelets in Atherothrombosis. Mayo Clinic Proceedings, 2006, 81, 59-68.	1.4	103
408	Conduite à tenir devant un patient porteur dâ€™une endoprothèse coronaire devant être anesthésié et opéré. Praticien En Anesthesie Reanimation, 2006, 10, 202-212.	0.0	0
411	Impact of Adenosine Diphosphate and Calcium Chelation on Platelet Aggregation Testing in Patients Receiving Clopidogrel Therapy. Journal of the American College of Cardiology, 2006, 47, 464-465.	1.2	13
412	Optimal Timing for the Initiation of Pre-Treatment With 300 mg Clopidogrel Before Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2006, 47, 939-943.	1.2	177
413	ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Interventionâ€™Summary Article. Journal of the American College of Cardiology, 2006, 47, 216-235.	1.2	372

#	ARTICLE	IF	CITATIONS
414	ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2006, 47, e1-e121.	1.2	435
415	Cost Effectiveness of Paclitaxel-Eluting Stents for Patients Undergoing Percutaneous Coronary Revascularization. Journal of the American College of Cardiology, 2006, 48, 253-261.	1.2	64
416	Insulin Therapy Is Associated With Platelet Dysfunction in Patients With Type 2 Diabetes Mellitus on Dual Oral Antiplatelet Treatment. Journal of the American College of Cardiology, 2006, 48, 298-304.	1.2	284
417	The Influence of Peripheral Arterial Disease on Outcomes. Journal of the American College of Cardiology, 2006, 48, 1567-1572.	1.2	152
418	Vascular Disease, Hypertension, and Prevention. Journal of the American College of Cardiology, 2006, 47, D3-D8.	1.2	11
419	A Randomized Comparison of High Clopidogrel Loading Doses in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2006, 48, 931-938.	1.2	509
420	Benefit of a 600-mg Loading Dose of Clopidogrel on Platelet Reactivity and Clinical Outcomes in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Coronary Stenting. Journal of the American College of Cardiology, 2006, 48, 1339-1345.	1.2	329
421	Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement. Journal of the American College of Cardiology, 2006, 48, 1742-1750.	1.2	558
422	Late Ischemic Events After Clopidogrel Cessation Following Drug-Eluting Stenting. Journal of the American College of Cardiology, 2006, 48, 2592-2595.	1.2	24
423	Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents. Journal of the American College of Cardiology, 2006, 48, 2584-2591.	1.2	1,242
424	Clopidogrel for up to one year after PCI is cost-effective for people with acute coronary syndromes. Evidence-based Cardiovascular Medicine, 2006, 10, 116-118.	0.0	1
425	Coronary Intervention for Persistent Occlusion after Myocardial Infarction. New England Journal of Medicine, 2006, 355, 2395-2407.	13.9	635
427	Systematic Review and Meta-analysis of Adverse Events of Low-dose Aspirin and Clopidogrel in Randomized Controlled Trials. American Journal of Medicine, 2006, 119, 624-638.	0.6	382
428	Late Thrombosis of Drug-Eluting Stents: A Meta-Analysis of Randomized Clinical Trials. American Journal of Medicine, 2006, 119, 1056-1061.	0.6	452
429	Early Administration of Clopidogrel Is Safe After Off-Pump Coronary Artery Bypass Surgery. Annals of Thoracic Surgery, 2006, 81, 815-819.	0.7	48
430	Subgroup analyses in therapeutic cardiovascular clinical trials: Are most of them misleading?. American Heart Journal, 2006, 151, 257-264.	1.2	108
431	Rationale and design of ACTIVE: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. American Heart Journal, 2006, 151, 1187-1193.	1.2	94
432	Bare metal stent restenosis is not a benign clinical entity. American Heart Journal, 2006, 151, 1260-1264.	1.2	367

#	ARTICLE	IF	CITATIONS
433	Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. <i>American Heart Journal</i> , 2006, 151, 521.e1-521.e4.	1.2	72
434	Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). <i>American Heart Journal</i> . 2006. 152. 627-635.	1.2	290
435	Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: Insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial. <i>American Heart Journal</i> , 2006, 152, 876-881.	1.2	21
436	The Role of Antiplatelet Therapy in Carotid Stenting for Ischemic Stroke Prevention. <i>Stroke</i> , 2006, 37, 1572-1577.	1.0	68
437	Association between platelet P2Y12 haplotype and risk of cardiovascular events in chronic coronary disease. <i>Thrombosis Research</i> , 2006, 118, 679-683.	0.8	21
438	Carotid Artery Stenting. , 2006, , 467-488.		0
439	A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent. <i>Chinese Medical Journal</i> , 2006, 119, 360-366.	0.9	27
440	Blood Clots. , 2006, , 169-174.		0
441	Guidelines for the management of acute coronary syndromes 2006. <i>Medical Journal of Australia</i> , 2006, 184, S1-S32.	0.8	121
442	Potent low dose platelet inhibitory effects of clopidogrel and aspirin on coronary thrombus formation in an animal model of acute unstable angina. <i>Thrombosis and Haemostasis</i> , 2006, 95, 354-361.	1.8	5
443	Angina. , 2006, , 35-56.		0
444	Myocardial Infarction as a Presentation of Clinical In-Stent Restenosis. <i>Circulation Journal</i> , 2006, 70, 1026-1029.	0.7	72
445	Clopidogrel to Treat Patients With Non-â€“ST-Segment Elevation Acute Coronary Syndromes After Hospital Discharge. <i>Archives of Internal Medicine</i> , 2006, 166, 806.	4.3	47
446	Antithrombotic therapy in secondary stroke prevention. <i>Aging Health</i> , 2006, 2, 787-797.	0.3	0
447	Effects of tomato extract on platelet function: a double-blinded crossover study in healthy humans. <i>American Journal of Clinical Nutrition</i> , 2006, 84, 561-569.	2.2	95
448	Do patients undergoing percutaneous coronary intervention benefit from clopidogrel pretreatment?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 12-13.	3.3	0
449	Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice. <i>European Heart Journal</i> , 2006, 27, 2661-2666.	1.0	57
450	Clopidogrel in ST-elevation myocardial infarction. <i>Country Review Ukraine</i> , 2006, 8, G31-G34.	0.8	3

#	ARTICLE	IF	CITATIONS
451	Drug interactions in the setting of acute coronary syndromes and dual anti-platelet therapy. Country Review Ukraine, 2006, 8, G35-G37.	0.8	4
452	Pharmacology of thienopyridines: rationale for dual pathway inhibition. Country Review Ukraine, 2006, 8, G3-G9.	0.8	20
453	Clinical evaluation of clopidogrel across the whole spectrum of indications: primary and secondary prevention of coronary artery disease. Country Review Ukraine, 2006, 8, G10-G14.	0.8	2
454	Clinical efficacy of clopidogrel across the whole spectrum of indications: percutaneous coronary intervention. Country Review Ukraine, 2006, 8, G20-G24.	0.8	1
455	Premature withdrawal and alternative therapies to dual oral antiplatelet therapy. Country Review Ukraine, 2006, 8, G46-G52.	0.8	43
457	CHARISMA. Stroke, 2006, 37, 2428-2429.	1.0	6
458	Survey of Clopidogrel Use in a Teaching Hospital. Journal of Pharmacy Practice and Research, 2006, 36, 40-43.	0.5	0
459	The Clinical Potential of a Point-of-Care Assay to Assess Interindividual Variability in Platelet Aggregation Among Patients Taking Clopidogrel. Critical Pathways in Cardiology, 2006, 5, 103-113.	0.2	1
460	Current Concepts in the Management of Intracranial Atherosclerotic Disease. Neurosurgery, 2006, 59, S210-S218.	0.6	21
461	Safety and efficacy of low-dose unfractionated heparin during percutaneous coronary revascularisation and the relationship between activated clotting time and haemorrhagic or ischaemic complications: our results. Journal of Cardiovascular Medicine, 2006, 7, 866-871.	0.6	4
462	Variability of Response to Clopidogrel. Cardiology in Review, 2006, 14, 136-142.	0.6	27
463	Acute Coronary Syndromes Clinical Practice Guidelines. Critical Pathways in Cardiology, 2006, 5, 69-102.	0.2	4
464	Multimodality Stroke Prevention. Neurologist, 2006, 12, 14-31.	0.4	17
465	ANTIPLATELET THERAPY IN PERIPHERAL OCCLUSIVE ARTERIAL DISEASE. ANZ Journal of Surgery, 2006, 76, 364-372.	0.3	0
466	Diabetes mellitus and platelet function after administration of aspirin and a single 600mg dose of clopidogrel. Journal of Thrombosis and Haemostasis, 2006, 4, 2566-2568.	1.9	11
467	The potential role of antiplatelet agents in modulating inflammatory markers in atherothrombosis. Journal of Thrombosis and Haemostasis, 2006, 4, 2308-2316.	1.9	23
468	Life after CHARISMA. International Journal of Stroke, 2006, 1, 167-168.	2.9	1
470	Duration of Clopidogrel Therapy with Drug-Eluting Stents. Journal of Interventional Cardiology, 2006, 19, S40-S46.	0.5	7

#	ARTICLE	IF	CITATIONS
471	Aspirin and Clopidogrel Resistance: Consideration and Management. <i>Journal of Interventional Cardiology</i> , 2006, 19, 439-448.	0.5	51
472	Debate of Adjunctive Pharmacology for Percutaneous Coronary Intervention: Anticoagulation and Clopidogrel Are Not (Always) Enough. <i>Journal of Interventional Cardiology</i> , 2006, 19, 456-463.	0.5	0
473	The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. <i>Kidney International</i> , 2006, 70, 2021-2030.	2.6	227
474	Clinical Policy: Critical Issues in the Evaluation and Management of Adult Patients with Non- σ ST-Segment Elevation Acute Coronary Syndromes. <i>Annals of Emergency Medicine</i> , 2006, 48, 270-301.	0.3	49
475	Aspirin resistance, an emerging, often overlooked, factor in the management of patients with coronary artery disease. <i>Clinical Cardiology</i> , 2006, 29, 144-148.	0.7	4
476	Antiplatelet Drug Resistance and Drug-Drug Interactions: Role of Cytochrome P450 3A4. <i>Pharmaceutical Research</i> , 2006, 23, 2691-2708.	1.7	41
477	The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 22, 103-110.	1.0	63
478	How to revascularize patients with diabetes mellitus. <i>Clinical Research in Cardiology</i> , 2006, 95, 195-203.	1.5	16
480	Use of antiplatelet drugs in secondary prevention in patients with atherothrombotic disease. <i>Comprehensive Therapy</i> , 2006, 32, 182-188.	0.2	1
481	Aortic arch atheroma and the risk of stroke. <i>Current Atherosclerosis Reports</i> , 2006, 8, 343-346.	2.0	22
482	Clopidogrel treatment surrounding percutaneous coronary intervention: When should it be started and stopped?. <i>Current Cardiology Reports</i> , 2006, 8, 267-271.	1.3	10
483	Antiplatelet resistance with aspirin and clopidogrel: Is it real and does it matter?. <i>Current Cardiology Reports</i> , 2006, 8, 301-306.	1.3	7
484	Antiplatelet agents and perioperative bleeding. <i>Canadian Journal of Anaesthesia</i> , 2006, 53, S103-S112.	0.7	56
485	Endovascular Popliteal Aneurysm Repair: Are the Results Comparable to Open Surgery?. <i>European Journal of Vascular and Endovascular Surgery</i> , 2006, 32, 149-154.	0.8	55
486	Variability in Responsiveness to Clopidogrel in Patients with Intermittent Claudication. <i>European Journal of Vascular and Endovascular Surgery</i> , 2006, 32, 71-75.	0.8	12
487	Clopidogrel Loading Dose (300 Versus 600 mg) Strategies for Patients With Stable Angina Pectoris Subjected to Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2006, 97, 984-989.	0.7	39
488	Outcome of Percutaneous Coronary Intervention in Unstable Angina Pectoris Versus Stable Angina Pectoris in Two Different Time Periods. <i>American Journal of Cardiology</i> , 2006, 98, 447-452.	0.7	10
489	Onset and Offset of Platelet Inhibition After High-Dose Clopidogrel Loading and Standard Daily Therapy Measured by a Point-of-Care Assay in Healthy Volunteers. <i>American Journal of Cardiology</i> , 2006, 98, 681-684.	0.7	130

#	ARTICLE	IF	CITATIONS
490	Effectiveness and Safety of Glycoprotein IIb/IIIa Inhibitors and Clopidogrel Alone and in Combination in Non-ST-Segment Elevation Myocardial Infarction (from the National Registry of Myocardial) Tj ETQq0 0 0 rgBTd/Overlocku10 Tf 50 7		
491	Effect of Clopidogrel Plus Aspirin on ST Segments in Patients With ST-Elevation Acute Myocardial Infarction. American Journal of Cardiology, 2006, 98, 1435-1438.	0.7	0
492	Clopidogrel Response Variability, Resistance, or Both?. American Journal of Cardiology, 2006, 98, S18-S24.	0.7	38
493	Critical Pathways Using Platelet Testing to Potentially Optimize the Use of Oral Antiplatelet Therapy. American Journal of Cardiology, 2006, 98, S33-S38.	0.7	7
495	Antiagregaci3n oral e intervencionismo coronario percut4neo. Revista Espanola De Cardiologia Suplementos, 2006, 6, 49H-56H.	0.2	0
496	Newer Pharmacotherapy in Patients Undergoing Percutaneous Coronary Interventions: A Guide for Pharmacists and Other Health Care Professionals. Pharmacotherapy, 2006, 26, 1537-1556.	1.2	16
497	Clopidogrel-Induced Hepatotoxicity and Fever. Pharmacotherapy, 2006, 26, 1023-1026.	1.2	18
498	ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention" summary article: A report of the American college of cardiology/American heart association task force on practice guidelines(ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary) Tj ETQq1 1 0.784314 45 gBT /Ove	0.7	45
499	Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2006, 68, 56-61.	0.7	68
500	Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID)"A single-center study comparing Cypher4,4 sirolimus-eluting with Taxus4,4 paclitaxel-eluting stents. Catheterization and Cardiovascular Interventions, 2006, 68, 663-668.	0.7	10
501	Day case transradial coronary angioplasty: A four-year single-center experience. Catheterization and Cardiovascular Interventions, 2006, 68, 549-553.	0.7	46
502	The role of covered stents: More than an occasional cameo?. Catheterization and Cardiovascular Interventions, 2006, 68, 21-26.	0.7	8
503	Triple antiplatelet treatment in patients presenting4with non-ST-segment elevation acute4coronary syndromes. Country Review Ukraine, 2006, 8, G59-G63.	0.8	2
504	Clopidogrel in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention. Expert Opinion on Pharmacotherapy, 2006, 7, 1669-1673.	0.9	0
505	A point-of-care assay to measure platelet aggregation in patients taking clopidogrel. Future Cardiology, 2006, 2, 255-267.	0.5	1
506	Antiplatelet therapy: current strategies and future trends. Future Cardiology, 2006, 2, 343-366.	0.5	31
507	Perioperative in-stent thrombosis after lung resection performed within 3 months of coronary stenting4. European Journal of Cardio-thoracic Surgery, 2006, 30, 793-796.	0.6	33
508	Pretreatment with intracoronary adenosine reduces the incidence of myonecrosis after non-urgent percutaneous coronary intervention: a prospective randomized study. European Heart Journal, 2006, 28, 19-25.	1.0	47

#	ARTICLE	IF	CITATIONS
509	Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. <i>European Heart Journal</i> , 2006, 27, 2420-2425.	1.0	453
510	Should high risk patients receive clopidogrel as well as aspirin post coronary arterial bypass grafting?. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2006, 5, 755-760.	0.5	7
511	Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study. <i>European Journal of Cardio-thoracic Surgery</i> , 2006, 29, 190-195.	0.6	80
512	Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study. <i>Postgraduate Medical Journal</i> , 2006, 82, 404-410.	0.9	35
513	Thromboelastography: Potential bedside tool to assess the effects of antiplatelet therapy?. <i>Platelets</i> , 2006, 17, 385-392.	1.1	74
514	A Randomized Study Comparing Same-Day Home Discharge and Abciximab Bolus Only to Overnight Hospitalization and Abciximab Bolus and Infusion After Transradial Coronary Stent Implantation. <i>Circulation</i> , 2006, 114, 2636-2643.	1.6	315
515	Is Clopidogrel Cardiovascular Medicine's Double-Edged Sword?. <i>Circulation</i> , 2006, 113, 1638-1640.	1.6	21
516	Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment. <i>Heart</i> , 2006, 92, 49-51.	1.2	18
517	Coronary Revascularization in Diabetic Chronic Kidney Disease/End-Stage Renal Disease: A Nephrologist's Perspective. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 209-220.	2.2	16
518	Clopidogrel Resistance: Myth or Reality?. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2006, 11, 47-53.	1.0	30
519	Clopidogrel Withdrawal Is Associated With Proinflammatory and Prothrombotic Effects in Patients With Diabetes and Coronary Artery Disease. <i>Diabetes</i> , 2006, 55, 780-784.	0.3	146
520	AGI-1067: A Novel Vascular Protectant for Prevention of Restenosis. <i>Annals of Pharmacotherapy</i> , 2006, 40, 66-73.	0.9	11
521	Clopidogrel resistance: fact and fiction. <i>Future Cardiology</i> , 2006, 2, 215-228.	0.5	19
522	Bradykinin and Its Metabolite Bradykinin 1-5 Inhibit Thrombin-Induced Platelet Aggregation in Humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 318, 1287-1292.	1.3	38
523	ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary Article. <i>Circulation</i> , 2006, 113, 156-175.	1.6	987
524	Upper gastrointestinal haemorrhage complicating antiplatelet treatment with aspirin and/or clopidogrel: Where we are now?. <i>Platelets</i> , 2006, 17, 1-6.	1.1	48
525	Safety of Coronary Sirolimus-Eluting Stents in Daily Clinical Practice. <i>Circulation</i> , 2006, 113, 1434-1441.	1.6	316
526	Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. <i>European Heart Journal</i> , 2006, 27, 1166-1173.	1.0	513

#	ARTICLE	IF	CITATIONS
527	Clopidogrel in Patients With Acute Coronary Syndromes: Learning From Clinical Practice. Archives of Internal Medicine, 2006, 166, 2292.	4.3	1
528	Clopidogrel Treatment Prior to Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2006, 295, 1581.	3.8	9
529	Clopidogrel resistance / Clopidogrel-Resistenz. Das Medizinische Laboratorium, 2006, 30, 310-316.	0.0	2
530	Addition of clopidogrel to aspirin, but not early use of metoprolol, improved overall outcome in acute myocardial infarction. Evidence-Based Medicine, 2006, 11, 82-83.	0.6	1
531	Abciximab in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment<SUBTITLE>The ISAR-REACT 2 Randomized Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2006, 295, 1531.	3.8	682
532	Should clopidogrel be stopped prior to urgent cardiac surgery?. Interactive Cardiovascular and Thoracic Surgery, 2006, 5, 630-636.	0.5	19
533	Clopidogrel Response Variability and Future Therapies. Circulation, 2006, 114, e600-6.	1.6	106
534	Antiplatelet Therapy after Percutaneous Coronary Intervention. Cerebrovascular Diseases, 2006, 21, 25-34.	0.8	14
535	The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes. Circulation, 2006, 114, 2850-2870.	1.6	346
536	Antiplatelet therapy and the vascular tree. Heart, 2006, 92, 3-4.	1.2	24
537	Drug Insight: clopidogrel nonresponsiveness. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 387-395.	3.3	105
538	Coronary stents and perioperative anti-platelet regimen: dilemma of bleeding and stent thrombosis. British Journal of Anaesthesia, 2006, 96, 675-677.	1.5	53
539	The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease. Expert Opinion on Drug Safety, 2006, 5, 815-826.	1.0	17
540	Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. New England Journal of Medicine, 2006, 354, 1706-1717.	13.9	2,582
541	PAR4, but Not PAR1, Signals Human Platelet Aggregation via Ca ²⁺ Mobilization and Synergistic P2Y ₁₂ Receptor Activation. Journal of Biological Chemistry, 2006, 281, 26665-26674.	1.6	99
542	The cost-effectiveness of clopidogrel: a review by indication. Expert Review of Pharmacoeconomics and Outcomes Research, 2006, 6, 123-130.	0.7	0
543	The 5-Year Projection on the Future of Interventional Cardiology. The American Heart Hospital Journal, 2006, 4, 195-201.	0.2	3
544	Aspirin and clopidogrel resistance: an emerging clinical entity. European Heart Journal, 2006, 27, 647-654.	1.0	286

#	ARTICLE	IF	CITATIONS
545	Determination of Clopidogrel Resistance by Whole Blood Platelet Aggregometry and Inhibitors of the P2Y12 Receptor. <i>Clinical Chemistry</i> , 2006, 52, 383-388.	1.5	67
546	Effect of Clopidogrel Premedication in Off-Pump Cardiac Surgery. <i>Circulation</i> , 2006, 113, 1667-1674.	1.6	112
547	Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. <i>European Heart Journal</i> , 2006, 27, 1038-1047.	1.0	688
549	Clopidogrel: a pharmacoeconomic review. <i>Journal of Medical Economics</i> , 2007, 10, 553-571.	1.0	0
550	Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. <i>European Heart Journal</i> , 2007, 29, 277-278.	1.0	190
551	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-“ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2007, 116, e148-304.	1.6	1,247
552	Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 939-953.	0.6	1
553	Drug-Eluting Stents: Can We Move Beyond Stent Thrombosis?. <i>The American Heart Hospital Journal</i> , 2007, 5, 155-158.	0.2	2
554	Outcomes of Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention With Drug-Eluting Stents for Patients With Multivessel Coronary Artery Disease. <i>Circulation</i> , 2007, 116, 1200-6.	1.6	134
555	Late Coronary Stent Thrombosis. <i>Circulation</i> , 2007, 116, 1952-1965.	1.6	218
556	Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. <i>European Heart Journal</i> , 2007, 28, 726-732.	1.0	270
557	Aggressive antiplatelet strategies: time to reconsider?. <i>European Heart Journal</i> , 2007, 28, 2183-2184.	1.0	9
558	A comparison between coronary artery bypass grafting surgery and drug eluting stent for the treatment of unprotected left main coronary artery disease in elderly patients (aged ≥ 75 years). <i>European Heart Journal</i> , 2007, 28, 2714-2719.	1.0	82
559	Pharmacological antithrombotic adjuncts to percutaneous coronary intervention. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 759-776.	0.9	1
560	The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis. <i>Country Review Ukraine</i> , 2007, 9, D10-D19.	0.8	1
561	Efficacy and Safety of Clopidogrel 600 mg Administered Pre-Hospitally to Improve Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction (CIPAMI): Study Rationale and Design. <i>Cardiology</i> , 2007, 108, 265-272.	0.6	25
562	Combination Antiplatelet Therapy with Aspirin and Clopidogrel: The Role of Antecedent and Concomitant Doses of Aspirin. <i>Cardiology</i> , 2007, 107, 307-312.	0.6	4
563	PCI for Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2007, 357, 414-418.	13.9	36

#	ARTICLE	IF	CITATIONS
564	A Day in the Life of Oscar the Cat. <i>New England Journal of Medicine</i> , 2007, 357, 328-329.	13.9	40
565	Does prolonged clopidogrel therapy improve outcome in patients with drug-eluting or bare-metal stents?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 302-303.	3.3	1
566	Clopidogrel use with stenting. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1399-1402.	0.9	1
567	Recombinant nematode anticoagulant protein c2 in non-ST segment elevation acute coronary syndrome and beyond. <i>Future Cardiology</i> , 2007, 3, 365-375.	0.5	3
568	A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. <i>European Heart Journal</i> , 2007, 28, 1814-1819.	1.0	198
569	An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. <i>European Heart Journal</i> , 2007, 28, 2200-2207.	1.0	68
570	Drug evaluation of clopidogrel in patients with ischemic stroke. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2825-2838.	0.9	8
571	Drug-Eluting Stents: The Next Chapter of the Coronary Stent Saga. <i>The American Heart Hospital Journal</i> , 2007, 5, 173-176.	0.2	0
572	Antithrombotic treatment for peripheral arterial disease. <i>Heart</i> , 2007, 93, 303-308.	1.2	19
573	Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2007, 14, 312-318.	3.1	110
574	Clopidogrel: an updated and comprehensive review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 621-631.	1.5	16
575	Coronary artery stents and non-cardiac surgery. <i>British Journal of Anaesthesia</i> , 2007, 98, 560-574.	1.5	109
576	Secondary Prevention of Stroke and Transient Ischemic Attack. <i>Circulation</i> , 2007, 115, 1615-1621.	1.6	53
577	Incidence and Predictors of Drug-Eluting Stent Thrombosis During and After Discontinuation of Thienopyridine Treatment. <i>Circulation</i> , 2007, 116, 745-754.	1.6	430
578	Effect of Antiplatelet Therapy on Thromboembolic Complications of Elective Coil Embolization of Cerebral Aneurysms. <i>American Journal of Neuroradiology</i> , 2007, 28, 1778-1782.	1.2	141
579	Clopidogrel and Long-term Outcomes After Drug-Eluting Stent Implantation. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1769.	3.8	2
580	Clopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent Implantation. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 159.	3.8	778
581	Brain Injury Secondary to Carotid Intervention. <i>Journal of Endovascular Therapy</i> , 2007, 14, 219-231.	0.8	14

#	ARTICLE	IF	CITATIONS
582	Usefulness of Antiplatelet Drugs in Ischaemic Stroke Prevention – Update on New Trials. <i>Cerebrovascular Diseases</i> , 2007, 24, 112-115.	0.8	0
583	Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease. <i>Circulation</i> , 2007, 115, 2196-2207.	1.6	191
584	Drug-Eluting Stent Update 2007. <i>Circulation</i> , 2007, 116, 961-968.	1.6	58
585	Early percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction: results of two German multicentre registries (ACOS and GOAL). <i>Acute Cardiac Care</i> , 2007, 9, 97-103.	0.2	3
586	Editorial [PCI and Stable Coronary Heart Disease - COURAGE to Change Our Minds?]. <i>Current Vascular Pharmacology</i> , 2007, 5, 173-174.	0.8	1
587	Role of Clopidogrel in Managing Atherothrombotic Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2007, 146, 434.	2.0	38
588	Cilostazol Could Ameliorate Platelet Responsiveness to Clopidogrel in Patients Undergoing Primary Percutaneous Coronary Intervention. <i>Circulation Journal</i> , 2007, 71, 1867-1872.	0.7	48
589	Effects of Continuous Administration of Clopidogrel Before Off-Pump Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome A Propensity Score Analysis. <i>Circulation Journal</i> , 2007, 72, 626-632.	0.7	25
590	Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. , 2007, , CD005158.		15
592	Multivessel Percutaneous Coronary Intervention in Chinese Patients with Acute Myocardial Infarction and Simple Nonculprit Arteries. <i>American Journal of the Medical Sciences</i> , 2007, 333, 376-380.	0.4	9
593	The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin. <i>Thrombosis and Haemostasis</i> , 2007, 98, 201-209.	1.8	32
594	The role of clopidogrel in the management of ischemic heart disease. <i>Current Opinion in Cardiology</i> , 2007, 22, 273-279.	0.8	13
595	Clopidogrel Desensitization Protocol for the Treatment of Thienopyridine Hypersensitivity. <i>Critical Pathways in Cardiology</i> , 2007, 6, 26-29.	0.2	13
596	Management of patients with cardiac stents undergoing noncardiac surgery. <i>Current Opinion in Anaesthesiology</i> , 2007, 20, 274-278.	0.9	23
597	Drug-Eluting Stents. <i>Cardiology in Review</i> , 2007, 15, 1-12.	0.6	37
598	Case Report on Clopidogrel Rash After Coronary Placement of a Paclitaxol-Coated Stent. <i>Critical Pathways in Cardiology</i> , 2007, 6, 24-25.	0.2	3
599	Hematologic Adverse Effects of Clopidogrel. <i>American Journal of Therapeutics</i> , 2007, 14, 106-112.	0.5	28
600	The conundrum of late and very late stent thrombosis following drug-eluting stent implantation. <i>Current Opinion in Cardiology</i> , 2007, 22, 565-571.	0.8	31

#	ARTICLE	IF	CITATIONS
601	Therapeutic Benefit of Low-Dose Clopidogrel in Patients Undergoing Carotid Surgery Is Linked to Variability in the Platelet Adenosine Diphosphate Response and Patients' Weight. <i>Stroke</i> , 2007, 38, 2464-2469.	1.0	13
602	Antiplatelet therapy in patients undergoing coronary stent implantation: Italian Society of Interventional Cardiology consensus document. <i>Journal of Cardiovascular Medicine</i> , 2007, 8, 782-791.	0.6	4
603	Platelet function in clopidogrel-treated patients with acute coronary syndrome. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 335-339.	0.5	39
604	Antiplatelet therapy in type 2 diabetes mellitus. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2007, 14, 124-131.	1.2	43
605	Very late paclitaxel-eluting stent thrombosis despite 21 months of clopidogrel treatment after percutaneous coronary intervention. <i>Journal of Cardiovascular Medicine</i> , 2007, 8, 625-628.	0.6	2
606	Effect of Clopidogrel Premedication in Off-Pump Cardiac Surgery: Are We Forfeiting the Benefits of Reduced Hemorrhagic Sequelae?. <i>Yearbook of Cardiology</i> , 2007, 2007, 264-266.	0.0	0
608	Current incidence and clinical outcomes of bivalirudin administration among patients undergoing primary coronary intervention for stent thrombosis elevation acute myocardial infarction. <i>Coronary Artery Disease</i> , 2007, 18, 141-148.	0.3	13
609	Point-of-Care Monitoring for Optimal Antiplatelet Therapy in Acute Clinical Settings. <i>Point of Care</i> , 2007, 6, 208-212.	0.5	1
610	Use of Antiplatelet Drugs in Secondary Prevention in Older Persons With Atherothrombotic Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2007, 62, 518-524.	1.7	4
611	Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel. <i>Journal of Cardiovascular Pharmacology</i> , 2007, 50, 555-562.	0.8	159
612	Dual antiplatelet therapy in high-risk patients. <i>Country Review Ukraine</i> , 2007, 9, D3-D9.	0.8	8
613	Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12® rapid analyzer: The VERify Thrombosis risk ASsessment (VERITAS) study. <i>Thrombosis Research</i> , 2007, 119, 277-284.	0.8	198
614	Whole blood aggregometry for evaluation of the antiplatelet effects of clopidogrel. <i>Thrombosis Research</i> , 2007, 119, 285-291.	0.8	27
615	Clopidogrel resistance?. <i>Thrombosis Research</i> , 2007, 120, 311-321.	0.8	151
616	The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment. <i>Thrombosis Research</i> , 2007, 120, 353-359.	0.8	25
617	Gastroduodenal mucosal injury in patients on antiplatelet therapy. <i>Thrombosis Research</i> , 2007, 120, 465-469.	0.8	12
618	Assessment of clopidogrel responsiveness: Measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. <i>Thrombosis Research</i> , 2007, 121, 107-115.	0.8	51
619	Antiplatelet agents make a comeback in ST-elevation myocardial infarction. <i>American Heart Journal</i> , 2007, 154, 603-606.	1.2	0

#	ARTICLE	IF	CITATIONS
620	Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: A Clopidogrel for the Reduction of Events During Observation (CREDO) substudy. <i>American Heart Journal</i> , 2007, 153, 36-41.	1.2	14
621	Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort. <i>American Heart Journal</i> , 2007, 153, 289-295.	1.2	50
622	Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease. <i>American Heart Journal</i> , 2007, 153, 371-377.	1.2	9
623	Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: Evidence from a meta-regression. <i>American Heart Journal</i> , 2007, 153, 587-593.	1.2	16
624	Acute myocardial infarction and drug-eluting stents: A green light for their use or time for measured restraint?. <i>American Heart Journal</i> , 2007, 153, 719-721.	1.2	15
625	Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis. <i>American Heart Journal</i> , 2007, 154, 221-231.	1.2	390
626	Globalization of cardiovascular clinical research: The balance between meeting medical needs and maintaining scientific standards. <i>American Heart Journal</i> , 2007, 154, 232-238.	1.2	43
627	Optimal platelet inhibition in patients undergoing PCI: Data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study. <i>American Heart Journal</i> , 2007, 154, 344.e1-344.e5.	1.2	10
628	The impact of oral antiplatelet responsiveness on the long-term prognosis after coronary stenting. <i>American Heart Journal</i> , 2007, 154, 676-681.	1.2	23
629	Dual antiplatelet agent failure: A new syndrome or clinical nonentity?. <i>American Heart Journal</i> , 2007, 154, 732-735.	1.2	12
630	Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease. <i>American Heart Journal</i> , 2007, 154, 694.e1-694.e7.	1.2	22
631	Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome. <i>American Heart Journal</i> , 2007, 154, 846-851.	1.2	45
632	Prolonged application of clopidogrel reduces inflammation after percutaneous coronary intervention in the porcine model. <i>Cardiovascular Revascularization Medicine</i> , 2007, 8, 183-188.	0.3	16
633	Abciximab offers greater benefits to insulin-dependent diabetic patients undergoing coronary stent implantation. <i>Cardiovascular Revascularization Medicine</i> , 2007, 8, 175-182.	0.3	6
634	Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: A European model based on the CLARITY and COMMIT trials. <i>Clinical Therapeutics</i> , 2007, 29, 1184-1202.	1.1	20
635	The Effect of Preoperative Clopidogrel on Bleeding After Coronary Artery Bypass Surgery. <i>Journal of Surgical Education</i> , 2007, 64, 88-92.	1.2	49
637	A tale of two stents: perioperative management of patients with drug-eluting coronary stents. <i>Journal of Clinical Anesthesia</i> , 2007, 19, 386-396.	0.7	15
638	Risks associated with drug-eluting stents – Authors' reply. <i>Lancet</i> , The, 2007, 369, 1785-1786.	6.3	0

#	ARTICLE	IF	CITATIONS
639	Percutaneous Coronary Interventions and Antiplatelet Therapy in the Perioperative Period. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2007, 21, 436-442.	0.6	8
640	Pro: Continuation of Aspirin/Clopidogrel for Cardiac Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2007, 21, 602-605.	0.6	1
641	Con: Continuation of Aspirin/Clopidogrel for Cardiac Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2007, 21, 606-609.	0.6	2
642	Safety of the cardiac triple therapy: The experience of the Quebec Heart Institute. <i>Canadian Journal of Cardiology</i> , 2007, 23, 80B-83B.	0.8	2
643	Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. <i>European Heart Journal</i> , 2007, 28, 1598-1660.	1.0	1,699
644	Variability in Individual Responsiveness to Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1505-1516.	1.2	886
645	Antiplatelet Therapy for Atherothrombotic Disease: An Update for the Primary Care Physician. <i>Mayo Clinic Proceedings</i> , 2007, 82, 583-593.	1.4	20
646	Does Glycoprotein IIIa Gene (PIA) Polymorphism Influence Clopidogrel Resistance?. <i>Drugs and Aging</i> , 2007, 24, 345-350.	1.3	11
647	Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?. <i>European Heart Journal</i> , 2007, 28, 1717-1722.	1.0	121
648	Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. <i>British Journal of Anaesthesia</i> , 2007, 99, 316-328.	1.5	286
650	Platelet Inhibitors and Monitoring Platelet Function: Implications for Bleeding. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 51-63.	0.9	5
651	Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines. <i>Current Medical Research and Opinion</i> , 2007, 23, 1453-1462.	0.9	16
652	Rapid Desensitization Protocols for Patients with Cardiovascular Disease and Aspirin Hypersensitivity in an Era of Dual Antiplatelet Therapy. <i>Annals of Pharmacotherapy</i> , 2007, 41, 61-67.	0.9	27
653	Long-Term Clopidogrel Therapy in Patients Receiving Percutaneous Coronary Intervention. <i>Pharmacoeconomics</i> , 2007, 25, 769-782.	1.7	20
654	Oral Antiplatelet Therapy in Secondary Prevention of Cardiovascular Events. <i>Pharmacoeconomics</i> , 2007, 25, 1063-1082.	1.7	21
655	Clopidogrel: a guide to its use in the prevention of thrombosis. <i>Drugs and Therapy Perspectives</i> , 2007, 23, 1-4.	0.3	0
656	The Role of Clopidogrel in Revascularized and Nonrevascularized Patients with Acute Coronary Syndromes. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 159-168.	1.0	4
657	Incremental Effect of Clopidogrel on Important Outcomes in Patients with Cardiovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 289-297.	1.0	55

#	ARTICLE	IF	CITATIONS
658	ADP Receptor Antagonism. American Journal of Cardiovascular Drugs, 2007, 7, 423-432.	1.0	52
659	Clopidogrel poor responders: An objective definition based on Bayesian classification. Platelets, 2007, 18, 428-435.	1.1	25
660	Clopidogrel resistance – The cardiologist's perspective. Platelets, 2007, 18, 175-181.	1.1	12
661	Clopidogrel anti-platelet effect: An evaluation by optical aggregometry, impedance aggregometry, and the Platelet Function Analyzer (PFA-100®). Platelets, 2007, 18, 491-496.	1.1	50
662	Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease. Circulation, 2007, 115, 708-716.	1.6	435
663	Clinical Aspects of Platelet Inhibitors and Thrombus Formation. Circulation Research, 2007, 100, 1261-1275.	2.0	327
665	Management of non-ST-Segment Elevation Myocardial Infarction. Medical Clinics of North America, 2007, 91, 683-700.	1.1	3
666	Acute Coronary Syndromes: Unstable Angina/Non-ST Elevation Myocardial Infarction. Critical Care Clinics, 2007, 23, 709-735.	1.0	10
668	Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. Revista Espanola De Cardiologia, 2007, 60, 1070.e1-1070.e80.	0.6	29
670	Clopidogrel. Drugs, 2007, 67, 613-646.	4.9	67
671	Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert Review of Cardiovascular Therapy, 2007, 5, 45-55.	0.6	76
672	Benefits of Drug-Eluting Stents in Coronary Heart Disease Treatment with Emphasis on the Diabetic Subgroup. Heart Lung and Circulation, 2007, 16, 7-9.	0.2	0
673	Contemporary Treatment of In-Stent Restenosis and the Incidence of Recurrent In-Stent Restenosis in the Era of Drug-Eluting Stents. Heart Lung and Circulation, 2007, 16, 269-273.	0.2	4
674	Clopidogrel Resistance. Heart Lung and Circulation, 2007, 16, S17-S28.	0.2	24
675	Impact of Platelet Reactivity After Clopidogrel Administration on Drug-Eluting Stent Thrombosis. Journal of the American College of Cardiology, 2007, 49, 2312-2317.	1.2	607
676	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2007, 50, e1-e157.	1.2	1,587
677	Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial. Journal of the American College of Cardiology, 2007, 49, 1982-1988.	1.2	752
678	Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2007, 50, 1844-1851.	1.2	471

#	ARTICLE	IF	CITATIONS
679	AZD6140. Expert Opinion on Investigational Drugs, 2007, 16, 225-229.	1.9	50
680	Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 2007, 357, 2001-2015.	13.9	5,933
681	Treatment with Drug-Eluting Stents. , 2007, , 135-156.		0
685	Evolução cl�nica tardia de pacientes multiarteriais tratados por revasculariza�o percut�nea e cir�rgica. Revista Brasileira De Cardiologia Invasiva, 2007, 15, 35-43.	0.1	1
686	Pharmacoeconomic Analysis of Clopidogrel in Secondary Prevention of Coronary Artery Disease. Journal of Managed Care Pharmacy, 2007, 13, 326-336.	2.2	14
687	Aspirin and Clopidogrel Resistance in Drug Eluting Stent Era. Korean Circulation Journal, 2007, 37, 135.	0.7	7
688	Pacientes com angina inst�vel tratados por meio de interven�es coronarianas percut�neas no novo mil�nio: o que os caracteriza?. Arquivos Brasileiros De Cardiologia, 2007, 88, 26-30.	0.3	1
689	ADP Receptor Antagonists. , 2007, , 1127-1144.		13
690	A novel P2Y12 adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models. Thrombosis and Haemostasis, 2007, 97, 847-855.	1.8	39
691	Perioperative Complications in Patients with Drug-Eluting Stents: A Three-Year Audit at Geelong Hospital. Anaesthesia and Intensive Care, 2007, 35, 939-944.	0.2	16
692	Recurrent very late stent thrombosis after bare-metal stent implantation. Catheterization and Cardiovascular Interventions, 2007, 70, 52-54.	0.7	8
693	Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatid in coronary stent intervention; Results from the ESPRIT trial. Catheterization and Cardiovascular Interventions, 2007, 70, 44-51.	0.7	10
694	Stent thrombosis with drug-eluting stents: A re-examination of the evidence. Catheterization and Cardiovascular Interventions, 2007, 69, 782-789.	0.7	25
695	Late or very late stent thrombosis can also occur with bare metal stents. Catheterization and Cardiovascular Interventions, 2007, 70, 229-232.	0.7	12
696	Oral antiplatelet therapy for percutaneous coronary revascularization. Catheterization and Cardiovascular Interventions, 2007, 69, 637-642.	0.7	5
697	Overview of the 2006 Food and Drug Administration Circulatory System Devices Panel meeting on drug-eluting stent thrombosis. Catheterization and Cardiovascular Interventions, 2007, 69, 1064-1074.	0.7	62
698	Anti�platelet and anti�thrombotic approaches in patients undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2007, 70, 388-406.	0.7	16
699	Platelet function and antiplatelet therapy. British Journal of Surgery, 2007, 94, 674-682.	0.1	31

#	ARTICLE	IF	CITATIONS
700	Platelet-neutrophil-interactions: Linking hemostasis and inflammation. <i>Blood Reviews</i> , 2007, 21, 99-111.	2.8	544
701	Antithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy. <i>Thrombosis Journal</i> , 2007, 5, 11.	0.9	2
702	Utilisation review of clopidogrel: are they used under the FDA-approved indications?. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 1031-1037.	0.9	2
703	Myocardial infarction: contemporary management strategies. <i>Journal of Internal Medicine</i> , 2007, 262, 59-77.	2.7	15
704	Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease. <i>European Journal of Clinical Investigation</i> , 2007, 37, 157-164.	1.7	15
705	Optimizing Platelet P2Y12 Inhibition for Patients Undergoing PCI. <i>Cardiovascular Drug Reviews</i> , 2007, 25, 188-203.	4.4	29
706	Prasugrel: A Novel Thienopyridine Antiplatelet Agent. A Review of Preclinical and Clinical Studies and the Mechanistic Basis for Its Distinct Antiplatelet Profile. <i>Cardiovascular Drug Reviews</i> , 2007, 25, 357-374.	4.4	227
707	Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: a report of three cases. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 879-881.	1.9	18
708	Evaluation of the platelet response to clopidogrel with light transmittance aggregometry: peak aggregation or late aggregation?. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 884-886.	1.9	23
709	Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1839-1847.	1.9	180
710	Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 2429-2436.	1.9	668
711	The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 54-61.	1.9	200
712	Clinical use of clopidogrel in acute coronary syndrome. <i>International Journal of Clinical Practice</i> , 2007, 61, 473-481.	0.8	7
713	FDA Advisory Panel on the Safety and Efficacy of Drug-Eluting Stents: Summary of Findings and Recommendations. <i>Journal of Interventional Cardiology</i> , 2007, 20, 425-446.	0.5	23
714	Non-ST segment elevation acute coronary syndromes: Treatment guidelines for the nurse practitioner. <i>Journal of the American Academy of Nurse Practitioners</i> , 2007, 19, 277-289.	1.4	2
715	Contemporary Issues in Clopidogrel Therapy: New Evidence Shaping Clinical Practice. <i>Pharmacotherapy</i> , 2007, 27, 553-563.	1.2	10
716	Risk of Major Bleeding with Concomitant Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients Receiving Long-Term Warfarin Therapy. <i>Pharmacotherapy</i> , 2007, 27, 691-696.	1.2	82
717	Recombinant Activated Factor VII Treatment of Retroperitoneal Hematoma in a Patient with Renal Failure Receiving Enoxaparin and Clopidogrel. <i>Pharmacotherapy</i> , 2007, 27, 755-759.	1.2	21

#	ARTICLE	IF	CITATIONS
718	Perioperative use of anti-platelet drugs. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2007, 21, 241-256.	1.7	61
719	The Evolving Pattern of Symptomatic Coronary Artery Disease in the United States and Canada: Baseline Characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial. <i>American Journal of Cardiology</i> , 2007, 99, 208-212.	0.7	70
720	Assessment of Bleeding Events in Clinical Trials—Proposal of a New Classification. <i>American Journal of Cardiology</i> , 2007, 99, 288-290.	0.7	68
721	Long-Term Versus Short-Term Clopidogrel Therapy in Patients Undergoing Coronary Stenting (from the Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 349-352.	0.7	29
722	Gender-Based Outcomes in Percutaneous Coronary Intervention With Drug-Eluting Stents (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 626-631.	0.7	68
723	Analysis of 36 Reported Cases of Late Thrombosis in Drug-Eluting Stents Placed in Coronary Arteries. <i>American Journal of Cardiology</i> , 2007, 99, 1039-1043.	0.7	60
724	Efficacy of Drug Therapy in the Secondary Prevention of Cardiovascular Disease and Stroke. <i>American Journal of Cardiology</i> , 2007, 99, S1-S35.	0.7	20
726	Effects of preoperative aspirin and clopidogrel therapy on perioperative blood loss and blood transfusion requirements in patients undergoing off-pump coronary artery bypass graft surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2007, 134, 59-64.	0.4	59
727	Criterios económicos en la selección de nuevos tratamientos por el cardiólogo clínico. <i>Revista Española De Cardiología Suplementos</i> , 2007, 7, 12C-20C.	0.2	1
728	Towards FASTER treatment of TIA and minor stroke. <i>Lancet Neurology</i> , The, 2007, 6, 941-943.	4.9	3
729	Evolution of Anticoagulant and Antiplatelet Therapy: Benefits and Risks of Contemporary Pharmacologic Agents and Their Implications for Myonecrosis and Bleeding in Percutaneous Coronary Intervention. <i>Clinical Cardiology</i> , 2007, 30, II4-II15.	0.7	3
730	A case report of simultaneous thrombosis of two coronary artery stents in association with clopidogrel resistance. <i>Clinical Cardiology</i> , 2007, 30, 200-203.	0.7	10
731	Contemporary use of clopidogrel in patients with coronary artery disease. <i>Current Cardiology Reports</i> , 2007, 9, 257-263.	1.3	5
732	Management of coronary artery disease in patients with type 2 diabetes mellitus. <i>Current Cardiology Reports</i> , 2007, 9, 264-271.	1.3	7
733	New antiplatelet therapies for acute coronary syndromes. <i>Current Cardiology Reports</i> , 2007, 9, 303-311.	1.3	4
734	Aspirin and nonsteroidal anti-inflammatory drug hypersensitivity. <i>Clinical Reviews in Allergy and Immunology</i> , 2007, 32, 97-109.	2.9	24
737	Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. <i>Journal of Thrombosis and Thrombolysis</i> , 2007, 24, 85-91.	1.0	41
738	Reinforcing a Continuum of Care: In-Hospital Initiation of Long-Term Secondary Prevention Following Acute Coronary Syndromes. <i>Cardiovascular Drugs and Therapy</i> , 2007, 21, 375-388.	1.3	14

#	ARTICLE	IF	CITATIONS
739	Current strategies for ischemic stroke prevention: role of multimodal combination therapies. <i>Journal of Neurology</i> , 2007, 254, 1414-1426.	1.8	22
741	Clopidogrel and risk for acute coronary events. <i>Current Atherosclerosis Reports</i> , 2007, 9, 401-408.	2.0	5
743	Optimal management of platelet function after coronary stenting. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2007, 9, 37-45.	0.4	8
744	Is there a role for combinations of antiplatelet agents in stroke prevention?. <i>Current Treatment Options in Neurology</i> , 2007, 9, 442-450.	0.7	1
746	The Antiplatelet Effect of Higher Loading and Maintenance Dose Regimens of Clopidogrel. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 612-619.	1.1	52
747	Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 25, 239-246.	1.0	5
748	Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2008, 35, 593-618.	0.8	50
749	Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 589-597.	0.8	41
752	Aspirin resistance in atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2008, 10, 149-157.	2.0	1
753	Clopidogrel and coronary stents: Risks and benefits. <i>Current Atherosclerosis Reports</i> , 2008, 10, 303-308.	2.0	0
754	Optimal treatment of the diabetic patient with multivessel disease. <i>Current Cardiology Reports</i> , 2008, 10, 272-284.	1.3	1
755	Use of antiplatelet agents to prevent stroke: What is the role for combinations of medications?. <i>Current Neurology and Neuroscience Reports</i> , 2008, 8, 29-34.	2.0	5
756	Antiplatelet therapy in the era of late stent thrombosis. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2008, 10, 12-17.	0.4	4
757	Genetic determinants of responsiveness to antiplatelet therapy. <i>Current Cardiovascular Risk Reports</i> , 2008, 2, 476-484.	0.8	2
758	Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. <i>Clinical Research in Cardiology</i> , 2008, 97, 160-168.	1.5	12
759	Management and outcome of peptic ulcers or erosions in patients receiving a combination of aspirin plus clopidogrel. <i>Journal of Gastroenterology</i> , 2008, 43, 679-686.	2.3	27
760	2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 71, E1-40.	0.7	26
761	Usage patterns and 2-year outcomes with the TAXUS express stent: Results of the US ARRIVE 1 registry. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 433-445.	0.7	39

#	ARTICLE	IF	CITATIONS
762	Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trial. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 917-924.	0.7	3
763	Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention. <i>Clinical Cardiology</i> , 2008, 31, 128-135.	0.7	2
764	Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches. <i>Clinical Cardiology</i> , 2008, 31, 121-127.	0.7	7
765	Antiplatelet Strategies: Evaluating Their Current Role in the Setting of Acute Coronary Syndromes. <i>Clinical Cardiology</i> , 2008, 31, 12-19.	0.7	9
766	Indications for Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Evidence-Based Recommendations for Use. <i>Annals of Pharmacotherapy</i> , 2008, 42, 550-557.	0.9	57
767	Managing antiplatelet therapy in the ACS patient: Straight from the emergency department to you. <i>Journal of Hospital Medicine</i> , 2008, 3, S15-S19.	0.7	0
768	Vulnerable Plaque: Scope of the Problem. <i>Journal of Interventional Cardiology</i> , 2008, 21, 443-451.	0.5	5
769	Using Triple Antiplatelet Therapy in Patients with Non-ST Elevation Acute Coronary Syndrome Managed Invasively: A Cost-Effectiveness Analysis. <i>Value in Health</i> , 2008, 11, 853-861.	0.1	9
770	Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients. <i>Fundamental and Clinical Pharmacology</i> , 2008, 22, 315-321.	1.0	57
771	Novel antithrombotic agents and the risk of bleeding. <i>Transfusion</i> , 2008, 48, 47S-50S.	0.8	1
772	Initiation and persistence with clopidogrel treatment after acute myocardial infarction – a nationwide study. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 875-884.	1.1	28
773	Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2008, 33, 439-449.	0.7	42
774	Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2008, 33, 591-601.	0.7	22
775	Combination Antiplatelet Agents for Secondary Prevention of Ischemic Stroke. <i>Pharmacotherapy</i> , 2008, 28, 1233-1242.	1.2	14
776	Effects of a Waiting Period After Clopidogrel Treatment Before Performing Coronary Artery Bypass Grafting. <i>Pharmacotherapy</i> , 2008, 28, 151-155.	1.2	7
777	Meta-Analysis of the Efficacy and Safety of Clopidogrel Plus Aspirin as Compared to Antiplatelet Monotherapy for the Prevention of Vascular Events. <i>American Journal of Cardiology</i> , 2008, 101, 960-966.	0.7	116
778	Effect of Abciximab on Clinical and Angiographic Restenosis in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2008, 101, 1226-1231.	0.7	5
779	Excess Rates of Nonfatal Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel (Preventing Clinical Events or Chasing) Tj ETQq1 1 0.784314 rgBT /Overlook compensation for U.S. Patent Application P-17232, “Method for Treating Vascular Diseases With Prasugrel.” assigned to Eli Lilly and Company, Indianapolis, Indiana. He has received funding for research studies with clopidogr. <i>American Journal of Cardiology</i> , 2008, 101, 1364-1366.	0.7	14

#	ARTICLE	IF	CITATIONS
780	Relation of Low Response to Clopidogrel Assessed With Point-of-Care Assay to Periprocedural Myonecrosis in Patients Undergoing Elective Coronary Stenting for Stable Angina Pectoris. American Journal of Cardiology, 2008, 101, 1700-1703.	0.7	64
781	Dynamics of Platelet Functional Recovery Following a Clopidogrel Loading Dose in Healthy Volunteers. American Journal of Cardiology, 2008, 102, 790-795.	0.7	28
782	A Perspective on the Efficacy and Safety of Intensive Antiplatelet Therapy in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrelâ€“Thrombolysis in Myocardial Infarction 38. American Journal of Cardiology, 2008, 101, 1367-1370.	0.7	10
783	The Editor's Roundtable: Bare-Metal Stents Versus Drug-Eluting Stentsâ€“Indications and Complications. American Journal of Cardiology, 2008, 102, 32-39.	0.7	0
784	Comparison of Increased Aspirin Dose Versus Combined Aspirin Plus Clopidogrel Therapy in Patients With Diabetes Mellitus and Coronary Heart Disease and Impaired Antiplatelet Response to Low-Dose Aspirin. American Journal of Cardiology, 2008, 102, 396-400.	0.7	20
785	Effect of Prolonged Thienopyridine Use After Drug-Eluting Stent Implantation (from the TAXUS) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 427 Td (0.7	15
786	Comparison of the Impact of Short (<1 Year) and Long-Term (>=1 Year) Clopidogrel Use Following Percutaneous Coronary Intervention on Mortality. American Journal of Cardiology, 2008, 102, 1159-1162.	0.7	32
787	Patterns of Upstream Antiplatelet Therapy Use Before Primary Percutaneous Coronary Intervention for Acute ST-Elevation Myocardial Infarction (from the CRUSADE National Quality Improvement) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 427 Td (0.7	0
788	Incidence of Bleeding and Compliance on Prolonged Dual Antiplatelet Therapy (Aspirin +) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 427 Td (1477-1481.	0.7	23
789	Impact of â€œNuisanceâ€•Bleeding on Clopidogrel Compliance in Patients Undergoing Intracoronary Drug-Eluting Stent Implantation. American Journal of Cardiology, 2008, 102, 1614-1617.	0.7	121
790	Drug-Eluting Stents in the Real World: How Intravascular Ultrasound Can Improve Clinical Outcome. American Journal of Cardiology, 2008, 102, 24J-28J.	0.7	21
791	Reducing the risk of vascular surgery. Current Anaesthesia and Critical Care, 2008, 19, 128-137.	0.3	3
792	ACC/AHA Nonâ€“ST Elevation Myocardial Infarction Guidelines' Revision 2007: Implications for Nursing Practice. Progress in Cardiovascular Nursing, 2008, 23, 53-56.	0.5	0
793	Short- and long-term efficacy of aspirin and clopidogrel for thromboprophylaxis for mechanical heart valves: An in vivo study in swine. Journal of Thoracic and Cardiovascular Surgery, 2008, 136, 908-914.	0.4	17
794	Contemporary Approach to the Diagnosis and Management of Nonâ€“ST-Segment Elevation Acute Coronary Syndromes. Progress in Cardiovascular Diseases, 2008, 50, 311-351.	1.6	16
795	Benefits and limitations of current antiplatelet therapies. American Journal of Health-System Pharmacy, 2008, 65, S5-S10.	0.5	6
797	Safety of Clopidogrel and Aspirin for??Stroke Prevention. Drug Safety, 2008, 31, 449-458.	1.4	4
799	Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin. Journal of the American College of Cardiology, 2008, 51, 256-260.	1.2	890

#	ARTICLE	IF	CITATIONS
800	2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2008, 51, 172-209.	1.2	590
801	The Role of Aspirin in Cardiovascular Prevention. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1829-1843.	1.2	248
802	Clopidogrel 600-Mg Double Loading Dose Achieves Stronger Platelet Inhibition Than Conventional Regimens. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1066-1072.	1.2	65
803	Long-Term Outcomes by Clopidogrel Duration and Stent Type in a Diabetic Population With De Novo Coronary Artery Lesions. <i>Journal of the American College of Cardiology</i> , 2008, 51, 2220-2227.	1.2	110
804	Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2008, 51, 2028-2033.	1.2	314
805	Role of Reticulated Platelets and Platelet Size Heterogeneity on Platelet Activity After Dual Antiplatelet Therapy With Aspirin and Clopidogrel in Patients With Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2008, 52, 743-749.	1.2	302
806	Incidence and Clinical Impact of Dual Nonresponsiveness to Aspirin and Clopidogrel in Patients With Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2008, 52, 734-739.	1.2	189
807	Long-Term Impact of Drug-Eluting Stents Versus Bare-Metal Stents on All-Cause Mortality. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1041-1048.	1.2	41
809	Bleeding Events with Antithrombotic Therapy in Patients with Unstable Angina or non-ST-segment Elevation Myocardial Infarction; Insights from a Large Clinical Practice Registry (GRACE). <i>Heart Lung and Circulation</i> , 2008, 17, 5-8.	0.2	6
810	Flow cytometric assessment of vasodilator-stimulated phosphoprotein: Prognostic value of recurrent cardiovascular events after acute coronary syndromes. <i>Archives of Cardiovascular Diseases</i> , 2008, 101, 743-751.	0.7	8
811	Stent thrombosis in 2008: Definition, predictors, prognosis and treatment. <i>Archives of Cardiovascular Diseases</i> , 2008, 101, 769-777.	0.7	49
812	Survival Benefit With Concomitant Clopidogrel and Glycoprotein IIb/IIIa Inhibitor Therapy at Ad Hoc Percutaneous Coronary Intervention. <i>Mayo Clinic Proceedings</i> , 2008, 83, 995-1001.	1.4	7
813	Diagnosis and Treatment of Non-ST-Segment Elevation Myocardial Infarction. , 2008, , 60-72.		0
814	Successful Treatment of Rotary Pump Thrombus With the Glycoprotein IIb/IIIa Inhibitor Tirofiban. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 925-927.	0.3	53
815	Distal protection device protects microvascular integrity during primary percutaneous intervention in acute myocardial infarction: A prospective, randomized, multicenter trial. <i>International Journal of Cardiology</i> , 2008, 123, 162-168.	0.8	20
816	Cerebellar hematoma complicating 600Âmg loading dose of Clopidogrel in combination with Tirofiban. <i>International Journal of Cardiology</i> , 2008, 127, e170-e171.	0.8	0
817	Prolonged combination anti-platelet therapy following per-cutaneous coronary intervention (PCI) is impractical in the elderly. <i>International Journal of Cardiology</i> , 2008, 125, 268-269.	0.8	0
818	Predictors of outcome in patients undergoing PCI. Results of the RIVIERA study. <i>International Journal of Cardiology</i> , 2008, 129, 379-387.	0.8	70

#	ARTICLE	IF	CITATIONS
820	Antiplatelet Therapy in Acute Coronary Syndromes: The Emergency Physician's Perspective. <i>Journal of Emergency Medicine</i> , 2008, 35, 5-13.	0.3	11
821	Do Patients with Acute Myocardial Infarction Benefit from Treatment with Clopidogrel?. <i>Journal of Emergency Medicine</i> , 2008, 34, 479-483.	0.3	0
822	Multiple antithrombotic agents increase the risk of postoperative hemorrhage in dermatologic surgery. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 810-816.	0.6	41
823	Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: A Clopidogrel as Adjunctive Reperfusion Therapy—Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study. <i>American Heart Journal</i> , 2008, 155, 133-139.	1.2	11
824	Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial. <i>American Heart Journal</i> , 2008, 155, 382-387.	1.2	17
825	The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial. <i>American Heart Journal</i> , 2008, 155, 687-693.	1.2	175
826	Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. <i>American Heart Journal</i> , 2008, 155, 910-917.	1.2	38
827	The economic consequences of non—evidence-based clopidogrel use. <i>American Heart Journal</i> , 2008, 155, 904-909.	1.2	25
828	High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients—A Pravastatin or Atorvastatin Evaluation and Infection Therapy—Thrombolysis in Myocardial Infarction 22 (PROVE IT—TIMI 22) analysis. <i>American Heart Journal</i> , 2008, 155, 954-958.	1.2	33
829	Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: Practical implications, new clinical data, and recommended guideline revisions. <i>American Heart Journal</i> , 2008, 155, 781-790.	1.2	21
830	One-year clinical outcome after abciximab bolus-only compared with abciximab bolus and 12-hour infusion in the Randomized EARly Discharge after Transradial Stenting of Coronary Arteries (EASY) Study. <i>American Heart Journal</i> , 2008, 156, 135-140.	1.2	41
831	Correlates of late and very late thrombosis of drug eluting stents. <i>American Heart Journal</i> , 2008, 156, 141-147.	1.2	31
832	Platelet inhibitor therapy: Current perspectives and emerging novel agents: Introduction. <i>American Heart Journal</i> , 2008, 156, 1S-2S.	1.2	2
833	Current antiplatelet therapies: Benefits and limitations. <i>American Heart Journal</i> , 2008, 156, 3S-9S.	1.2	48
834	ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy. <i>American Journal of Emergency Medicine</i> , 2008, 26, 212-220.	0.7	9
835	Antiplatelet Therapy for Postdischarge Medical Management of Acute Coronary Syndrome. <i>American Journal of Medicine</i> , 2008, 121, 171-178.	0.6	3
836	Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests. <i>Thrombosis Research</i> , 2008, 122, 336-345.	0.8	48
837	Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. <i>Thrombosis Research</i> , 2008, 122, 776-781.	0.8	153

#	ARTICLE	IF	CITATIONS
838	Benefits and risks of clopidogrel use in patients with coronary artery disease: Evidence from randomized studies and registries. <i>Clinical Therapeutics</i> , 2008, 30, 2191-2202.	1.1	11
839	Clopidogrel Treatment Before Coronary Artery Bypass Graft Surgery Increases Postoperative Morbidity and Blood Product Requirements. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2008, 22, 60-66.	0.6	46
840	A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: Results of a double-blind, randomized study. <i>Atherosclerosis</i> , 2008, 196, 689-695.	0.4	75
841	Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. <i>Lancet, The</i> , 2008, 371, 1353-1363.	6.3	420
842	Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis. <i>Lancet, The</i> , 2008, 371, 2134-2143.	6.3	110
843	2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. <i>Circulation</i> , 2008, 117, 261-295.	1.6	715
844	Antiplatelet Agents and Arterial Thrombosis. <i>Cardiology Clinics</i> , 2008, 26, 189-201.	0.9	9
845	Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: A potential antiplatelet therapeutic target. <i>Platelets</i> , 2008, 19, 595-604.	1.1	101
846	Aspirin and Platelet Adenosine Diphosphate Receptor Antagonists in Acute Coronary Syndromes and Percutaneous Coronary Intervention. <i>American Journal of Cardiovascular Drugs</i> , 2008, 8, 91-112.	1.0	21
847	Pharmacologic Inhibition of Platelet Function. <i>American Journal of Cardiovascular Drugs</i> , 2008, 8, 283-295.	1.0	2
849	Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: clinical evidence for and against the combination. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 377-386.	0.9	7
850	Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials. <i>Current Medical Research and Opinion</i> , 2008, 24, 2089-2101.	0.9	20
851	Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy. <i>Platelets</i> , 2008, 19, 104-110.	1.1	36
852	Guideline on antiplatelet and anticoagulation management in cardiac surgery. <i>European Journal of Cardio-thoracic Surgery</i> , 2008, 34, 73-92.	0.6	280
853	Chapter 64 Antithrombotic agents for stroke prevention. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 94, 1277-1294.	1.0	2
854	Platelet Activation and Atherothrombosis. <i>New England Journal of Medicine</i> , 2008, 358, 1638-1639.	13.9	29
855	The use of the VerifyNow system to monitor antiplatelet therapy: A review of the current evidence. <i>Platelets</i> , 2008, 19, 479-488.	1.1	106
856	A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. <i>European Heart Journal</i> , 2008, 29, 2202-2211.	1.0	183

#	ARTICLE	IF	CITATIONS
857	Dual Antiplatelet Therapy Monitoring for Neurointerventional Procedures Using a Point-of-Care Platelet Function Test: A Single-Center Experience. <i>American Journal of Neuroradiology</i> , 2008, 29, 1389-1394.	1.2	126
858	Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 766-780.	3.3	80
859	Safety of drug-eluting stents. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 316-328.	3.3	18
860	2007 Guideline Update for Unstable Angina/Non- σ ST-Segment Elevation Myocardial Infarction: Focus on Antiplatelet and Anticoagulant Therapies. <i>Annals of Pharmacotherapy</i> , 2008, 42, 989-1001.	0.9	14
861	Dual antiplatelet therapy with clopidogrel and aspirin. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 1134-1143.	0.5	9
862	Which patients receiving warfarin can be treated safely with a drug-eluting stent?. <i>Heart</i> , 2008, 94, 275-277.	1.2	1
863	Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad. <i>European Heart Journal</i> , 2008, 29, 1729-1738.	1.0	32
864	European perspective on the use of antiplatelet agents in atherothrombotic disease. <i>European Heart Journal Supplements</i> , 2008, 10, I14-I18.	0.0	1
865	Updating the Chest Pain Algorithm. <i>Critical Pathways in Cardiology</i> , 2008, 7, 211-222.	0.2	6
866	Effect of Clopidogrel on Adhesion Molecules, Hemostasis, and Fibrinolysis in Coronary Heart Disease. <i>Journal of Cardiovascular Pharmacology</i> , 2008, 51, 616-620.	0.8	4
867	Antiplatelet therapy in acute coronary syndromes. <i>Country Review Ukraine</i> , 2008, 10, A4-A12.	0.8	2
868	Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. <i>European Heart Journal</i> , 2008, 29, 1504-1509.	1.0	45
869	Clopidogrel pre-treatment in stable angina: for all patients \geq 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. <i>European Heart Journal</i> , 2008, 29, 1495-1503.	1.0	132
870	Routine pre-treatment with clopidogrel before diagnostic coronary angiography: the question is right, but what about the answer?. <i>European Heart Journal</i> , 2008, 29, 1475-1477.	1.0	2
871	Dual Antithrombotic Therapy Increases Severe Bleeding Events in Patients With Stroke and Cardiovascular Disease. <i>Stroke</i> , 2008, 39, 1740-1745.	1.0	231
872	Antiplatelet Drugs. <i>Chest</i> , 2008, 133, 199S-233S.	0.4	478
873	Increased Major Bleeding Complications Related to Triple Antithrombotic Therapy Usage in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Artery Stenting. <i>Chest</i> , 2008, 134, 559-567.	0.4	117
874	Glycoprotein IIb/IIIa Receptor Inhibition with Abciximab during Percutaneous Coronary Interventions Increases the Risk of Bleeding in Patients with Impaired Renal Function. <i>Cardiology</i> , 2008, 111, 247-253.	0.6	10

#	ARTICLE	IF	CITATIONS
875	Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100. Platelets, 2008, 19, 335-341.	1.1	28
876	Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diabetes and Vascular Disease Research, 2008, 5, 138-144.	0.9	109
877	Cost-Effectiveness of Clopidogrel: Seeing through the Smoke. Medical Decision Making, 2008, 28, 803-809.	1.2	3
878	Therapeutic Controversies: Aspirin, Clopidogrel, and Warfarin: Is the Combination Appropriate and Effective or Inappropriate and Too Dangerous?. Annals of Pharmacotherapy, 2008, 42, 790-805.	0.9	42
879	P2Y ₁₂ Antagonism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, s33-8.	1.1	91
880	Ensuring appropriate use of antiplatelet agents in the treatment of acute coronary syndromes have cardiovascular physicians been given enough grace in getting it right?. Heart, 2008, 94, 135-137.	1.2	0
881	Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome. American Journal of Health-System Pharmacy, 2008, 65, S22-S28.	0.5	5
882	Review: Recurrent stroke: where do we stand with the secondary prevention of noncardioembolic ischaemic strokes?. Therapeutic Advances in Cardiovascular Disease, 2008, 2, 387-405.	1.0	12
883	Clopidogrel in addition to aspirin reduces one-year major adverse cardiac and cerebrovascular events in unselected patients with non-ST segment elevation myocardial infarction. Acute Cardiac Care, 2008, 10, 43-48.	0.2	9
884	Patients with peripheral arterial disease in the CHARISMA trial. European Heart Journal, 2008, 30, 192-201.	1.0	290
885	The chimeric monoclonal antibody abciximab: a systematic review of its safety in contemporary practice. Expert Opinion on Drug Safety, 2008, 7, 809-819.	1.0	25
886	CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics, 2008, 9, 1251-1259.	0.6	209
887	Impact of Pretreatment With Clopidogrel on Initial Patency and Outcome in Patients Treated With Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Circulation, 2008, 118, 1828-1836.	1.6	70
888	Prescribing Practice of General Practitioners in Northern Ireland for Peripheral Arterial Disease. Angiology, 2008, 59, 57-63.	0.8	5
889	Management of Coronary Artery Disease in Type 2 Diabetes Mellitus. , 2008, , 289-319.		1
890	Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up—a large series of all-comers. Annals of Medicine, 2008, 40, 296-302.	1.5	2
891	Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?. Circulation: Cardiovascular Interventions, 2008, 1, 217-225.	1.4	15
892	Patent Foramen Ovale and Cryptogenic Stroke: To Close or Not to Close? Closure: What Else!. Circulation, 2008, 118, 1989-1997.	1.6	59

#	ARTICLE	IF	CITATIONS
893	Pharmacoeconomic Concepts in Antiplatelet Therapy: Understanding Cost-Effectiveness Analyses Using Clopidogrel as an Example. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2008, 13, 107-119.	1.0	4
894	Restrictive access to clopidogrel and mortality following coronary stent implantation. <i>Cmaj</i> , 2008, 178, 413-420.	0.9	22
895	Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention. <i>New England Journal of Medicine</i> , 2008, 359, 688-696.	13.9	323
896	Incidence of Death and Acute Myocardial Infarction Associated With Stopping Clopidogrel After Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 532.	3.8	330
897	Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent. <i>European Journal of Cardio-thoracic Surgery</i> , 2008, 34, 93-108.	0.6	70
898	Prasugrel: a novel platelet ADP P2Y ₁₂ receptor antagonist. A review on its mechanism of action and clinical development. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2893-2900.	0.9	43
899	A Novel Endovascular Device for Emboli Rerouting. <i>Stroke</i> , 2008, 39, 2860-2866.	1.0	9
900	Emergency Medical Services Management of ST-Elevation Myocardial Infarction. <i>Prehospital Emergency Care</i> , 2008, 12, 395-403.	1.0	12
901	Atherothrombotic Disease and the Role of Antiplatelet Therapy in Women. <i>Journal of Women's Health</i> , 2008, 17, 35-46.	1.5	6
902	Secondary Stroke Prevention: From Guidelines to Clinical Practice. <i>Journal of the National Medical Association</i> , 2008, 100, 1125-1137.	0.6	20
903	A Double-blind Placebo-controlled Investigation of the Psychomotor Profile of Clopidogrel in Healthy Volunteers. <i>Journal of Cardiovascular Pharmacology</i> , 2008, 52, 507-509.	0.8	2
904	Benefits and risks with antiplatelet therapy: how great a problem is bleeding?. <i>European Heart Journal Supplements</i> , 2008, 10, I19-I24.	0.0	10
905	Duration of antiplatelet therapy following intracoronary stenting: are changes needed?. <i>European Heart Journal Supplements</i> , 2008, 10, I25-I29.	0.0	5
906	Dual antiplatelet therapy in the drug-eluting stent era. <i>Country Review Ukraine</i> , 2008, 10, D38-D44.	0.8	2
907	Long-term treatment strategies for atherothrombotic disease: do platelets define the course?. <i>European Heart Journal Supplements</i> , 2008, 10, I8-I13.	0.0	0
908	When and how to discontinue antiplatelet therapy. <i>Country Review Ukraine</i> , 2008, 10, A35-A41.	0.8	16
909	Acute ST-Segment Elevation Myocardial Infarction. <i>Chest</i> , 2008, 133, 708S-775S.	0.4	110
910	Clopidogrel Use in Coronary Heart Disease and Percutaneous Coronary Intervention. <i>Journal of Investigative Medicine</i> , 2008, 56, 689-700.	0.7	3

#	ARTICLE	IF	CITATIONS
911	Trends in Usage of Alternative Antiplatelet Therapy After Stroke and Transient Ischemic Attack. <i>Stroke</i> , 2008, 39, 1228-1232.	1.0	13
912	The Primary and Secondary Prevention of Coronary Artery Disease. <i>Chest</i> , 2008, 133, 776S-814S.	0.4	234
913	Antithrombotic Therapy for Non- σ ST-Segment Elevation Acute Coronary Syndromes. <i>Chest</i> , 2008, 133, 670S-707S.	0.4	145
914	Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention. <i>Anesthesia and Analgesia</i> , 2008, 107, 552-569.	1.1	62
915	Antiplatelet therapy in percutaneous coronary intervention. <i>Country Review Ukraine</i> , 2008, 10, A13-A20.	0.8	8
916	Unmet needs in antiplatelet therapy. <i>Country Review Ukraine</i> , 2008, 10, D3-D11.	0.8	7
917	Comparing the Activated Clotting Times Obtained From 2 Point-of-Care Devices in Patients Receiving Unfractionated Heparin During Percutaneous Coronary Intervention. <i>Point of Care</i> , 2008, 7, 30-33.	0.5	1
918	Progress Is Precarious. <i>Anesthesia and Analgesia</i> , 2008, 107, 362-364.	1.1	3
919	The Effects of Clopidogrel on Elderly Traumatic Brain Injured Patients. <i>Journal of Trauma</i> , 2008, 65, 1303-1308.	2.3	99
920	Prasugrel. <i>Cardiology in Review</i> , 2008, 16, 314-318.	0.6	16
921	Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence. <i>Future Cardiology</i> , 2008, 4, 33-55.	0.5	17
922	Effects of Coronary Prestenting Platelet Inhibition on Coronary Poststenting Inflammation. <i>Journal of Cardiovascular Pharmacology</i> , 2008, 51, 286-292.	0.8	6
923	Coronary Artery Stents: II. Perioperative Considerations and Management. <i>Anesthesia and Analgesia</i> , 2008, 107, 570-590.	1.1	104
924	Effects of Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention After Pretreatment With Clopidogrel. <i>Critical Pathways in Cardiology</i> , 2008, 7, 5-10.	0.2	11
925	Clinical implications of clopidogrel resistance. <i>Thrombosis and Haemostasis</i> , 2008, 100, 196-203.	1.8	79
926	Adjunctive pharmacotherapy during PCI. , 2008, , 53-64.		0
927	Percutaneous coronary intervention for acute myocardial infarction. , 2008, , 243-254.		0
928	A Randomised Controlled Trial of Triple Antiplatelet Therapy (Aspirin, Clopidogrel and Dipyridamole) in the Secondary Prevention of Stroke: Safety, Tolerability and Feasibility. <i>PLoS ONE</i> , 2008, 3, e2852.	1.1	29

#	ARTICLE	IF	CITATIONS
929	Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial. <i>Thrombosis and Haemostasis</i> , 2008, 99, 155-160.	1.8	28
930	Analysis of platelet β_2 -adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy. <i>Thrombosis and Haemostasis</i> , 2008, 100, 829-838.	1.8	31
931	Clopidogrel and Bleeding after General Surgery Procedures. <i>American Surgeon</i> , 2008, 74, 721-725.	0.4	23
932	Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention. <i>Vascular Health and Risk Management</i> , 2009, 5, 275.	1.0	4
933	Diabetes mellitus: a prothrombotic state. Implications for outcomes after coronary revascularization. <i>Vascular Health and Risk Management</i> , 2009, 5, 101.	1.0	11
934	Perioperative Clopidogrel is Seven Days Enough?. <i>American Surgeon</i> , 2009, 75, 909-913.	0.4	7
935	Prasugrel for the treatment of patients with acute coronary syndrome. <i>Vascular Health and Risk Management</i> , 2009, 5, 321.	1.0	1
936	Strategy for the Treatment of Clopidogrel Low Responsiveness in Diabetes Mellitus and Stent Implantation. <i>Korean Circulation Journal</i> , 2009, 39, 459.	0.7	4
937	The influence of clinical characteristics, laboratory and inflammatory markers on α -high on-treatment platelet reactivity [™] as measured with different platelet function tests. <i>Thrombosis and Haemostasis</i> , 2009, 102, 719-727.	1.8	88
938	Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention. <i>Vascular Health and Risk Management</i> , 2009, 5, 677.	1.0	0
939	Secondary Stroke Prevention, and the Role of Antiplatelet Therapies. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2208.	0.1	0
940	Platelet P2Y ₁₂ receptor inhibition by thienopyridines: status and future. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1317-1332.	1.9	20
941	Polyvascular atherosclerotic disease: recognizing the risks and managing the syndrome. <i>Current Medical Research and Opinion</i> , 2009, 25, 2631-2641.	0.9	22
942	Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON [™] TIMI 38. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 984-998.	1.0	73
943	Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a nationally representative managed-care population. <i>Current Medical Research and Opinion</i> , 2009, 25, 2327-2334.	0.9	11
944	Clopidogrel Inhibits CYP2C19-Dependent Hydroxylation of Omeprazole Related to CYP2C19 Genetic Polymorphisms. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 574-581.	1.0	39
945	Review: Platelet Function Testing and Implications for Clinical Practice. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2009, 14, 157-169.	1.0	44
946	Prediction of Prasugrel Active Metabolite Concentrations From 2 Downstream Inactive Metabolite Concentrations Using Multilinear Regression Analysis. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 973-983.	1.0	1

#	ARTICLE	IF	CITATIONS
947	Potential unrecognised costs of clopidogrel pretreatment in acute coronary syndrome. <i>Journal of Medical Economics</i> , 2009, 12, 325-330.	1.0	2
948	Percutaneous Coronary Intervention in Perspective. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 574-579.	1.4	3
949	Relationship Between Baseline Inflammatory Markers, Antiplatelet Therapy, and Adverse Cardiac Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 503-512.	1.4	27
950	Variability in aggregometry response before and after initiation of clopidogrel therapy. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2009, 69, 673-679.	0.6	5
951	Intravenous Platelet Blockade with Cangrelor during PCI. <i>New England Journal of Medicine</i> , 2009, 361, 2330-2341.	13.9	560
952	Personalized medicine and antiplatelet therapy: ready for prime time?. <i>European Heart Journal</i> , 2009, 30, 1943-1963.	1.0	37
953	Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 17-23.	0.6	5
954	Platelet reactivity and nonresponse to dual antiplatelet therapy: A review. <i>Platelets</i> , 2009, 20, 531-538.	1.1	13
955	Thrombosis and Antithrombotic Therapy in Women. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 284-288.	1.1	51
956	Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. <i>European Heart Journal</i> , 2009, 30, 2226-2232.	1.0	95
957	Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention. <i>Future Cardiology</i> , 2009, 5, 237-246.	0.5	1
958	Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures. <i>American Journal of Gastroenterology</i> , 2009, 104, 2903-2917.	0.2	35
959	Bedside Evaluation of Thienopyridine Antiplatelet Therapy. <i>Circulation</i> , 2009, 119, 2625-2632.	1.6	118
960	Platelet P2Y12 Receptor Influences the Vessel Wall Response to Arterial Injury and Thrombosis. <i>Circulation</i> , 2009, 119, 116-122.	1.6	67
961	The dangers of stopping clopidogrel perioperatively: a cardiologist's perspective. <i>Clinical Risk</i> , 2009, 15, 106-108.	0.1	0
962	Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome. <i>Circulation</i> , 2009, 120, 2322-2329.	1.6	210
963	2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused)	1.6	1,073
964	Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent Implantation. <i>Circulation</i> , 2009, 119, 987-995.	1.6	345

#	ARTICLE	IF	CITATIONS
965	Update on dual antiplatelet therapy for percutaneous coronary intervention. <i>Heart</i> , 2009, 95, 861-865.	1.2	3
966	Perioperative use of dual antiplatelet therapy for patients with coronary artery stents. <i>British Journal of Hospital Medicine (London, England)</i> : 2005, 2009, 70, 117-117.	0.2	0
967	Reoperation for Bleeding in Patients Undergoing Coronary Artery Bypass Surgery. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 583-590.	0.9	155
968	Platelet interactions as therapeutic targets for prevention of atherothrombosis. <i>Future Cardiology</i> , 2009, 5, 285-296.	0.5	3
969	Peripheral Arterial Disease: Considerations in Risks, Diagnosis, and Treatment. <i>Journal of the National Medical Association</i> , 2009, 101, 999-1008.	0.6	31
970	Aspirin Plus Clopidogrel and Risk of Infection After Coronary Artery Bypass Surgery. <i>Archives of Internal Medicine</i> , 2009, 169, 788.	4.3	61
971	Antiplatelet Agents in the Perioperative Period. <i>Archives of Surgery</i> , 2009, 144, 69.	2.3	80
972	The Potential Role of Prasugrel in Secondary Prevention of Ischemic Events in Patients with Acute Coronary Syndromes. <i>Postgraduate Medicine</i> , 2009, 121, 59-72.	0.9	5
973	Cangrelor in percutaneous coronary intervention. <i>Expert Review of Clinical Pharmacology</i> , 2009, 2, 137-145.	1.3	3
974	Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting. <i>New England Journal of Medicine</i> , 2009, 360, 2672-2675.	13.9	3
975	Use of stress testing prior to percutaneous coronary intervention in patients with stable coronary artery disease. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 1061-1066.	0.6	1
976	Update on Antiplatelet Therapy in Acute Coronary Syndromes. <i>American Journal of Cardiovascular Drugs</i> , 2009, 9, 13-17.	1.0	1
979	Postoperative blood loss in patients undergoing coronary artery bypass surgery after preoperative treatment with clopidogrel. A prospective randomised controlled study. <i>European Journal of Cardio-thoracic Surgery</i> , 2009, 36, 856-862.	0.6	78
980	Prasugrel: A New Thienopyridine Inhibitor. <i>Journal of Pharmacy Practice</i> , 2009, 22, 158-165.	0.5	2
981	Gastrointestinal Complications After 3 Months of Dual Antiplatelet Therapy for Drug-eluting Stents as Assessed by Wireless Capsule Endoscopy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 171-176.	0.7	7
982	Clopidogrel versus prasugrel in rabbits. <i>Thrombosis and Haemostasis</i> , 2009, 101, 108-115.	1.8	28
983	P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. <i>European Heart Journal</i> , 2009, 30, 1964-1977.	1.0	353
984	Adherence to guidelines for sensitivity analysis: cost-effectiveness analyses of dual oral antiplatelet therapy. <i>Journal of Medical Economics</i> , 2009, 12, 141-153.	1.0	2

#	ARTICLE	IF	CITATIONS
985	Clopidogrel for the Hot Patient. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 495-496.	1.4	5
986	The Role of Aspirin in Cardiovascular Disease Prevention in Women. <i>American Journal of Lifestyle Medicine</i> , 2009, 3, 123-134.	0.8	3
987	Avoiding and Managing Bleeding Complications in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Angiology</i> , 2009, 60, 148-158.	0.8	2
988	Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry. <i>Heart</i> , 2009, 95, 1579-1586.	1.2	31
989	Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 937.	3.8	874
990	Clopidogrel Adherence following Percutaneous Coronary Intervention with a Drug-Eluting Stent in a VA Medical Center. <i>Journal of Pharmacy Technology</i> , 2009, 25, 164-168.	0.5	8
991	Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: A look at the clinical and pharmacological evidence. , 2009, 123, 178-186.		75
992	Impact of preoperative clopidogrel in off pump coronary artery bypass surgery: A propensity score analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2009, 137, 309-313.	0.4	32
993	Antiplatelet agents used for early intervention in acute coronary syndrome: Myocardial salvage versus bleeding complications. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2009, 138, 807-810.e7.	0.4	13
994	Clopidogrel-Induced Hepatocellular Injury and Cholestatic Jaundice in an Elderly Patient: Case Report and Review of the Literature. <i>Pharmacotherapy</i> , 2009, 29, 608-612.	1.2	24
995	Safety and Tolerability of Antiplatelet Therapies for the Secondary Prevention of Atherothrombotic Disease. <i>Pharmacotherapy</i> , 2009, 29, 812-821.	1.2	15
996	Pharmacokinetics and Pharmacodynamics of Prasugrel, a Thienopyridine P2Y12 Inhibitor. <i>Pharmacotherapy</i> , 2009, 29, 1089-1102.	1.2	78
997	The Problem of Stent Thrombosis Associated With Drug-Eluting Stents and the Optimal Duration of Dual Antiplatelet Therapy. <i>Preventive Cardiology</i> , 2009, 12, 59-64.	1.1	1
998	Current Controversies in the Pharmacogenomics of Clopidogrel. <i>Progress in Cardiovascular Nursing</i> , 2009, 24, 105-109.	0.5	1
999	Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Acute and Subacute Stent Thrombosis. <i>American Journal of Cardiology</i> , 2009, 103, 5-10.	0.7	271
1000	Role of Antiplatelet Therapy Across the Spectrum of Patients with Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2009, 103, 11A-19A.	0.7	24
1001	Temporal Relation Between Clopidogrel Cessation and Stent Thrombosis After Drug-Eluting Stent Implantation. <i>American Journal of Cardiology</i> , 2009, 103, 801-805.	0.7	61
1002	Evidence for Using Clopidogrel Alone or in Addition to Aspirin in Post Coronary Artery Bypass Surgery Patients. <i>American Journal of Cardiology</i> , 2009, 103, 1687-1693.	0.7	31

#	ARTICLE	IF	CITATIONS
1003	Relation of Genetic Polymorphisms in the Cytochrome P450 Gene With Clopidogrel Resistance After Drug-Eluting Stent Implantation in Koreans. <i>American Journal of Cardiology</i> , 2009, 104, 46-51.	0.7	93
1004	Definition, Incidence, Correlates, and Clinical Impact of "Nuisance" Bleeding in Patients Undergoing Drug-Eluting Stent Implantation. <i>American Journal of Cardiology</i> , 2009, 104, 30C-33C.	0.7	5
1005	Is It Possible to Safely Administer Early a Loading Dose of Clopidogrel Before Coronary Angiography to Patients Who Are Candidates for Percutaneous Coronary Intervention?. <i>American Journal of Cardiology</i> , 2009, 104, 1505-1510.	0.7	4
1006	Anaesthesia and coronary artery stents. <i>Current Anaesthesia and Critical Care</i> , 2009, 20, 150-154.	0.3	1
1007	Risk and management of upper gastrointestinal bleeding associated with prolonged dual-antiplatelet therapy after percutaneous coronary intervention. <i>Cardiovascular Revascularization Medicine</i> , 2009, 10, 36-44.	0.3	29
1008	Drug-eluting or bare-metal stents in subjects over 75 years of age: what is the best therapeutic strategy? Data from 460 consecutive patients with 1-year outcome. <i>Cardiovascular Revascularization Medicine</i> , 2009, 10, 94-102.	0.3	5
1009	ESVS Guidelines. Invasive Treatment for Carotid Stenosis: Indications, Techniques. <i>European Journal of Vascular and Endovascular Surgery</i> , 2009, 37, 1-19.	0.8	532
1010	Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 866-870.	0.7	6
1011	Antiplatelet therapy after endovascular intervention: Does combination therapy really work and what is the optimum duration of therapy?. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, S7-S11.	0.7	6
1012	Antiplatelet therapy in percutaneous coronary intervention: A critical review of the 2007 AHA/ACC/SCAI guidelines and beyond. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 579-597.	0.7	26
1013	Acknowledging a failed strategy. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 871-873.	0.7	2
1014	Long term efficacy of abciximab bolus only compared to abciximab bolus and infusion after transradial coronary stenting. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 1010-1016.	0.7	7
1015	2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused) <i>TJ ETQq0 0 0 pGBT /Overlock 10 Tf</i>	0.7	56
1017	How to manage patients with need for antiplatelet therapy in the setting of (un-)planned surgery. <i>Clinical Research in Cardiology</i> , 2009, 98, 8-15.	1.5	30
1018	Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study. <i>Clinical Research in Cardiology</i> , 2009, 98, 533-540.	1.5	36
1019	Oral Antiplatelet Therapy for Acute and Chronic Management of NSTEMI ACS: Residual Ischemic Risk and Opportunities for Improvement. <i>Cardiovascular Drugs and Therapy</i> , 2009, 23, 489-499.	1.3	6
1020	Comparison of the effects of pretreatment with tirofiban, clopidogrel or both on the inhibition of platelet aggregation and activation in patients with acute coronary syndromes. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 36-43.	1.0	5
1021	Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 151-155.	1.0	14

#	ARTICLE	IF	CITATIONS
1022	Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug) Trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 24, 410-417.	2.0	16
1023	Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 366-380.	1.0	24
1024	Neuentwicklungen in der Thrombozytenaggregationshemmung – sinnvolle Alternativen für ASS/Clopidogrel-Non-Responder?. <i>Clinical Research in Cardiology Supplements</i> , 2009, 4, 184-191.	2.0	0
1025	Thienopyridine therapy and risk for cardiovascular events in secondary prevention. <i>Current Atherosclerosis Reports</i> , 2009, 11, 364-370.	2.0	4
1026	Contemporary issues on clopidogrel therapy. <i>Internal and Emergency Medicine</i> , 2009, 4, 201-211.	1.0	1
1027	Contemporary issues on clopidogrel therapy: a critical appraisal. <i>Internal and Emergency Medicine</i> , 2009, 4, 195-198.	1.0	2
1028	Perioperative handling of patients on antiplatelet therapy with need for surgery. <i>Internal and Emergency Medicine</i> , 2009, 4, 279-288.	1.0	74
1029	Prasugrel: Clinical development and therapeutic application. <i>Advances in Therapy</i> , 2009, 26, 999-1011.	1.3	10
1030	Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome. <i>Heart and Vessels</i> , 2009, 24, 73-78.	0.5	16
1031	Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention: a cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 362-369.	0.9	25
1032	Endoscopic band ligation could decrease recurrent bleeding in Mallory-Weiss syndrome as compared to haemostasis by hemoclips plus epinephrine. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 399-405.	1.9	35
1033	Long-term clopidogrel administration following severe coronary injury reduces proliferation and inflammation via inhibition of nuclear factor- κ B and activator protein 1 activation in pigs. <i>European Journal of Clinical Investigation</i> , 2009, 39, 174-182.	1.7	10
1034	The Impact of Diabetes Mellitus on Two-Year Mortality Following Contemporary Percutaneous Coronary Intervention: Implications for Revascularization Practice. <i>Journal of Interventional Cardiology</i> , 2009, 22, 420-426.	0.5	2
1035	Crushed Clopidogrel Administered via Nasogastric Tube Has Faster and Greater Absorption than Oral Whole Tablets. <i>Journal of Interventional Cardiology</i> , 2009, 22, 385-389.	0.5	39
1036	Week-Long High-Maintenance Dose Clopidogrel Regimen Achieves Better Platelet Aggregation Inhibition than a Standard Loading Dose before Percutaneous Coronary Intervention: Results of a Double-Blind, Randomized Clinical Trial. <i>Journal of Interventional Cardiology</i> , 2009, 22, 368-377.	0.5	7
1037	Identification of patients at risk of ischemic events for long-term secondary prevention. <i>Journal of the American Academy of Nurse Practitioners</i> , 2009, 21, 677-689.	1.4	5
1038	The management of patients with hip fractures who are taking Clopidogrel. <i>Australasian Journal on Ageing</i> , 2009, 28, 194-197.	0.4	23
1039	Management of patients with unstable angina / non-ST-elevation myocardial infarction: a critical review of the 2007 ACC/AHA guidelines. <i>International Journal of Clinical Practice</i> , 2009, 63, 642-655.	0.8	7

#	ARTICLE	IF	CITATIONS
1040	Cost-Effectiveness of Clopidogrel plus Aspirin versus Aspirin Alone for Secondary Prevention of Cardiovascular Events: Results from the CHARISMA Trial. <i>Value in Health</i> , 2009, 12, 872-879.	0.1	29
1041	Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 1-9.	1.0	11
1042	Identifying the "Optimal" Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1279-1285.	1.1	34
1043	Clopidogrel response variability: Current status and future directions. <i>Thrombosis and Haemostasis</i> , 2009, 102, 07-14.	1.8	114
1044	Effect of Intracoronary Nicardipine on Cardiac Enzymes After Elective Percutaneous Coronary Intervention. <i>Clinical Cardiology</i> , 2009, 32, 315-320.	0.7	4
1045	The patient with cardiovascular disease: Treatment strategies for preventing major events. <i>Clinical Cardiology</i> , 2009, 29, 4-12.	0.7	1
1046	Antiplatelet therapy and coronary artery bypass graft surgery: perioperative safety and efficacy. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 169-182.	1.0	43
1049	Biological and pharmacological aspects of perioperative hemorrhagic complications associated with oral platelet-directed antithrombotic agents. <i>Thrombosis Research</i> , 2009, 123, 419-428.	0.8	3
1050	Impact of P2Y12 Inhibitory Effects Induced by Clopidogrel on Platelet Procoagulant Activity in Type 2 Diabetes Mellitus Patients. <i>Thrombosis Research</i> , 2009, 124, 318-322.	0.8	37
1051	Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent. <i>Thrombosis Research</i> , 2009, 124, 46-51.	0.8	38
1052	Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions " Limited inhibition of the P2Y12 receptor. <i>Thrombosis Research</i> , 2009, 124, 193-198.	0.8	7
1053	Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome. <i>Thrombosis Research</i> , 2009, 124, 6-13.	0.8	48
1054	Influence of platelet reactivity and response to clopidogrel on myocardial damage following percutaneous coronary intervention in patients with non-st-segment elevation acute coronary syndrome. <i>Thrombosis Research</i> , 2009, 124, 678-682.	0.8	3
1055	Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery. <i>Thrombosis Research</i> , 2009, 124, 572-577.	0.8	41
1056	Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene. <i>International Journal of Cardiology</i> , 2009, 133, 341-345.	0.8	78
1057	Long-term cost-effectiveness of clopidogrel in STEMI patients. <i>International Journal of Cardiology</i> , 2009, 135, 353-360.	0.8	10
1058	Aspirin resistance: What the cardiologist needs to know?. <i>International Journal of Cardiology</i> , 2009, 132, 153-156.	0.8	8
1059	Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary syndromes: When does the risk outweigh the benefit?. <i>International Journal of Cardiology</i> , 2009, 133, 8-17.	0.8	7

#	ARTICLE	IF	CITATIONS
1060	Evidence-based prescribing and adherence to antiplatelet therapy—How much difference do they make to patients with atherothrombosis?. <i>International Journal of Cardiology</i> , 2009, 134, 150-159.	0.8	11
1061	Glycoprotein IIb/IIIa Inhibitors in the Emergency Department for Patients with Non-ST-Elevation Acute Coronary Syndromes: Principles and Practices. <i>Journal of Emergency Medicine</i> , 2009, 36, 162-170.	0.3	1
1062	Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. <i>American Heart Journal</i> , 2009, 157, 369-374.	1.2	69
1063	Facts and controversies of aspirin and clopidogrel therapy. <i>American Heart Journal</i> , 2009, 157, 412-422.	1.2	20
1064	Late coronary intervention for totally occluded left anterior descending coronary arteries in stable patients after myocardial infarction: Results from the Occluded Artery Trial (OAT). <i>American Heart Journal</i> , 2009, 157, 724-732.	1.2	8
1065	Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And Efficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. <i>American Heart Journal</i> , 2009, 157, 620-624.e2.	1.2	91
1066	Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: A randomized, controlled study. <i>American Heart Journal</i> , 2009, 157, 733-739.	1.2	396
1067	Efficacy of Xience/promus versus Cypher in rEducing Late Loss after stENTing (EXCELLENT) trial: Study design and rationale of a Korean multicenter prospective randomized trial. <i>American Heart Journal</i> , 2009, 157, 811-817.e1.	1.2	34
1068	The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents. <i>American Heart Journal</i> , 2009, 157, 899-907.	1.2	35
1069	Stent thrombosis up to 3 years after stenting for ST-segment elevation myocardial infarction versus for stable angina—Comparison of the effects of drug-eluting versus bare-metal stents. <i>American Heart Journal</i> , 2009, 158, 271-276.	1.2	41
1070	The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRAACER) trial: study design and rationale. <i>American Heart Journal</i> , 2009, 158, 327-334.e4.	1.2	120
1071	Timing of clopidogrel loading before percutaneous coronary intervention in clopidogrel-naive patients with stable or unstable angina: A comparison of two strategies. <i>American Heart Journal</i> , 2009, 158, 585-591.	1.2	13
1072	Association of platelet responsiveness with clopidogrel metabolism: Role of compliance in the assessment of “resistance”. <i>American Heart Journal</i> , 2009, 158, 925-932.	1.2	64
1073	Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. <i>Archives of Cardiovascular Diseases</i> , 2009, 102, 485-496.	0.7	30
1074	Same-day-discharge ad hoc percutaneous coronary intervention: Initial single-centre experience. <i>Archives of Cardiovascular Diseases</i> , 2009, 102, 743-748.	0.7	16
1075	Advanced Age, Antithrombotic Strategy, and Bleeding in Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1021-1030.	1.2	125
1076	Randomized Comparison of Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With High Post-Treatment Platelet Reactivity. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1101-1109.	1.2	431
1077	Clinical Effectiveness of Coronary Stents in Elderly Persons. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1629-1641.	1.2	135

#	ARTICLE	IF	CITATIONS
1078	Combining Antiplatelet and Anticoagulant Therapies. <i>Journal of the American College of Cardiology</i> , 2009, 54, 95-109.	1.2	140
1079	The Relative Efficacy and Safety of Clopidogrel in Women and Men. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1935-1945.	1.2	119
1080	Hunting for the "Sweet Spot" in P2Y12 Receptor Blockade. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1447-1449.	1.2	3
1081	Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures. <i>Journal of the American College of Cardiology</i> , 2009, 54, 2261-2276.	1.2	44
1082	Differentiating ischemic stroke subtypes: Risk factors and secondary prevention. <i>Journal of the Neurological Sciences</i> , 2009, 279, 1-8.	0.3	45
1083	Antiplatelet therapy for the primary and secondary prevention of cerebrovascular events in patients with extracranial carotid artery disease. <i>Journal of Vascular Surgery</i> , 2009, 50, 431-439.	0.6	12
1084	Current evidence and clinical implications of aspirin resistance. <i>Journal of Vascular Surgery</i> , 2009, 50, 1500-1510.	0.6	44
1085	Variable platelet responsiveness to aspirin and clopidogrel: role of platelet function and genetic polymorphism testing. <i>Translational Research</i> , 2009, 154, 309-313.	2.2	13
1086	Post-Treatment Platelet Reactivity Predicts Long-Term Adverse Events Better Than the Response to Clopidogrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009, 62, 126-135.	0.4	4
1087	In-Hospital Outcomes Associated With Fibrinolytic and Thienopyridine Use in Patients With ST-Segment Elevation Acute Myocardial Infarction. <i>The Global Registry of Acute Coronary Events. Revista Espanola De Cardiologia (English Ed)</i> , 2009, 62, 501-509.	0.4	1
1088	Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over study. <i>Journal of Translational Medicine</i> , 2009, 7, 42.	1.8	10
1089	Long-term effect of chronic oral anticoagulation: focus on coronary artery disease. <i>Future Cardiology</i> , 2009, 5, 259-271.	0.5	4
1090	Acute Coronary Syndromes: Diagnosis and Management, Part I. <i>Mayo Clinic Proceedings</i> , 2009, 84, 917-938.	1.4	310
1091	Pharmacotherapy for Cardiac Diseases. , 2009, , 383-392.		0
1092	Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. <i>Nature Reviews Cardiology</i> , 2009, 6, 273-282.	6.1	90
1093	Effect of Age on the Pharmacokinetics and Pharmacodynamics of Prasugrel during Multiple Dosing. <i>Drugs and Aging</i> , 2009, 26, 781-790.	1.3	12
1094	Ticagrelor in ACS "what does PLATO teach us?". <i>Nature Reviews Cardiology</i> , 2009, 6, 737-738.	6.1	18
1095	An Appraisal of Dual Antiplatelet Therapy with Clopidogrel and Aspirin for Prevention of Cardiovascular Events. <i>Journal of the American Board of Family Medicine</i> , 2009, 22, 51-56.	0.8	18

#	ARTICLE	IF	CITATIONS
1096	Oral Antiplatelet Therapy in the Secondary Prevention of Atherothrombotic Events. American Journal of Cardiovascular Drugs, 2009, 9, 197-209.	1.0	8
1097	Cost Effectiveness of Fondaparinux in Non-ST-Elevation Acute Coronary Syndrome. Pharmacoeconomics, 2009, 27, 585-595.	1.7	12
1098	Role of Prasugrel, a Novel P2Y12 Receptor Antagonist, in the Management of Acute Coronary Syndromes. American Journal of Cardiovascular Drugs, 2009, 9, 213-229.	1.0	34
1099	Differences in responses of platelets to fluid shear stress in patients with peripheral artery disease (PAD) and coronary artery disease (CAD). Platelets, 2009, 20, 199-205.	1.1	13
1100	Incidence, predictors, and clinical impact of bleeding after transradial coronary stenting and maximal antiplatelet therapy. American Heart Journal, 2009, 157, 164-169.	1.2	102
1101	Genetic Determinants of Response to Clopidogrel and Cardiovascular Events. New England Journal of Medicine, 2009, 360, 363-375.	13.9	1,581
1102	Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: A position statement of the Canadian Cardiovascular Society. Canadian Journal of Cardiology, 2009, 25, 683-689.	0.8	78
1103	Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet, The, 2009, 373, 309-317.	6.3	864
1104	Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet, The, 2009, 373, 919-928.	6.3	295
1105	Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet, The, 2009, 373, 723-731.	6.3	981
1106	The ischaemia/bleeding balance in PCI. Lancet, The, 2009, 373, 872-873.	6.3	1
1109	2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused) Tj ETQq1 1 0.784314 rggBT /Ove	1.2	1,378
1110	Prasugrel: A Novel Platelet ADP P2Y ₁₂ Receptor Antagonist. Cardiovascular Therapeutics, 2009, 27, 194-198.	1.1	6
1111	Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics, 2009, 10, 1799-1817.	0.6	100
1112	Cangrelor: a review on its mechanism of action and clinical development. Expert Review of Cardiovascular Therapy, 2009, 7, 1195-1201.	0.6	81
1113	P2Y12 Inhibitors in Cardiovascular Disease: Focus on Prasugrel. Annals of Pharmacotherapy, 2009, 43, 64-76.	0.9	11
1114	Developments in antiplatelet therapy for acute coronary syndromes and considerations for long-term management. Current Medical Research and Opinion, 2009, 25, 1477-1490.	0.9	9
1115	Management of Patients with High Gastrointestinal Risk on Antiplatelet Therapy. Gastroenterology Clinics of North America, 2009, 38, 289-303.	1.0	22

#	ARTICLE	IF	CITATIONS
1116	Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care. <i>Mayo Clinic Proceedings</i> , 2009, 84, 149-160.	1.4	19
1118	A new generation of antiplatelet agents. <i>Current Opinion in Cardiology</i> , 2009, 24, 307-312.	0.8	8
1119	New P2Y12 antagonists. <i>Current Opinion in Hematology</i> , 2009, 16, 371-377.	1.2	28
1120	Stent choice in primary percutaneous coronary intervention: drug-eluting stents or bare metal stents?. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, S17-S26.	0.6	5
1121	FACTORS ASSOCIATED WITH ASPIRIN RESISTANCE IN PATIENTS PREMEDICATED WITH ASPIRIN AND CLOPIDOGREL FOR ENDOVASCULAR NEUROSURGERY. <i>Neurosurgery</i> , 2009, 64, 890-896.	0.6	27
1122	Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. <i>Coronary Artery Disease</i> , 2009, 20, 207-213.	0.3	12
1123	Clopidogrel Prescribing and Concordance with the Pharmaceutical Benefits Scheme in Hospital Patients. <i>Journal of Pharmacy Practice and Research</i> , 2009, 39, 265-268.	0.5	0
1124	Clopidogrel pretreatment before primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: comparison of high loading dose (600mg) versus low loading dose (300mg). <i>Coronary Artery Disease</i> , 2009, 20, 150-154.	0.3	17
1125	Variability in Platelet Response to the Antiplatelet Agents Aspirin and Clopidogrel. <i>Critical Pathways in Cardiology</i> , 2009, 8, 20-28.	0.2	9
1126	Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis. <i>Thrombosis and Haemostasis</i> , 2009, 102, 248-257.	1.8	359
1127	Current practice and limitations of dual antiplatelet therapy in acute coronary syndrome. <i>European Heart Journal Supplements</i> , 2009, 11, G4-G8.	0.0	3
1128	Optimizing Antiplatelet Therapy in High-Risk Patients With Atrial Fibrillation. <i>Stroke</i> , 2009, 40, 3883-3885.	1.0	1
1129	Upper Gastrointestinal Bleeding in Patients Receiving Dual Antiplatelet Therapy after Coronary Stenting. <i>Internal Medicine</i> , 2009, 48, 1725-1730.	0.3	50
1130	Comparison of Low vs Moderate Dose of Atorvastatin in Clopidogrel Resistance After Coronary Stenting in Korean Patients With Acute Coronary Syndrome. <i>Circulation Journal</i> , 2009, 73, 1111-1118.	0.7	3
1131	New anticoagulants for atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 446-453.	0.6	4
1132	Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents. <i>Current Opinion in Cardiology</i> , 2010, 25, 305-311.	0.8	6
1133	Predictors of Early Discontinuation of Dual-Antiplatelet Therapy: Room for Improvement. <i>Circulation</i> , 2010, 122, 946-948.	1.6	3
1134	Premature preoperative discontinuation of antiplatelet drug therapy in cardiovascular risk patients: a preliminary study on the role of P2Y12 receptor monitoring. <i>European Journal of Anaesthesiology</i> , 2010, 27, 138-145.	0.7	6

#	ARTICLE	IF	CITATIONS
1135	Perioperative stent thrombosis. <i>Interventional Cardiology</i> , 2010, 2, 821-828.	0.0	0
1136	Pantoprazole Does Not Influence the Antiplatelet Effect of Clopidogrel-A Whole Blood Aggregometry Study After Coronary Stenting. <i>Journal of Cardiovascular Pharmacology</i> , 2010, 56, 91-97.	0.8	48
1137	Thromboembolic Complications of Elective Coil Embolization of Unruptured Aneurysms. <i>Neurosurgery</i> , 2010, 67, 743-748.	0.6	88
1138	Serial Change in Platelet Activation Markers With Aspirin and Clopidogrel After Acute Ischemic Stroke. <i>Clinical Neuropharmacology</i> , 2010, 33, 40-45.	0.2	9
1139	The influence of bisoprolol dose on ADP-induced platelet aggregability in patients on dual antiplatelet therapy. <i>Coronary Artery Disease</i> , 2010, 21, 472-476.	0.3	2
1140	Preventing Serious Sequelae After an Acute Coronary Syndrome: The Consequences of Thrombosis Versus Bleeding With Antiplatelet Therapy. <i>Journal of Cardiovascular Pharmacology</i> , 2010, 55, 585-594.	0.8	7
1141	The patient with coronary stents and antiplatelet agents: what to do and how to deal?. <i>European Journal of Anaesthesiology</i> , 2010, 27, 406-410.	0.7	8
1142	High on-clopidogrel platelet reactivity and risk of MACE after PCI with stent implantation. <i>Interventional Cardiology</i> , 2010, 2, 619-621.	0.0	0
1143	Rapid Change in Prescribing Behavior in Hospitals Participating in Get With The Guidelines® Stroke After Release of the Management of Atherothrombosis With Clopidogrel in High-Risk Patients (MATCH) Clinical Trial Results. <i>Stroke</i> , 2010, 41, 2094-2097.	1.0	12
1144	Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. <i>Thrombosis and Haemostasis</i> , 2010, 103, 71-82.	1.8	116
1145	Basic Principles of Platelet Biology and Clinical Implications. <i>Circulation Journal</i> , 2010, 74, 597-607.	0.7	239
1146	Use of antiplatelet therapies during primary percutaneous coronary intervention for acute myocardial infarction. <i>Interventional Cardiology</i> , 2010, 2, 705-718.	0.0	2
1147	Platelet P2Y ₁₂ receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies. <i>Thrombosis and Haemostasis</i> , 2010, 103, 535-544.	1.8	39
1148	A New Era for Antiplatelet Therapy in Patients With Acute Coronary Syndrome. <i>American Journal of the Medical Sciences</i> , 2010, 340, 407-411.	0.4	8
1149	The Causes and Outcomes of Inadequate Implementation of Existing Guidelines for Antiplatelet Treatment in Patients With Acute Coronary Syndrome: The Experience From Taiwan Acute Coronary Syndrome Descriptive Registry (TACCORD Registry). <i>Clinical Cardiology</i> , 2010, 33, E40-8.	0.7	30
1150	Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y ₁₂ receptor antagonist. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 151-158.	0.6	76
1151	Mechanism of action and clinical development of platelet thrombin receptor antagonists. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1191-1200.	0.6	20
1152	Factors associated with clopidogrel nonresponsiveness. <i>Future Cardiology</i> , 2010, 6, 195-210.	0.5	10

#	ARTICLE	IF	CITATIONS
1153	Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 487-496.	0.8	174
1154	The State of Periprocedural Antiplatelet Therapy After Recent Trials. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 571-583.	1.1	45
1155	Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. <i>Basic Research in Cardiology</i> , 2010, 105, 379-387.	2.5	62
1157	Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus. <i>Wiener Medizinische Wochenschrift</i> , 2010, 160, 30-38.	0.5	10
1158	Low responsiveness to thienopyridine in hemodialysis patients. <i>Cardiovascular Intervention and Therapeutics</i> , 2010, 25, 18-23.	1.2	4
1159	Reevaluation of clopidogrel: let the data speak for themselves. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2010, 30, 299-306.	1.0	1
1161	Antiplatelet and Anticoagulant Therapies in Acute Coronary Syndromes. <i>Cardiovascular Drugs and Therapy</i> , 2010, 24, 61-70.	1.3	8
1162	Role of Dual Antiplatelet Therapy in Symptomatic Patients with Established Vascular Disease: Putting the CHARISMA Trial into Therapeutic Perspective. <i>Cardiovascular Drugs and Therapy</i> , 2010, 24, 207-216.	1.3	2
1163	Incidence of hemorrhage among anticoagulated patients receiving antiplatelet therapy after percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 29, 316-321.	1.0	12
1164	Secondary prevention strategies for coronary heart disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 29, 8-24.	1.0	24
1165	Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 486-495.	1.0	32
1166	Antiplatelet therapy for atherothrombotic disease: How can we improve the outcomes?. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 240-249.	1.0	1
1167	Risk of Adverse Clinical Outcomes with Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Percutaneous Coronary Intervention. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1964-1968.	1.1	66
1168	Safety and efficacy of clopidogrel treatment in Japanese patients undergoing drug-eluting stent implantation. <i>Journal of Cardiology</i> , 2010, 55, 34-40.	0.8	3
1169	Lessons from the SYNTAX trial. <i>Journal of the Saudi Heart Association</i> , 2010, 22, 35-41.	0.2	3
1170	Management of ST-elevation myocardial infarction. <i>Medicine</i> , 2010, 38, 431-437.	0.2	0
1171	Current strategies in antiplatelet therapy – Does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?. , 2010, 127, 95-107.		18
1172	Recent therapeutic approaches to platelet activation in coronary artery disease. , 2010, 127, 108-120.		24

#	ARTICLE	IF	CITATIONS
1173	Oral Antiplatelet Therapy in Patients with Diabetes Mellitus and Acute Coronary Syndromes. Trends in Cardiovascular Medicine, 2010, 20, 211-217.	2.3	3
1174	Duration of clopidogrel treatment and risk of mortality and recurrent myocardial infarction among 11 680 patients with myocardial infarction treated with percutaneous coronary intervention: a cohort study. BMC Cardiovascular Disorders, 2010, 10, 6.	0.7	8
1175	Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis. BMC Medicine, 2010, 8, 36.	2.3	41
1176	The potential interaction between clopidogrel and proton pump inhibitors: a systematic review. BMC Medicine, 2010, 8, 81.	2.3	22
1177	Genetic Causes of Clopidogrel Nonresponsiveness: Which Ones Really Count?. Pharmacotherapy, 2010, 30, 265-274.	1.2	41
1178	Drug Interaction Between Clopidogrel and Proton Pump Inhibitors. Pharmacotherapy, 2010, 30, 275-289.	1.2	26
1179	Clopidogrel and Proton Pump Inhibitors: Between a Rock and a Hard Place. Pharmacotherapy, 2010, 30, 762-765.	1.2	4
1180	Impact of Acute Coronary Syndromes on Two-Year Clinical Outcomes in Patients With Unprotected Left Main Coronary Artery Stenosis Treated With Drug-Eluting Stents. American Journal of Cardiology, 2010, 105, 174-178.	0.7	11
1181	Efficacy of High-Dose Clopidogrel Treatment (600 mg) Less Than Two Hours Before Percutaneous Coronary Intervention in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. American Journal of Cardiology, 2010, 105, 323-332.	0.7	24
1182	Relation of Proton Pump Inhibitor Use After Percutaneous Coronary Intervention With Drug-Eluting Stents to Outcomes. American Journal of Cardiology, 2010, 105, 833-838.	0.7	73
1184	Controversies in Oral Antiplatelet Therapy in Patients Undergoing Aortocoronary Bypass Surgery. Annals of Thoracic Surgery, 2010, 90, 1040-1051.	0.7	26
1185	Bioequivalence of two tablet formulations of clopidogrel in healthy argentinian volunteers: A single-dose, randomized-sequence, open-label crossover study. Clinical Therapeutics, 2010, 32, 161-170.	1.1	25
1186	Antiplatelet Therapy After Placement of a Drug-Eluting Stent: A Review of Efficacy and Safety Studies. Clinical Therapeutics, 2010, 32, 2265-2281.	1.1	21
1187	Antiplatelet Agents in Acute Coronary Syndromes. Current Problems in Cardiology, 2010, 35, 123-170.	1.1	16
1188	Early and late outcomes of clopidogrel and Coumadin combination for patients on oral anticoagulants undergoing coronary stenting. Cardiovascular Revascularization Medicine, 2010, 11, 159-162.	0.3	6
1190	Coronary Stents and Noncardiac Surgery: Current Clinical Challenges and Conundrums. Preventive Cardiology, 2010, 13, 8-13.	1.1	8
1191	A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. Catheterization and Cardiovascular Interventions, 2010, 75, 158-166.	0.7	55
1192	Oral antiplatelet therapy in PCI patients. Catheterization and Cardiovascular Interventions, 2010, 75, S7-14.	0.7	1

#	ARTICLE	IF	CITATIONS
1193	European Resuscitation Council Guidelines for Resuscitation 2010 Section 5. Initial management of acute coronary syndromes. <i>Resuscitation</i> , 2010, 81, 1353-1363.	1.3	58
1194	Part 9: Acute coronary syndromes. <i>Resuscitation</i> , 2010, 81, e175-e212.	1.3	43
1195	Perioperative Management of Patients With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 131-142.	1.1	74
1196	Carriage of Cytochrome 2C19 Polymorphism Is Associated With Risk of High Post-Treatment Platelet Reactivity on High Maintenance-Dose Clopidogrel of 150 mg/day. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 731-741.	1.1	78
1197	Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 250-256.	1.9	305
1198	Antiplatelet drugs and risk of subarachnoid hemorrhage: a population-based case-control study. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1468-1474.	1.9	43
1199	Prasugrel vs. clopidogrel for cytochrome P450 2C19 genotyped subgroups: integration of the TRITON-TIMI 38 trial data. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1678-1684.	1.9	92
1200	Do not adjust the platelet count in light transmittance aggregometry when predicting thrombotic events after percutaneous coronary intervention. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2326-2328.	1.9	8
1201	Defining Patients at High Risk for Gastrointestinal Hemorrhage after Drug-Eluting Stent Placement: A Cost Utility Analysis. <i>Journal of Interventional Cardiology</i> , 2010, 23, 179-187.	0.5	2
1202	Antiplatelet therapies for the treatment of cardiovascular disease. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 154-169.	21.5	329
1203	Proton pump inhibitor and clopidogrel interaction: The case for watchful waiting. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1342-1347.	1.4	3
1204	Determinants to optimize response to clopidogrel in acute coronary syndrome. <i>Pharmacogenomics and Personalized Medicine</i> , 2010, 3, 33.	0.4	17
1205	Antiplatelet Therapy. , 2010, , 452-469.		0
1206	Reperfusion Therapies for Acute ST Segment Elevation Myocardial Infarction. , 2010, , 110-144.		0
1207	Diagnosis and Management of Coronary Artery Disease. , 2010, , 286-294.		0
1208	Determination of the Prevalence of Aspirin and Clopidogrel Resistances in Patients with Coronary Artery Disease by using Various Platelet-function Tests. <i>Annals of Laboratory Medicine</i> , 2010, 30, 460-468.	1.2	15
1209	Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome. <i>Drug Design, Development and Therapy</i> , 2010, 4, 203.	2.0	7
1210	Differences in Efficacy and Safety of Pharmaceutical Treatments between Men and Women: An Umbrella Review. <i>PLoS ONE</i> , 2010, 5, e11895.	1.1	19

#	ARTICLE	IF	CITATIONS
1211	Pre-Procedural Platelet Reactivity After Clopidogrel Loading in Korean Patients Undergoing Scheduled Percutaneous Coronary Intervention. <i>Journal of Atherosclerosis and Thrombosis</i> , 2010, 17, 1122-1131.	0.9	15
1212	Emerging antiplatelet agents, differential pharmacology, and clinical utility. <i>Journal of Blood Medicine</i> , 2010, 1, 79.	0.7	6
1213	Impact of genetic polymorphisms on clinical response to antithrombotics. <i>Pharmacogenomics and Personalized Medicine</i> , 2010, 3, 87.	0.4	6
1214	Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: role of tirofiban. <i>Journal of Blood Medicine</i> , 2010, 1, 61.	0.7	2
1215	Risk assessment and aspirin use in Asian and Western populations. <i>Vascular Health and Risk Management</i> , 2010, 6, 943.	1.0	21
1216	Impact of race and gender on antithrombotic therapy. <i>Thrombosis and Haemostasis</i> , 2010, 104, 471-484.	1.8	68
1217	Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases. <i>Drug, Healthcare and Patient Safety</i> , 2010, 2, 233.	1.0	9
1218	Comparison of Platelet P2Y12 ADP Receptor-Mediated Pathway Inhibition in Triple Versus Dual Antiplatelet Therapy as Assessed by VASP-Phosphorylation in Japanese Patients Undergoing Coronary Stenting. <i>International Heart Journal</i> , 2010, 51, 303-307.	0.5	5
1219	Medical Management of Unstable Angina and Non-“ST Segment Elevation Myocardial Infarction. , 2010, , 183-195.		0
1220	Review Article: Combination of Clopidogrel and Proton Pump Inhibitors: Implications for Clinicians. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2010, 15, 326-337.	1.0	18
1221	Combination Antithrombotic Therapies. <i>Circulation</i> , 2010, 121, 569-583.	1.6	112
1222	Current Guidelines on Antiplatelet Agents for Secondary Prevention of Noncardiogenic Stroke: An Evidence-Based Review. <i>Postgraduate Medicine</i> , 2010, 122, 49-53.	0.9	9
1223	Aspirin Plus Clopidogrel Versus Aspirin Alone After Coronary Artery Bypass Grafting. <i>Circulation</i> , 2010, 122, 2680-2687.	1.6	183
1224	Part 9: Acute Coronary Syndromes. <i>Circulation</i> , 2010, 122, S422-65.	1.6	93
1225	SCH 602539, a Protease-Activated Receptor-1 Antagonist, Inhibits Thrombosis Alone and in Combination With Cangrelor in a Folts Model of Arterial Thrombosis in Cynomolgus Monkeys. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 2143-2149.	1.1	46
1226	Cost-Effectiveness Analysis of Short-Term Clopidogrel Therapy for ST Elevation Myocardial Infarction. <i>Critical Pathways in Cardiology</i> , 2010, 9, 14-18.	0.2	6
1227	An Algorithm for Use of Prasugrel (Effient) in Patients Undergoing Cardiac Catheterization and Percutaneous Coronary Intervention. <i>Critical Pathways in Cardiology</i> , 2010, 9, 192-198.	0.2	10
1228	Duration of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Drug-eluting Stents. <i>Critical Pathways in Cardiology</i> , 2010, 9, 203-206.	0.2	8

#	ARTICLE	IF	CITATIONS
1229	Bleeding Complications With Dual Antiplatelet Therapy Among Patients With Stable Vascular Disease or Risk Factors for Vascular Disease. <i>Circulation</i> , 2010, 121, 2575-2583.	1.6	218
1230	Prasugrel. <i>Critical Pathways in Cardiology</i> , 2010, 9, 199-202.	0.2	3
1231	Preinterventional Clopidogrel Response Variability for Coil Embolization of Intracranial Aneurysms: Clinical Implications. <i>American Journal of Neuroradiology</i> , 2010, 31, 1206-1210.	1.2	92
1232	Vascular surgery: operating on patients on clopidogrel or warfarin. <i>Clinical Risk</i> , 2010, 16, 135-140.	0.1	0
1233	Long-Term Aspirin and Clopidogrel Response Evaluated by Light Transmission Aggregometry, VerifyNow, and Thrombelastography in Patients Undergoing Percutaneous Coronary Intervention. <i>Clinical Chemistry</i> , 2010, 56, 839-847.	1.5	52
1234	Response Variation in Patients Treated With Clopidogrel. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2010, 16, 483-484.	0.7	0
1235	Incidence, Predictors, and Prognostic Implications of Hospitalization for Late Bleeding After Percutaneous Coronary Intervention for Patients Older Than 65 Years. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 140-147.	1.4	69
1236	Ticagrelor Effectively and Reversibly Blocks Murine Platelet P2Y ₁₂ -Mediated Thrombosis and Demonstrates a Requirement for Sustained P2Y ₁₂ Inhibition to Prevent Subsequent Neointima. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 2385-2391.	1.1	50
1237	Pharmacogenetics guided anticoagulation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, S119-27.	1.4	0
1238	Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 754.	3.8	744
1239	Correlation of Inhibition of Platelet Aggregation With Cardiovascular and Bleeding Outcomes in Acute Coronary Syndromes. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 904-913.	1.0	5
1240	Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 393-407.	1.5	20
1241	Clopidogrel Before Elective Percutaneous Coronary Intervention. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 373-379.	1.0	2
1242	Development and performance of the zotarolimus-eluting Endeavor [®] coronary stent. <i>Expert Review of Medical Devices</i> , 2010, 7, 449-459.	1.4	8
1243	Platelet function tests for the monitoring of P2Y ₁₂ inhibitors. <i>Expert Opinion on Medical Diagnostics</i> , 2010, 4, 251-265.	1.6	2
1244	Oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention: Balancing efficacy and bleeding risk. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, S7-S17.	0.5	4
1245	Increased Risk of Bleeding in Patients on Clopidogrel Therapy After Drug-Eluting Stents Implantation. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 230-235.	1.4	41
1246	Antiplatelet Therapy Prasugrel: A Novel Platelet ADP P2Y ₁₂ Receptor Antagonist. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2010, 16, 170-176.	0.7	19

#	ARTICLE	IF	CITATIONS
1247	Long-Term Results of Carotid Artery Stents to Manage Symptomatic Carotid Artery Stenosis and Factors That Affect Outcome. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 50-56.	1.4	26
1248	Clopidogrel hypersensitivity: clinical challenges and options for management. <i>Expert Review of Clinical Pharmacology</i> , 2010, 3, 553-561.	1.3	14
1249	Cytochrome 2C19 Polymorphism and Response to Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 450-459.	1.4	18
1250	Part 10: Acute Coronary Syndromes. <i>Circulation</i> , 2010, 122, S787-817.	1.6	224
1251	Pattern of clopidogrel use in hospitalized patients receiving percutaneous coronary interventions. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, 1430-1437.	0.5	12
1252	Anti-thrombotic medications for the neurointerventionist: aspirin and clopidogrel. <i>Journal of NeuroInterventional Surgery</i> , 2010, 2, 44-49.	2.0	28
1253	A review of the use of common antiplatelet agents in orthopaedic practice. <i>Journal of Bone and Joint Surgery: British Volume</i> , 2010, 92-B, 1186-1191.	3.4	15
1254	Platelet thrombin receptor antagonism and atherothrombosis. <i>European Heart Journal</i> , 2010, 31, 17-28.	1.0	214
1255	Review article: Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease. <i>Diabetes and Vascular Disease Research</i> , 2010, 7, 274-288.	0.9	8
1256	Prasugrel as Antiplatelet Therapy in Patients With Acute Coronary Syndromes or Undergoing Percutaneous Coronary Intervention. <i>Critical Care Nurse</i> , 2010, 30, 45-54.	0.5	5
1257	The Evidence Base for Platelet Function Testing in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 277-283.	1.4	10
1258	Update on the clinical development of cangrelor. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1069-1077.	0.6	24
1259	Personalized Approaches to Clopidogrel Therapy. <i>Stroke</i> , 2010, 41, 2997-3002.	1.0	38
1260	Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke. <i>Neurology</i> , 2010, 74, 1891-1896.	1.5	16
1261	Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization. <i>Biomarkers in Medicine</i> , 2010, 4, 421-434.	0.6	4
1262	Risk of Rehospitalization for Patients Using Clopidogrel With a Proton Pump Inhibitor. <i>Archives of Internal Medicine</i> , 2010, 170, 704.	4.3	126
1263	Clinical Impact of Enhanced Inhibition of P2Y ₁₂ -Mediated Platelet Aggregation in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. <i>Hospital Practice (1995)</i> , 2010, 38, 38-43.	0.5	3
1264	Is it naive to load only clopidogrel-naive patients prior to PCI?. <i>European Heart Journal</i> , 2010, 31, 1298-1300.	1.0	0

#	ARTICLE	IF	CITATIONS
1265	Optimal Duration of Clopidogrel Use after Implantation of Drug-Eluting Stents â€” Still in Doubt. <i>New England Journal of Medicine</i> , 2010, 362, 1441-1443.	13.9	17
1266	National Estimates of Emergency Department Visits for Hemorrhage-Related Adverse Events From Clopidogrel Plus Aspirin and From Warfarin. <i>Archives of Internal Medicine</i> , 2010, 170, 1926-33.	4.3	92
1267	Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial. <i>Current Medical Research and Opinion</i> , 2010, 26, 641-651.	0.9	8
1268	Emerging Oral Antiplatelet Therapies for Acute Coronary Syndromes. <i>Hospital Practice (1995)</i> , 2010, 38, 29-37.	0.5	2
1269	Thrombin receptor antagonism â€”the potential of antiplatelet medication SCH 530348. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1015-1022.	0.9	13
1270	Elinogrel: pharmacological principles, preclinical and early phase clinical testing. <i>Future Cardiology</i> , 2010, 6, 445-453.	0.5	51
1271	Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2010, 363, 930-942.	13.9	681
1272	Prasugrel. <i>Italian Journal of Medicine</i> , 2010, 4, 43-50.	0.2	1
1273	Prasugrel® en pratique dans lâ€™urgence, pour quels patients ?. <i>JEUR/Journal EuropÃ©en Des Urgences</i> , 2010, 23, S48-S51.	0.0	0
1275	Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1557-1567.	1.9	10
1276	Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial. <i>Current Medical Research and Opinion</i> , 2010, 26, 2077-2085.	0.9	8
1277	Pharmacokinetics and Pharmacodynamics of a Bolus and Infusion of Cangrelor: A Direct, Parenteral P2Y12 Receptor Antagonist. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 27-35.	1.0	128
1278	Randomized Comparison of Percutaneous Coronary Intervention With Coronary Artery Bypass Grafting in Diabetic Patients. <i>Journal of the American College of Cardiology</i> , 2010, 55, 432-440.	1.2	421
1279	Clopidogrel and Heart Failure Survival. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1308-1309.	1.2	3
1280	Coronary Stents. <i>Journal of the American College of Cardiology</i> , 2010, 56, S1-S42.	1.2	447
1281	New P2Y12Inhibitors Versus Clopidogrel in Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1542-1551.	1.2	104
1282	Dual antiplatelet therapy in the secondary prevention of atherothrombosis: Need for new therapeutic approaches. <i>Archives of Cardiovascular Diseases</i> , 2010, 103, 497-501.	0.7	0
1283	Endovenectomy of the common femoral vein and intraoperative iliac vein recanalization for chronic iliofemoral venous occlusion. <i>Journal of Vascular Surgery</i> , 2010, 52, 243-247.	0.6	52

#	ARTICLE	IF	CITATIONS
1284	Clopidogrel with or without Omeprazole in Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2010, 363, 1909-1917.	13.9	1,019
1285	Effect of Intrinsic and Extrinsic Factors on the Clinical Pharmacokinetics and Pharmacodynamics of Prasugrel. <i>Clinical Pharmacokinetics</i> , 2010, 49, 777-798.	1.6	54
1286	Platelet Adenosine Diphosphate P2Y12 Receptor Antagonism: Benefits and Limitations of Current Treatment Strategies and Future Directions. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2010, 63, 60-76.	0.4	36
1287	Diferencias en la agregaci3n plaquetaria de sangre coronaria y perif3rica de pacientes con enfermedad coronaria. Implicaciones cl3nicas. <i>Revista Colombiana De Cardiologia</i> , 2010, 17, 255-264.	0.1	0
1288	Antiplatelet therapy and vascular disease: an update. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010, 4, 249-275.	1.0	16
1289	Guidelines for the Management of Antiplatelet Therapy in Patients With Coronary Stents Undergoing Non-Cardiac Surgery. <i>Heart Lung and Circulation</i> , 2010, 19, 2-10.	0.2	38
1290	A comparison between the Plateletworks4-assay and light transmittance aggregometry for monitoring the inhibitory effects of clopidogrel. <i>International Journal of Cardiology</i> , 2010, 140, 123-126.	0.8	49
1291	Incidence and determinants of myocardial infarction following percutaneous coronary interventions according to the revised Joint Task Force definition of troponin T elevation. <i>International Journal of Cardiology</i> , 2010, 140, 66-72.	0.8	22
1292	Oral triple antiplatelet therapy after percutaneous coronary intervention: Subject with ongoing arguments?. <i>International Journal of Cardiology</i> , 2010, 144, 112-113.	0.8	0
1293	Optimal pretreatment timing for high load dosing (6004mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectiveness. <i>International Journal of Cardiology</i> , 2010, 144, 255-257.	0.8	13
1294	Clopidogrel and proton pump inhibitors: Are the goal posts shifting?. <i>Thrombosis Research</i> , 2010, 125, 110-111.	0.8	47
1295	Sustained enhancement of residual platelet reactivity after coronary stenting in patients with myocardial infarction compared to elective patients. <i>Thrombosis Research</i> , 2010, 125, e190-e196.	0.8	28
1296	Clopidogrel use and clinical events after drug-eluting stent implantation: Findings from the HealthCore Integrated Research Database. <i>American Heart Journal</i> , 2010, 159, 462-470.e1.	1.2	21
1297	Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. <i>American Heart Journal</i> , 2010, 159, 871-875.	1.2	51
1298	Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVALuate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). <i>American Heart Journal</i> , 2010, 160, 65-72.	1.2	72
1299	Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis. <i>American Heart Journal</i> , 2010, 160, 543-551.	1.2	188
1300	Rapid adoption of drug-eluting stents: Clinical practices and outcomes from the early drug-eluting stent era. <i>American Heart Journal</i> , 2010, 160, 767-774.e1.	1.2	15
1301	Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention. <i>American Heart Journal</i> , 2010, 160, 804-811.	1.2	66

#	ARTICLE	IF	CITATIONS
1302	Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. <i>American Heart Journal</i> , 2010, 160, 1035-1041.e1.	1.2	158
1303	Elevation of high-sensitivity cardiac troponin T and composite end points in randomized trials: Author reply. <i>American Heart Journal</i> , 2010, 160, e49.	1.2	0
1304	Elevation of high-sensitivity cardiac troponin T and composite end points in randomized trials. <i>American Heart Journal</i> , 2010, 160, e47.	1.2	0
1305	Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: Balancing safety and efficacy. <i>American Heart Journal</i> , 2010, 160, S36-S41.	1.2	6
1306	Proton Pump Inhibitors and Clopidogrel. <i>Cardiovascular Therapeutics</i> , 2010, 28, 169-176.	1.1	2
1307	Variability of residual platelet function despite clopidogrel treatment in patients with peripheral arterial occlusive disease. <i>Atherosclerosis</i> , 2010, 209, 504-509.	0.4	11
1309	Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. <i>Thrombosis and Haemostasis</i> , 2010, 104, 609-917.	1.8	60
1312	Controversies in the Use of Drug-Eluting Stents for Acute Myocardial Infarction: A Critical Appraisal of the Data. <i>Annual Review of Medicine</i> , 2010, 61, 215-231.	5.0	6
1313	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. , 2010, , 145-182.		1
1314	Analisi di costo-efficacia di prasugrel rispetto a clopidogrel nel trattamento di pazienti con sindrome coronarica acuta e intervento di angioplastica per via percutanea programmato. <i>Giornale Italiano Di Health Technology Assessment</i> , 2010, 3, 55-63.	0.1	0
1315	Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition. <i>Platelets</i> , 2010, 21, 563-570.	1.1	18
1316	A review of simple, non-invasive means of assessing peripheral arterial disease and implications for medical management. <i>Annals of Medicine</i> , 2010, 42, 115-126.	1.5	46
1317	Individual Variability of Response to Antiplatelet Therapy is an Important Determinant of Adverse Clinical Outcome. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2010, 17, 121-130.	1.0	3
1318	Heterogeneity of Efficacy and Safety of Antiplatelet Therapy in Cardiovascular and Cerebrovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 115-124.	1.0	4
1319	Platelet P2Y12 Receptor Inhibition. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 217-226.	1.0	24
1320	Periprocedural myocardial injury during elective percutaneous coronary intervention: is it important and how can it be prevented?. <i>Heart</i> , 2010, 96, 736-740.	1.2	60
1321	Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 119-133.	1.9	14
1322	Platelet response to aspirin and clopidogrel in patients with peripheral atherosclerosis. <i>Platelets</i> , 2011, 22, 537-546.	1.1	11

#	ARTICLE	IF	CITATIONS
1323	Factors associated with clopidogrel use, adherence, and persistence in patients with acute coronary syndromes undergoing percutaneous coronary intervention. <i>Current Medical Research and Opinion</i> , 2011, 27, 633-641.	0.9	33
1324	AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. <i>Circulation</i> , 2011, 124, 2458-2473.	1.6	1,369
1325	Prasugrel as alternative treatment strategy in a case with a hypersensitivity reaction to clopidogrel. <i>Platelets</i> , 2011, 22, 75-76.	1.1	13
1327	Perioperative Considerations and Management in Patients with Intravascular Stents. <i>Advances in Anesthesia</i> , 2011, 29, 85-112.	0.5	0
1328	Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors During Elective Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1190-1199.	1.2	61
1329	2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non- σ ST-Elevation Myocardial Infarction (Updating the 2007 Guideline). <i>Journal of the American College of Cardiology</i> , 2011, 57, 1920-1959.	1.2	332
1330	2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non- σ ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2011, 57, e215-e367.	1.2	420
1331	Outcome Comparison of 600- and 300-mg Loading Doses of Clopidogrel in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1592-1599.	1.2	107
1332	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2550-2583.	1.2	114
1333	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2011, 58, e44-e122.	1.2	2,027
1334	AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2432-2446.	1.2	700
1335	Sirolimus-Eluting Coronary Stents in Octogenarians. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 982-991.	1.1	10
1336	Dual Antiplatelet Therapy Duration and Clinical Outcomes Following Treatment With Zotarolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 1119-1128.	1.1	37
1337	Will We Ever Know the Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation? Editorials published in <i>JACC: Cardiovascular Interventions</i> reflect the views of the authors and do not necessarily represent the views of <i>JACC: Cardiovascular Interventions</i> or the American College of Cardiology. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 1129-1132.	1.1	15
1339	Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. <i>The Cochrane Library</i> , 2011, , CD005158.	1.5	20
1340	Ticagrelor: from concept to clinical evaluation. <i>Biomarkers in Medicine</i> , 2011, 5, 53-62.	0.6	8
1341	Safety of Clopidogrel in Older Patients. <i>Drugs and Aging</i> , 2011, 28, 119-129.	1.3	7
1342	The evolution of antiplatelet therapy in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2011, 8, 547-559.	6.1	84

#	ARTICLE	IF	CITATIONS
1343	The Influence of Low Platelet Count on Whole Blood Aggregometry Assessed by Multiplate. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011, 17, E211-E217.	0.7	91
1344	Cost-effectiveness of oral antiplatelet agents—current and future perspectives. <i>Nature Reviews Cardiology</i> , 2011, 8, 580-591.	6.1	8
1345	Review: Antiplatelet Therapy in Acute Coronary Syndromes. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2011, 16, 24-42.	1.0	9
1347	Hypercoagulable state after off-pump coronary artery bypass grafting: evidence, mechanisms and implications. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 599-608.	0.6	13
1348	Loss of short-term symptomatic benefit in patients with an occluded infarct artery is unrelated to non-protocol revascularization: Results from the Occluded Artery Trial (OAT). <i>American Heart Journal</i> , 2011, 161, 84-90.	1.2	1
1349	A Comparison of prasugrel at the time of percutaneous Coronary intervention or as pretreatment at the time of diagnosis in patients with non- ST -segment elevation myocardial infarction: Design and rationale for the ACCOAST study. <i>American Heart Journal</i> , 2011, 161, 650-656.e1.	1.2	23
1350	Clopidogrel loading dose and bleeding outcomes in patients undergoing urgent coronary artery bypass grafting. <i>American Heart Journal</i> , 2011, 161, 404-410.	1.2	22
1351	Oral antiplatelet therapy for atherothrombotic disease: Current evidence and new directions. <i>American Heart Journal</i> , 2011, 161, 450-461.	1.2	30
1352	Temporal trends and practice variations in clopidogrel loading doses in patients with non- ST -segment elevation myocardial infarction, from the National Cardiovascular Data Registry. <i>American Heart Journal</i> , 2011, 161, 689-697.	1.2	6
1353	Early clopidogrel use in non- ST elevation acute coronary syndrome and subsequent coronary artery bypass grafting. <i>American Heart Journal</i> , 2011, 161, 832-841.	1.2	16
1354	Upstream treatment of acute coronary syndrome in the ED. <i>American Journal of Emergency Medicine</i> , 2011, 29, 446-456.	0.7	0
1355	ED to catheterization laboratory: a roundtable integrating trials with practice. <i>American Journal of Emergency Medicine</i> , 2011, 29, 1203-1216.	0.7	0
1356	Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter. <i>Canadian Journal of Cardiology</i> , 2011, 27, 74-90.	0.8	273
1357	The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines. <i>Canadian Journal of Cardiology</i> , 2011, 27, S1-S59.	0.8	106
1358	Economic Evaluation of Clopidogrel Plus Aspirin for Secondary Prevention of Cardiovascular Events in Canada for Patients With Established Cardiovascular Disease: Results From the CHARISMA Trial. <i>Canadian Journal of Cardiology</i> , 2011, 27, 222-231.	0.8	2
1359	The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines Executive Summary. <i>Canadian Journal of Cardiology</i> , 2011, 27, 208-221.	0.8	50
1360	Antiplatelet therapy in the perioperative period. <i>European Journal of Internal Medicine</i> , 2011, 22, 26-31.	1.0	25
1361	Residual platelet reactivity after aspirin and clopidogrel treatment predicts 2-year major cardiovascular events in patients undergoing percutaneous coronary intervention. <i>European Journal of Internal Medicine</i> , 2011, 22, 471-477.	1.0	15

#	ARTICLE	IF	CITATIONS
1362	Does CYP2C19 inhibition lead to clopidogrel thrombogenicity?. <i>Medical Hypotheses</i> , 2011, 77, 448-450.	0.8	0
1363	Clopidogrel pretreatment in PCI: Absolute requirement or obsolete myth?. <i>International Journal of Cardiology</i> , 2011, 146, 305-310.	0.8	3
1364	Duration of evidence-based medical therapy and the hazard for atherothrombotic events following percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2011, 153, 262-266.	0.8	3
1365	Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. <i>Journal of Vascular Surgery</i> , 2011, 54, e1-e31.	0.6	546
1366	ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2011, 32, 2999-3054.	1.0	2,995
1367	Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2011, 42, 227-276.	1.0	1,433
1368	The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention. <i>Thrombosis Research</i> , 2011, 127, 23-28.	0.8	54
1369	Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention. <i>Thrombosis Research</i> , 2011, 128, e130-e136.	0.8	29
1370	Clopidogrel Resistance: Identifying and Overcoming a Barrier to Effective Antiplatelet Treatment. <i>Cardiovascular Therapeutics</i> , 2011, 29, e100-e111.	1.1	30
1371	Safety and Efficacy of Clopidogrel before Surgery. <i>Clinical Medicine Insights Therapeutics</i> , 2011, 3, CMT.S2334.	0.4	2
1373	Preoperative Aspirin Resistance does not Increase Myocardial Injury during Off-pump Coronary Artery Bypass Surgery. <i>Journal of Korean Medical Science</i> , 2011, 26, 1041.	1.1	6
1374	Resultados Chilenos del registro internacional de factores de riesgo y tratamiento de angina inestable e infarto al miocardio sin supradesnivel del segmento ST: ACCORD (ACute CORonary) Tj ETQq1 1 0.7843d4rgBT /Overlock 10		
1375	Clopidogrel withdrawal: Is there a "rebound" phenomenon?. <i>Thrombosis and Haemostasis</i> , 2011, 105, 211-220.	1.8	55
1376	Role of cytochrome P450 genotype in the steps toward personalized drug therapy. <i>Pharmacogenomics and Personalized Medicine</i> , 2011, 4, 123.	0.4	20
1377	Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview. <i>Vascular Health and Risk Management</i> , 2011, 7, 445.	1.0	15
1378	Does Anticoagulant or Antiplatelet Therapy Need to Be Discontinued for Transrectal Ultrasound-Guided Prostate Biopsies? A Systematic Literature Review. <i>Current Urology</i> , 2011, 5, 121-124.	0.4	2
1379	Explaining the unexpected: Insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. <i>Thrombosis and Haemostasis</i> , 2011, 105, 763-765.	1.8	36
1380	Antiplatelet combinations for prevention of atherothrombotic events. <i>Vascular Health and Risk Management</i> , 2011, 7, 23.	1.0	6

#	ARTICLE	IF	CITATIONS
1381	Drugs affecting coagulation and platelet function. , 2013, , 912-947.		0
1382	The genetic basis of platelet responsiveness to clopidogrel. <i>Thrombosis and Haemostasis</i> , 2011, 106, 203-210.	1.8	13
1383	National trend in prevalence, cost, and discharge disposition after subdural hematoma from 1998â€“2007*. <i>Critical Care Medicine</i> , 2011, 39, 1619-1625.	0.4	81
1384	Treatment of acute coronary syndrome: Part 1: Non-ST-segment acute coronary syndrome. <i>Critical Care Medicine</i> , 2011, 39, 2346-2353.	0.4	18
1385	Light Transmittance Aggregometry Induced by Different Concentrations of Adenosine Diphosphate to Monitor Clopidogrel Therapy: A Methodological Study. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 94-98.	1.0	16
1386	The Perils of Combination Antithrombotic Therapy and Potential Resolutions. <i>Stroke</i> , 2011, 42, 278-281.	1.0	7
1387	Delayed Thrombosis or Stenosis Following Enterprise-Assisted Stent-Coiling: Is It Safe? Midterm Results of the Interstate Collaboration of Enterprise Stent Coiling. <i>Neurosurgery</i> , 2011, 69, 908-914.	0.6	117
1388	Reversal of Clopidogrel-Induced Bleeding with rFVIIa in Healthy Subjects. <i>Anesthesia and Analgesia</i> , 2011, 113, 703-710.	1.1	26
1389	The Onset of Inhibition of Platelet Aggregation With Prasugrel Compared With Clopidogrel Loading Doses Using Gatekeeping Analysis of Integrated Clinical Pharmacology Data. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 57, 317-324.	0.8	16
1390	The rationale and evidence for triple antiplatelet therapy in acute coronary syndromes. <i>Clinical Investigation</i> , 2011, 1, 1155-1165.	0.0	0
1391	Antiplatelet therapy in elderly patients. <i>Aging Health</i> , 2011, 7, 311-320.	0.3	2
1392	Role of Platelets and Antiplatelet Therapy in Cardiovascular Disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2011, 18, 431-442.	0.9	46
1393	Flow Diversion in Aneurysms Trial: The Design of the FIAT Study. <i>Interventional Neuroradiology</i> , 2011, 17, 147-153.	0.7	36
1394	Antiplatelet therapy: thrombin receptor antagonists. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 658-671.	1.1	34
1395	Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 697-706.	1.1	43
1396	Combined influence of protonâ€pump inhibitors, calciumâ€channel blockers and CYP2C19*2 on onâ€treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1892-1901.	1.9	39
1397	The Secondary Prevention of Small Subcortical Strokes (SPS3) Study. <i>International Journal of Stroke</i> , 2011, 6, 164-175.	2.9	136
1398	Differential Impacts of CYP2C19 Gene Polymorphisms on the Antiplatelet Effects of Clopidogrel and Ticlopidine. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 229-233.	2.3	35

#	ARTICLE	IF	CITATIONS
1399	Pantoprazole for the prevention of gastrointestinal bleeding in high-risk patients with acute coronary syndromes. <i>Journal of Critical Care</i> , 2011, 26, 434.e1-434.e6.	1.0	15
1400	Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects. <i>Journal of Cardiology</i> , 2011, 57, 275-282.	0.8	13
1401	Effect of coronary endothelial function on outcomes in patients undergoing percutaneous coronary intervention. <i>Journal of Cardiology</i> , 2011, 57, 231-238.	0.8	23
1402	The potential benefits and risks of the use of dual antiplatelet therapy beyond 6 months following sirolimus-eluting stent implantation for low-risk patients. <i>Journal of Cardiology</i> , 2011, 57, 283-289.	0.8	10
1403	Individual variability in the disposition of and response to clopidogrel: Pharmacogenomics and beyond. , 2011, 129, 267-289.		52
1405	Myocardial Revascularization by Percutaneous Coronary Intervention: Past, Present, and the Future. <i>Current Problems in Cardiology</i> , 2011, 36, 375-401.	1.1	11
1406	Safety and Efficacy of Clopidogrel Reloading in Patients on Chronic Clopidogrel Therapy Who Present With an Acute Coronary Syndrome and Undergo Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2011, 107, 1779-1782.	0.7	8
1407	Effect of Clopidogrel Pretreatment on Ischemic Complications of Percutaneous Coronary Intervention Among Bivalirudin-Treated Patients (from the EVENT Registry). <i>American Journal of Cardiology</i> , 2011, 107, 1751-1756.	0.7	6
1408	Comparison of Efficacy and Safety of a Standard Versus a Loading Dose of Clopidogrel for Acute Myocardial Infarction in Patients ≥ 75 Years of Age (from the FAST-MI Registry). <i>American Journal of Cardiology</i> , 2011, 108, 755-759.	0.7	5
1409	Rate of Nuisance Bleedings and Impact on Compliance to Prasugrel in Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2011, 108, 1710-1713.	0.7	34
1410	Clopidogrel vs. Aspirin Treatment on Admission Improves 5-Year Survival After a First-ever Acute Ischemic Stroke. Data from the Athens Stroke Outcome Project. <i>Archives of Medical Research</i> , 2011, 42, 443-450.	1.5	6
1411	Simultaneous Hybrid Revascularization Versus Off-Pump Coronary Artery Bypass for Multivessel Coronary Artery Disease. <i>Annals of Thoracic Surgery</i> , 2011, 91, 432-438.	0.7	67
1412	Prolonged clopidogrel application reduces tissue factor expression after percutaneous coronary intervention in the porcine model. <i>Cardiovascular Revascularization Medicine</i> , 2011, 12, 47-55.	0.3	4
1413	Timing of thienopyridine loading and outcomes in the TRITON trial: the FDA Prasugrel Action Package outlook. <i>Cardiovascular Revascularization Medicine</i> , 2011, 12, 94-98.	0.3	7
1414	Clopidogrel in acute coronary syndromes: Where are we now?. <i>Thrombosis and Haemostasis</i> , 2011, 105, 766-773.	1.8	6
1415	Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention. <i>Pharmacogenomics</i> , 2011, 12, 1269-1280.	0.6	46
1416	Antiplatelet agents for the treatment and prevention of atherothrombosis. <i>European Heart Journal</i> , 2011, 32, 2922-2932.	1.0	203
1417	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, E266-355.	0.7	97

#	ARTICLE	IF	CITATIONS
1418	Is platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk?. Netherlands Heart Journal, 2011, 19, 279-284.	0.3	22
1419	Effect of gender difference on platelet reactivity. Netherlands Heart Journal, 2011, 19, 451-457.	0.3	67
1420	Prevalence of CYP2C19 polymorphisms in the Lebanese population. Molecular Biology Reports, 2011, 38, 5449-5452.	1.0	26
1421	Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600Åmg clopidogrel. Journal of Thrombosis and Thrombolysis, 2011, 32, 64-71.	1.0	33
1422	Genetic determinants of platelet response to clopidogrel. Journal of Thrombosis and Thrombolysis, 2011, 32, 459-466.	1.0	69
1423	Endoscopic resection of bladder cancer in patients receiving double platelet antiaggregant therapy. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 2281-2287.	1.3	16
1427	Significant Increase in Clopidogrel Use Across U.S. Childrenâ€™s Hospitals. Pediatric Cardiology, 2011, 32, 167-175.	0.6	27
1428	Clopidogrel and Proton Pump Inhibitors. JACC: Cardiovascular Interventions, 2011, 4, 365-380.	1.1	51
1429	How Should Patients Requiring Dual Antiplatelet Therapy be Managed When Undergoing Elective Endoscopic Gastrointestinal Procedures?. Current Treatment Options in Cardiovascular Medicine, 2011, 13, 46-56.	0.4	1
1430	Trend in Outcome and Financial Impact of Subdural Hemorrhage. Neurocritical Care, 2011, 14, 260-266.	1.2	34
1431	Considerations Regarding Antiplatelet Therapy in the Elderly. Current Cardiovascular Risk Reports, 2011, 5, 86-95.	0.8	0
1432	Current Status of Antiplatelet Agents to Prevent Stroke. Current Neurology and Neuroscience Reports, 2011, 11, 6-14.	2.0	9
1433	Clopidogrel and proton pump inhibitors: a clinically meaningful interaction?. Pharmacoepidemiology and Drug Safety, 2011, 20, 214-218.	0.9	4
1434	Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome. Pharmacoepidemiology and Drug Safety, 2011, 20, 1043-1049.	0.9	27
1435	Emerging clinical applications in cardiovascular pharmacogenomics. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2011, 3, 206-215.	6.6	7
1436	Triple therapy in hospitalized patients: Facts and controversies. Journal of Hospital Medicine, 2011, 6, 537-545.	0.7	1
1437	Hemodynamic effect of Neuroform stent on intimal hyperplasia and thrombus formation in a carotid aneurysm. Medical Engineering and Physics, 2011, 33, 573-580.	0.8	27
1438	Impact of Bleeding on Subsequent Early and Late Mortality After Drug-Eluting Stent Implantation. JACC: Cardiovascular Interventions, 2011, 4, 423-431.	1.1	24

#	ARTICLE	IF	CITATIONS
1439	Emerging Genomic Applications in Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 473-482.	1.1	35
1440	The optimal pharmacological formula for percutaneous coronary intervention. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1075-1086.	0.9	0
1441	Oral antiplatelet agents in ischemic heart disease: a review of the latest clinical evidence. <i>Clinical Investigation</i> , 2011, 1, 1315-1328.	0.0	0
1442	Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention. <i>Biomarkers in Medicine</i> , 2011, 5, 9-30.	0.6	3
1443	Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention with Drug-Eluting Stent Implantation: A Review of the Current Guidelines and Literature. <i>Hospital Practice (1995)</i> , 2011, 39, 32-40.	0.5	11
1444	Antiplatelet Drugs: Mechanisms and Risks of Bleeding Following Cardiac Operations. <i>International Journal of Angiology</i> , 2011, 20, 001-018.	0.2	18
1445	Unravelling the benefit against the risk of long-term dual antiplatelet therapy. <i>Current Opinion in Cardiology</i> , 2011, 26, S22-S30.	0.8	4
1446	Prescribing proton pump inhibitor and clopidogrel together. <i>Current Opinion in Gastroenterology</i> , 2011, 27, 558-564.	1.0	14
1447	High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. <i>Heart</i> , 2011, 97, 983-990.	1.2	71
1448	Results of a Survey Assessing Provider Beliefs of Adherence Barriers to Antiplatelet Medications. <i>Critical Pathways in Cardiology</i> , 2011, 10, 134-141.	0.2	7
1449	Comparison of a Point-of-Care Platelet Function Testing to Light Transmission Aggregometry in Patients Undergoing Percutaneous Coronary Intervention Pretreated With Aspirin and Clopidogrel. <i>Point of Care</i> , 2011, 10, 35-39.	0.5	3
1450	Use of Early Clopidogrel by Reperfusion Strategy Among Patients Presenting With ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 603-609.	0.9	5
1451	Perioperative management of clopidogrel therapy: the effects on in-hospital cardiac morbidity in older patients with hip fractures. <i>British Journal of Anaesthesia</i> , 2011, 107, 911-915.	1.5	36
1452	Mortality Associated With Atrial Fibrillation in Patients With Myocardial Infarction. <i>Circulation</i> , 2011, 123, 1587-1593.	1.6	264
1453	High-dose tirofiban pretreatment reduces the need for bail-out study medication in patients with ST-segment elevation myocardial infarction: results of a subgroup analysis of the On-TIME 2 trial. <i>Heart</i> , 2011, 97, 106-111.	1.2	11
1454	Platelet Biology and Implications for Antiplatelet Therapy in Atherothrombotic Disease. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011, 17, 371-380.	0.7	10
1455	Review: Antiplatelet Drugs: What Comes Next?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011, 17, 9-26.	0.7	19
1456	Pharmacodynamic Evaluation of Pantoprazole Therapy on Clopidogrel Effects. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 273-279.	1.4	35

#	ARTICLE	IF	CITATIONS
1457	Variability of clopidogrel response in patients with type 2 diabetes mellitus. <i>Diabetes and Vascular Disease Research</i> , 2011, 8, 245-253.	0.9	28
1458	Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2221-8.	3.8	313
1459	2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non- σ ST-Elevation Myocardial Infarction (Updating the 2007 Guideline). <i>Circulation</i> , 2011, 123, 2022-2060.	1.6	321
1460	Body weight: a risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting. <i>Journal of NeuroInterventional Surgery</i> , 2011, 3, 177-181.	2.0	31
1461	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. <i>Circulation</i> , 2011, 124, 2574-2609.	1.6	500
1462	Gastrointestinal Bleeding after Percutaneous Coronary Intervention. <i>Digestion</i> , 2011, 83, 153-160.	1.2	17
1463	Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes Undergoing PCI: A Long Way to Select Optimal Agent and Route. <i>ISRN Vascular Medicine</i> , 2011, 2011, 1-9.	0.7	1
1464	Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials. <i>Therapeutic Advances in Chronic Disease</i> , 2011, 2, 265-278.	1.1	25
1465	P2Y12 Receptor Inhibitors: Integrating Ticagrelor into the Management of Acute Coronary Syndrome. <i>Annals of Pharmacotherapy</i> , 2011, 45, 1151-1156.	0.9	9
1466	Upstream Clopidogrel Use and the Efficacy and Safety of Early Eptifibatid Treatment in Patients With Acute Coronary Syndrome. <i>Circulation</i> , 2011, 123, 722-730.	1.6	39
1467	Long-Term Effects of Percutaneous Coronary Intervention of the Totally Occluded Infarct-Related Artery in the Subacute Phase After Myocardial Infarction. <i>Circulation</i> , 2011, 124, 2320-2328.	1.6	34
1468	High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial. <i>Heart</i> , 2011, 97, 626-631.	1.2	13
1469	Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. <i>European Heart Journal</i> , 2011, 32, 2970-2988.	1.0	84
1470	The Perils of Combination Antithrombotic Therapy and Potential Resolutions. <i>Circulation</i> , 2011, 123, 232-235.	1.6	10
1471	Efficacy and Safety of Combination Antiplatelet Therapies in Patients With Symptomatic Intracranial Atherosclerotic Stenosis. <i>Stroke</i> , 2011, 42, 2883-2890.	1.0	126
1472	Systematic review of thienopyridine discontinuation and its impact upon clinical outcomes. <i>European Heart Journal</i> , 2011, 32, 2358-2364.	1.0	17
1473	Percutaneous coronary intervention in the elderly. <i>Nature Reviews Cardiology</i> , 2011, 8, 79-90.	6.1	72
1474	2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non- σ ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2011, 123, e426-579.	1.6	658

#	ARTICLE	IF	CITATIONS
1475	Incidence of death and recurring acute coronary syndrome after stopping clopidogrel therapy in a large commercially-insured population in the US. <i>Current Medical Research and Opinion</i> , 2011, 27, 1079-1087.	0.9	10
1476	Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 203-233.	1.0	1
1477	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. <i>Circulation</i> , 2011, 124, e574-651.	1.6	1,946
1478	Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. <i>European Heart Journal</i> , 2011, 32, 2954-2961.	1.0	85
1480	Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome. <i>Circulation</i> , 2011, 123, 798-813.	1.6	272
1481	Laboratory signs of aspirin response in haemodialysis patients. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2011, 71, 426-431.	0.6	3
1482	Effect of early clopidogrel discontinuation on rehospitalization in acute coronary syndrome: Results from two distinct patient populations. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 1015-1024.	0.5	10
1483	Impact of Dual Antiplatelet Therapy with Proton Pump Inhibitors on the Outcome of Patients with Acute Coronary Syndrome Undergoing Drug-Eluting Stent Implantation. <i>ISRN Cardiology</i> , 2012, 2012, 1-8.	1.6	10
1484	Relationship Between Plasma Inflammatory Markers and Platelet Aggregation in Patients With Clopidogrel Resistance After Angioplasty. <i>Angiology</i> , 2012, 63, 62-66.	0.8	25
1485	Comparison of Bolus Only With Bolus Plus Infusion of Bivalirudin in Patients Undergoing Elective Percutaneous Coronary Intervention: A Retrospective Observational Study. <i>Journal of Pharmacy Practice</i> , 2012, 25, 537-540.	0.5	2
1486	2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non- σ ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011) <i>Tj ETQq0100 rgBT /Overlock 1</i>	1.6	10
1487	Cardiovascular Devices and Platelet Interactions. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 296-304.	1.4	7
1488	Is There a Clinically Significant Interaction Between Calcium Channel Antagonists and Clopidogrel?. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 77-81.	1.4	30
1489	Antiplatelet Therapy in Acute Coronary Syndrome and Atrial Fibrillation: Aspirin. <i>Advances in Cardiology</i> , 2012, 47, 20-30.	2.6	2
1490	Increased Atherothrombotic Burden in Patients with Diabetes Mellitus and Acute Coronary Syndrome: A Review of Antiplatelet Therapy. <i>Cardiology Research and Practice</i> , 2012, 2012, 1-18.	0.5	26
1491	Antiplatelet Therapy for Carotid Artery Stenting. <i>Interventional Neurology</i> , 2012, 1, 151-163.	1.8	21
1492	Aspirin sensitivity and coronary artery disease: implications for the practicing cardiologist. <i>Future Cardiology</i> , 2012, 8, 555-562.	0.5	5
1494	Protease-Activated Receptor-1 Antagonists. <i>American Journal of Therapeutics</i> , 2012, 19, 465-469.	0.5	3

#	ARTICLE	IF	CITATIONS
1495	Cost analysis of re-exploration for bleeding after coronary artery bypass graft surgery. <i>British Journal of Anaesthesia</i> , 2012, 108, 216-222.	1.5	33
1496	Platelet Function Profile Post-Clopidogrel Therapy in Patients With Type 2 Diabetes Undergoing Coronary Stent Implantation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012, 18, 249-257.	0.7	2
1497	Insufficient Platelet Inhibition Is Related to Silent Embolic Cerebral Infarctions After Coronary Angiography. <i>Stroke</i> , 2012, 43, 727-732.	1.0	13
1498	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012, 33, 2569-2619.	1.0	5,034
1499	The Pattern of Platelet Response to Clopidogrel in Iranian Patients After Percutaneous Coronary Intervention. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1098-1105.	1.0	3
1500	Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 149-158.	0.9	11
1501	Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting. <i>Circulation</i> , 2012, 125, 2015-2026.	1.6	640
1502	Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1273-1285.	0.6	6
1503	Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease. <i>Platelets</i> , 2012, 23, 537-551.	1.1	17
1504	Antiplatelet therapy in ENT surgery: a review. <i>Journal of Laryngology and Otology</i> , 2012, 126, 331-336.	0.4	10
1505	The case for more intensive use of statins. <i>Therapeutic Advances in Chronic Disease</i> , 2012, 3, 201-210.	1.1	3
1506	Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 261-269.	1.4	244
1507	Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options. <i>Vascular Health and Risk Management</i> , 2012, 8, 77.	1.0	35
1508	Trends in Ambulatory Prescribing of Antiplatelet Therapy among US Ischemic Stroke Patients: 2000-2007. <i>Advances in Pharmacological Sciences</i> , 2012, 2012, 1-8.	3.7	14
1509	Long-term antiplatelet therapy. <i>Current Opinion in Cardiology</i> , 2012, 27, 347-354.	0.8	1
1510	Chronicle of an Unforetold Death. <i>Archives of Internal Medicine</i> , 2012, 172, 1174-7.	4.3	2
1511	Platelet Function Testing and Genotyping Improve Outcome in Patients Treated With Antithrombotic Agents. <i>Circulation</i> , 2012, 125, 1276-1287.	1.6	111
1512	Grabbing the Horns of a Dilemma. <i>Circulation</i> , 2012, 125, 1967-1970.	1.6	14

#	ARTICLE	IF	CITATIONS
1513	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. <i>Circulation</i> , 2012, 126, e354-471.	1.6	675
1514	Enterprise Stent-Assisted Coiling of Wide-Necked Intracranial Aneurysms: Clinical and Angiographic Follow-up. <i>Interventional Neuroradiology</i> , 2012, 18, 426-431.	0.7	18
1515	Treatment of acute coronary syndrome. <i>Critical Care Medicine</i> , 2012, 40, 1939-1945.	0.4	12
1516	Antiplatelet and Antithrombin Strategies in Acute Coronary Syndrome: State-Of-The-Art Review. <i>Current Cardiology Reviews</i> , 2012, 8, 239-249.	0.6	16
1517	EFFECTS OF DIFFERENT DOSES OF NAOXINTONG COMBINED WITH DUAL ANTIPLATELET THERAPY IN PATIENTS WITH CYTOCHROME P450 2C19*2 GENE MUTATION AFTER PERCUTANEOUS CORONARY INTERVENTION. <i>Heart</i> , 2012, 98, E96.1-E96.	1.2	0
1518	Prescribing proton pump inhibitors with clopidogrel. <i>BMJ, The</i> , 2012, 345, e4558-e4558.	3.0	4
1519	Long-term Results of Enterprise Stent-Assisted Coiling of Cerebral Aneurysms. <i>Neurosurgery</i> , 2012, 71, 239-244.	0.6	139
1520	A Randomized Crossover Study Comparing the Antiplatelet Effect of Plavix Versus Generic Clopidogrel. <i>Journal of Cardiovascular Pharmacology</i> , 2012, 60, 495-501.	0.8	10
1522	Primary and Secondary Prevention of Cardiovascular Disease. <i>Chest</i> , 2012, 141, e637S-e668S.	0.4	435
1524	Influence of Omeprazole and Famotidine on the Antiplatelet Effects of Clopidogrel in Addition to Aspirin in Patients With Acute Coronary Syndromes. <i>Circulation Journal</i> , 2012, 76, 2673-2680.	0.7	20
1525	Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. <i>Lancet, The</i> , 2012, 379, 1705-1711.	6.3	341
1526	The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. <i>European Heart Journal</i> , 2012, 33, 2143-2150.	1.0	86
1527	2012 Update to The Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations. <i>Annals of Thoracic Surgery</i> , 2012, 94, 1761-1781.	0.7	256
1528	Use of Aspirin and Clopidogrel After Coronary Artery Bypass Graft Surgery. <i>Annals of Pharmacotherapy</i> , 2012, 46, 678-687.	0.9	26
1529	Thienopyridines and Other ADP-Receptor Antagonists. <i>Handbook of Experimental Pharmacology</i> , 2012, , 165-198.	0.9	24
1530	Modern antiplatelet agents in coronary artery disease. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1261-1272.	0.6	3
1531	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2012, 60, e44-e164.	1.2	1,423
1532	Association of Clopidogrel Pretreatment With Mortality, Cardiovascular Events, and Major Bleeding Among Patients Undergoing Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2507.	3.8	175

#	ARTICLE	IF	CITATIONS
1533	Genetic Considerations. <i>Advances in Cardiology</i> , 2012, 47, 100-113.	2.6	3
1534	Bleeding and the Use of Antiplatelet Agents in the Management of Acute Coronary Syndromes and Atrial Fibrillation. <i>Advances in Cardiology</i> , 2012, 47, 125-140.	2.6	0
1535	Impact of Antiplatelet Therapy in Heart Disease. <i>Advances in Cardiology</i> , 2012, 47, 5-19.	2.6	4
1536	Prasugrel. <i>Advances in Cardiology</i> , 2012, 47, 39-63.	2.6	3
1537	TRITON and Beyond: New Insights into the Profile of Prasugrel. <i>Cardiovascular Therapeutics</i> , 2012, 30, e174-82.	1.1	17
1538	Clinical review: Traumatic brain injury in patients receiving antiplatelet medication. <i>Critical Care</i> , 2012, 16, 228.	2.5	61
1539	Management of peripheral arterial interventions with mono or dual antiplatelet therapy—the MIRROR study: a randomised and double-blinded clinical trial. <i>European Radiology</i> , 2012, 22, 1998-2006.	2.3	144
1540	Prognostic implication of macrocytosis on adverse outcomes after coronary intervention. <i>Atherosclerosis</i> , 2012, 221, 148-153.	0.4	38
1541	Platelet proteome and clopidogrel response in patients with stable angina undergoing percutaneous coronary intervention. <i>Clinical Biochemistry</i> , 2012, 45, 758-765.	0.8	18
1542	ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 173.	0.4	183
1543	Platelet aggregation at discharge: A useful tool in acute coronary syndromes?. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2012, 31, 545-554.	0.2	5
1544	Platelet aggregation at discharge: A useful tool in acute coronary syndromes?. <i>Revista Portuguesa De Cardiologia</i> , 2012, 31, 545-554.	0.2	5
1545	Concomitant use of clopidogrel and proton pump inhibitors may attenuate the prognosis of coronary heart disease in hemodialysis patients. <i>Dialysis Y Trasplante</i> , 2012, 33, 75-83.	0.4	0
1546	Comparison of early outcomes after primary stenting in Japanese patients with acute myocardial infarction between clopidogrel and ticlopidine in concomitant use with proton-pump inhibitor. <i>Journal of Cardiology</i> , 2012, 60, 7-11.	0.8	3
1547	The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within 1 month of treatment. <i>Platelets</i> , 2012, 23, 121-131.	1.1	18
1548	Pharmacogenetics of Clopidogrel: Comparison Between a Standard and a Rapid Genetic Testing. <i>Genetic Testing and Molecular Biomarkers</i> , 2012, 16, 500-503.	0.3	17
1549	Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study. <i>European Heart Journal</i> , 2012, 33, 2527-2534.	1.0	16
1550	Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 173.e1-173.e55.	0.6	31

#	ARTICLE	IF	CITATIONS
1551	The effect of clopidogrel besylate and clopidogrel hydrogensulfate on platelet aggregation in patients with coronary artery disease: A retrospective study. <i>Thrombosis Research</i> , 2012, 129, 700-703.	0.8	10
1552	Primary Prevention of Ischaemic Cardiovascular Disorders with Antiplatelet Agents. <i>Handbook of Experimental Pharmacology</i> , 2012, , 565-605.	0.9	9
1553	Association of Clopidogrel Treatment With Risk of Mortality and Cardiovascular Events Following Myocardial Infarction in Patients With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 882.	3.8	48
1554	Effect of Addition of Clopidogrel to Aspirin on Mortality. <i>Stroke</i> , 2012, 43, 2157-2162.	1.0	44
1555	Acute Coronary Syndrome in Patients With Atrial Fibrillation. <i>Circulation</i> , 2012, 126, 1176-1178.	1.6	3
1556	Nonfatal myocardial infarction and long-term outcomes in coronary artery disease. <i>American Heart Journal</i> , 2012, 163, 95-103.	1.2	0
1557	A high loading dose of clopidogrel reduces myocardial infarct size in patients undergoing primary percutaneous coronary intervention: A magnetic resonance imaging study. <i>American Heart Journal</i> , 2012, 163, 500-507.	1.2	26
1558	Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: Results from long-term follow-up of the Occluded Artery Trial (OAT) cohort. <i>American Heart Journal</i> , 2012, 163, 563-571.	1.2	36
1559	Coronary Artery Bypass Surgery Provides Long-Term Results Superior to Percutaneous Coronary Intervention. <i>Heart Lung and Circulation</i> , 2012, 21, 1-11.	0.2	17
1560	Outcomes of patients receiving clopidogrel prior to cardiac surgery. <i>International Journal of Cardiology</i> , 2012, 156, 34-40.	0.8	14
1561	Role of ASA in the primary and secondary prevention of cardiovascular events. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 113-123.	1.0	14
1562	Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2012, 11, CD005449.	1.5	7
1563	Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 824-834.	1.1	20
1564	Clopidogrel in Coronary Artery Disease: Update 2012. <i>Advances in Cardiology</i> , 2012, 47, 31-38.	2.6	4
1565	Periprocedural variations of platelet reactivity during elective percutaneous coronary intervention. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2452-2461.	1.9	34
1566	Comparative Pharmacokinetics and Pharmacodynamics of Platelet Adenosine Diphosphate Receptor Antagonists and their Clinical Implications. <i>Clinical Pharmacokinetics</i> , 2012, 51, 429-442.	1.6	66
1567	The Evolution of Antiplatelet Therapy in the Treatment of Acute Coronary Syndromes. <i>Drugs</i> , 2012, 72, 2087-2116.	4.9	106
1568	The risk of bleeding of triple therapy with vitamin K-antagonists, aspirin and clopidogrel after coronary stent implantation: Facts and questions. <i>Journal of Geriatric Cardiology</i> , 2012, 8, 207-214.	0.2	7

#	ARTICLE	IF	CITATIONS
1569	New Directions in Antiplatelet Therapy. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 433-445.	1.4	61
1570	Influence of Genetic Polymorphisms on the Effect of High- and Standard-Dose Clopidogrel After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1928-1937.	1.2	127
1571	A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2012, 59, 2159-2164.	1.2	569
1572	2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Tj ETQq1 1z0.7843144gBT / Dv	1.2	144
1573	TCT-740 Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. <i>Journal of the American College of Cardiology</i> , 2012, 60, B216.	1.2	0
1574	Safety and Efficacy of High- Versus Low-Dose Aspirin After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 1231-1238.	1.1	32
1575	Antithrombotic Strategies to Reduce Adverse Clinical Outcomes in Patients With Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2012, 110, 1200-1206.	0.7	5
1576	Heart Failure in Post-MI Patients With Persistent IRA Occlusion: Prevalence, Risk Factors, and the Long-Term Effect of PCI in the Occluded Artery Trial (OAT). <i>Journal of Cardiac Failure</i> , 2012, 18, 813-821.	0.7	3
1577	Synthesis and in vitro stability of nucleoside 5'-phosphonate derivatives. <i>European Journal of Medicinal Chemistry</i> , 2012, 54, 202-209.	2.6	8
1578	Antiplatelet Agents in Ischemic Heart Disease. <i>Handbook of Experimental Pharmacology</i> , 2012, , 495-518.	0.9	1
1579	Antithrombotics for secondary prevention of noncardioembolic ischaemic stroke. <i>Nature Reviews Neurology</i> , 2012, 8, 223-235.	4.9	16
1580	Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives. <i>Expert Review of Clinical Pharmacology</i> , 2012, 5, 319-336.	1.3	44
1581	Safety profile and bleeding risk of ticagrelor compared with clopidogrel. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 959-967.	1.0	8
1582	Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS?. <i>Platelets</i> , 2012, 23, 167-176.	1.1	6
1584	Evaluation and treatment of patients with cardiac disease undergoing bariatric surgery. <i>Surgery for Obesity and Related Diseases</i> , 2012, 8, 634-640.	1.0	16
1585	Clopidogrel versus Aspirin in Patients with Atherothrombosis. <i>Applied Health Economics and Health Policy</i> , 2012, 10, 331-342.	1.0	11
1586	Pharmacokinetic and Pharmacodynamic Effects of Elinogrel. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 347-356.	1.4	33
1587	The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes. <i>Pharmacoeconomics</i> , 2012, 30, 1067-1084.	1.7	35

#	ARTICLE	IF	CITATIONS
1589	InforMatrix: ADP antagonists in acute coronary syndromes. Expert Opinion on Pharmacotherapy, 2012, 13, 357-385.	0.9	0
1590	Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. European Heart Journal, 2012, 33, 3078-3087.	1.0	115
1591	Effects of Combined Aspirin and Clopidogrel Therapy on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. PLoS ONE, 2012, 7, e31642.	1.1	17
1592	Towards Personalized Medicine Based on Platelet Function Testing for Stent Thrombosis Patients. Thrombosis, 2012, 2012, 1-11.	1.4	9
1593	Discontinuation of Anticoagulant or Antiplatelet Therapy for Transrectal Ultrasound-Guided Prostate Biopsies: A Single-Center Experience. Korean Journal of Urology, 2012, 53, 234.	1.2	19
1594	Proton Pump Inhibitors and the Prevention of Recurrent GI Bleed in Patients Treated with Clopidogrel. Clinical Medicine Insights Therapeutics, 2012, 4, CMT.S7253.	0.4	0
1595	Does Dual Antiplatelet Therapy Affect Blood Loss and Transfusion Requirements in Robotic-Assisted Coronary Artery Surgery?. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2012, 7, 399-402.	0.4	13
1596	Seguridad de la angioplastia coronaria ambulatoria por via transradial: Experiencia de un centro. Revista Chilena De Cardiologia, 2012, 31, 90-95.	0.0	1
1597	Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel. Thrombosis and Haemostasis, 2012, 107, 338-345.	1.8	29
1598	A Comparison of Two Brands of Clopidogrel in Patients With Drug-Eluting Stent Implantation. Korean Circulation Journal, 2012, 42, 458.	0.7	5
1599	Evolving role of platelet function testing in coronary artery interventions. Vascular Health and Risk Management, 2012, 8, 65.	1.0	15
1600	Effects of 600 mg versus 300 mg Loading Dose of Clopidogrel in Asian Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Long-Term Follow-Up Study. Yonsei Medical Journal, 2012, 53, 906.	0.9	3
1601	Prasugrel as a Safe Alternative for Clopidogrel-Induced Polyarthralgias. Pharmacotherapy, 2012, 32, e24-6.	1.2	9
1602	CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. Pharmacogenomics, 2012, 13, 533-542.	0.6	35
1603	Antiplatelet Drugs. Chest, 2012, 141, e89S-e119S.	0.4	318
1604	Importance of potent P2Y12 receptor blockade in acute myocardial infarction: focus on prasugrel. Expert Opinion on Pharmacotherapy, 2012, 13, 1771-1796.	0.9	9
1605	A comprehensive comparative review of adenosine diphosphate receptor antagonists. Expert Opinion on Pharmacotherapy, 2012, 13, 175-191.	0.9	11
1606	Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation. Catheterization and Cardiovascular Interventions, 2012, 80, 395-405.	0.7	11

#	ARTICLE	IF	CITATIONS
1607	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary. Catheterization and Cardiovascular Interventions, 2012, 79, 453-495.	0.7	157
1608	Recent advances in the pharmacogenetics of clopidogrel. Human Genetics, 2012, 131, 653-664.	1.8	26
1609	Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus. Herz, 2012, 37, 264-272.	0.4	2
1610	High leukocyte count and interleukin-10 predict high on-treatment-platelet-reactivity in patients treated with clopidogrel. Journal of Thrombosis and Thrombolysis, 2012, 33, 349-354.	1.0	17
1611	Which Antiplatelet Agent for Whom? Which Patient Populations Benefit Most from Novel Antiplatelet Agents (Ticagrelor, Prasugrel)?. Current Cardiology Reports, 2012, 14, 486-492.	1.3	7
1612	Platelet Function and Inhibition in Ischemic Heart Disease. Current Cardiology Reports, 2012, 14, 457-467.	1.3	15
1614	Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clinical Research in Cardiology, 2012, 101, 305-312.	1.5	119
1615	Beneficial Impact of Prolonged Dual Antiplatelet Therapy after Drugâ€Eluting Stent Implantation. Journal of Interventional Cardiology, 2012, 25, 596-603.	0.5	8
1616	Comparison of Threeâ€Year Clinical Outcomes with Nonextended Versus Extended Dual Antiplatelet Therapy Between Firstâ€and Secondâ€Generation Drugâ€Eluting Stent Implantation in Patients with Acute Myocardial Infarction: Data from the Infarct Prognosis Study Registry. Journal of Interventional Cardiology, 2012, 25, 245-252.	0.5	0
1617	Modern Management of Acute Myocardial Infarction. Current Problems in Cardiology, 2012, 37, 237-310.	1.1	14
1618	The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients. Biochemical Pharmacology, 2012, 83, 903-908.	2.0	31
1619	Management of acute coronary syndrome: achievements and goals still to pursue. Novel developments in diagnosis and treatment. Journal of Internal Medicine, 2012, 271, 521-536.	2.7	18
1620	<i>P2RY1</i> and <i>P2RY12</i> polymorphisms and onâ€aspirin platelet reactivity in patients with coronary artery disease. International Journal of Laboratory Hematology, 2012, 34, 473-483.	0.7	34
1621	Low Risk of Intracranial and Systemic Hemorrhages in Patients on Dual Antiplatelet Treatment Beyond 1 Month Following Neuroendovascular Angioplasty and/or Stent Placement. Journal of Neuroimaging, 2012, 22, 67-73.	1.0	6
1622	Benefits and risks of using clopidogrel before coronary artery bypass surgery: Systematic review and meta-analysis of randomized trials and observational studies. Journal of Thoracic and Cardiovascular Surgery, 2012, 143, 665-675.e4.	0.4	77
1623	Concomitant use of clopidogrel and statins and risk of major adverse cardiovascular events following coronary stent implantation. British Journal of Clinical Pharmacology, 2012, 74, 161-170.	1.1	14
1624	Use of clopidogrel and calcium channel blockers and risk of major adverse cardiovascular events. European Journal of Clinical Investigation, 2012, 42, 266-274.	1.7	14
1625	Justification of 150â€fmg clopidogrel in patients with high onâ€clopidogrel platelet reactivity. European Journal of Clinical Investigation, 2012, 42, 384-392.	1.7	37

#	ARTICLE	IF	CITATIONS
1626	Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 181-197.	0.7	7
1627	Novel Antiplatelet Therapies. <i>Current Atherosclerosis Reports</i> , 2012, 14, 78-84.	2.0	7
1628	Promises of PAR-1 Inhibition in Acute Coronary Syndrome. <i>Current Cardiology Reports</i> , 2012, 14, 32-39.	1.3	13
1629	Clopidogrel and PPI Interaction: Clinically Relevant or Not?. <i>Current Cardiology Reports</i> , 2012, 14, 49-58.	1.3	12
1630	Stent Thrombosis: Understanding and Managing a Critical Problem. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2012, 14, 91-107.	0.4	8
1631	Optimal Management of Antiplatelet Therapy and Proton Pump Inhibition Following Percutaneous Coronary Intervention. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2012, 14, 24-38.	0.4	10
1632	Role of Antiplatelet Therapy in Secondary Prevention of Acute Coronary Syndrome. <i>Journal of Cardiovascular Translational Research</i> , 2012, 5, 41-51.	1.1	4
1633	Clopidogrel tapering as a strategy to attenuate platelet rebound phenomenon in patients with bare-metal stents. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 33, 16-21.	1.0	7
1634	Immature platelet fraction (IPF) determined with an automated method predicts clopidogrel hyporesponsiveness. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 33, 137-142.	1.0	55
1635	A randomised controlled pilot trial to evaluate and optimize the use of anti-platelet agents in the perioperative management in patients undergoing general and abdominal surgery—the APAP trial (ISRCTN45810007). <i>Langenbeck's Archives of Surgery</i> , 2012, 397, 297-306.	0.8	34
1636	Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTimal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. <i>Trials</i> , 2013, 14, 56.	0.7	13
1637	Prognostic Significance of Bleeding Location and Severity Among Patients With Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 709-717.	1.1	17
1638	Medical Management After Coronary Stent Implantation. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 189.	3.8	84
1639	Chronic kidney disease is associated with adverse outcomes among elderly patients taking clopidogrel after hospitalization for acute coronary syndrome. <i>BMC Nephrology</i> , 2013, 14, 107.	0.8	15
1640	Comparative effect of clopidogrel and aspirin versus aspirin alone on laboratory parameters: a retrospective, observational, cohort study. <i>Cardiovascular Diabetology</i> , 2013, 12, 87.	2.7	11
1642	Management of cardiovascular disease in patients with kidney disease. <i>Nature Reviews Cardiology</i> , 2013, 10, 261-273.	6.1	98
1643	ADP-Receptor Inhibitors in the Perioperative Period: The Good, the Bad, and the Ugly. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2013, 27, 779-795.	0.6	12
1644	Platelet Inhibition with Cangrelor during PCI. <i>New England Journal of Medicine</i> , 2013, 369, 393-394.	13.9	14

#	ARTICLE	IF	CITATIONS
1645	Clinical Implications of Platelet-Vessel Interaction. Journal of Cardiovascular Translational Research, 2013, 6, 310-315.	1.1	16
1646	Platelet Function Testing and Tailored Antiplatelet Therapy. Journal of Cardiovascular Translational Research, 2013, 6, 316-328.	1.1	34
1647	Platelet Function Profiles in Patients with Diabetes Mellitus. Journal of Cardiovascular Translational Research, 2013, 6, 329-345.	1.1	46
1648	Influence of Platelet Reactivity on Clinical Outcome of Patients with Stable Coronary Artery Disease. Journal of Cardiovascular Translational Research, 2013, 6, 346-354.	1.1	3
1649	Clinical Impact of Genetically Determined Platelet Reactivity. Journal of Cardiovascular Translational Research, 2013, 6, 398-403.	1.1	6
1650	CYP-Mediated Pharmacologic Interference with Optimal Platelet Inhibition. Journal of Cardiovascular Translational Research, 2013, 6, 404-410.	1.1	6
1651	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet, The, 2013, 382, 1714-1722.	6.3	537
1652	Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. Journal of Thrombosis and Thrombolysis, 2013, 36, 223-232.	1.0	31
1653	Follow-up of aspirin-resistant patients with end-stage kidney disease. International Urology and Nephrology, 2013, 45, 1097-1102.	0.6	9
1654	Clopidogrel in Infants with Systemic-to-Pulmonary-Artery Shunts. New England Journal of Medicine, 2013, 368, 2377-2384.	13.9	57
1655	Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet, The, 2013, 382, 1981-1992.	6.3	286
1656	Cangrelor: a new CHAMPION for percutaneous coronary intervention. Lancet, The, 2013, 382, 1960-1962.	6.3	3
1658	Platelet activity measured by a rapid turnaround assay identifies coronary artery bypass grafting patients at increased risk for bleeding and transfusion complications after clopidogrel administration. Journal of Thoracic and Cardiovascular Surgery, 2013, 146, 1259-1266.e1.	0.4	44
1659	Benefit of Long-Term Dual Anti-Platelet Therapy in Patients Treated With Drug-Eluting Stents: From the NHLBI Dynamic Registry. American Journal of Cardiology, 2013, 111, 486-492.	0.7	39
1660	Aspirin and aspirin resistance in coronary artery disease. Current Opinion in Pharmacology, 2013, 13, 242-250.	1.7	35
1661	Antiplatelet therapy after Genous EPC-capturing coronary stenosis implantation. International Journal of Cardiology, 2013, 167, 757-761.	0.8	10
1662	The CYP2C19 genotype does not impact the long-term prognosis of patients with coronary artery disease. Atherosclerosis, 2013, 227, 106-111.	0.4	12
1663	Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays. Thrombosis Research, 2013, 132, e105-e111.	0.8	24

#	ARTICLE	IF	CITATIONS
1664	Basics of Antithrombotic Therapy for Cardiovascular Disease. <i>Interventional Cardiology Clinics</i> , 2013, 2, 499-513.	0.2	1
1665	Discontinuation of preoperative clopidogrel is unnecessary in peripheral arterial surgery. <i>Journal of Vascular Surgery</i> , 2013, 58, 1586-1592.	0.6	30
1666	Optimal treatment of ACS patients: Issues and considerations for upstream antiplatelet therapy. <i>International Journal of Cardiology</i> , 2013, 163, 19-25.	0.8	3
1667	Switching antiplatelet regimens: Alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: A review of the literature and practical considerations for the interventional cardiologist. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 232-242.	0.7	19
1668	Antiplatelet therapy at the time of coronary artery bypass grafting: a multicentre cohort study. <i>European Journal of Cardio-thoracic Surgery</i> , 2013, 44, e133-e140.	0.6	36
1669	Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2510-22.	3.8	513
1670	Proton-pump inhibitors can decrease gastrointestinal bleeding after percutaneous coronary intervention. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 636-641.	0.7	12
1671	Routine Assessment of On-Clopidogrel Platelet Reactivity and Gene Polymorphisms in Predicting Clinical Outcome Following Drug-Eluting Stent Implantation in Patients With Stable Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 1166-1175.	1.1	49
1672	Clinical consequences of aspirin and clopidogrel resistance: an overview. <i>Acta Neurologica Scandinavica</i> , 2013, 128, 213-219.	1.0	31
1673	Impact of initial clinical presentation on clopidogrel low response. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 593-600.	0.7	1
1674	Perioperative management of antiplatelet therapy. <i>British Journal of Anaesthesia</i> , 2013, 111, i3-i17.	1.5	81
1675	Cardiovascular Prophylaxis and Aspirin Allergy. <i>Immunology and Allergy Clinics of North America</i> , 2013, 33, 263-274.	0.7	20
1676	Dual Antiplatelet Therapy Dilemmas: Duration and Choice of Antiplatelets in Acute Coronary Syndromes. <i>Current Cardiology Reports</i> , 2013, 15, 405.	1.3	5
1677	Is discontinuation of clopidogrel necessary for intracapsular hip fracture surgery? Analysis of 102 hemiarthroplasties. <i>Journal of Orthopaedics and Traumatology</i> , 2013, 14, 171-177.	1.0	28
1678	Gender Differences in Cardiovascular Therapy: Focus on Antithrombotic Therapy and Percutaneous Coronary Intervention. <i>Drugs</i> , 2013, 73, 1921-1933.	4.9	19
1679	Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: Economic Considerations. <i>Pharmacoeconomics</i> , 2013, 31, 959-970.	1.7	9
1680	Pretreatment with Prasugrel in Non-ST-Segment Elevation Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2013, 369, 999-1010.	13.9	539
1681	Avoiding stent thrombosis: advances in technique, antiplatelet pharmacotherapy and stent design. <i>Interventional Cardiology</i> , 2013, 5, 179-201.	0.0	0

#	ARTICLE	IF	CITATIONS
1682	The Clinical Outcomes of Percutaneous Coronary Intervention Performed Without Pre-Procedural Aspirin. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2083-2089.	1.2	15
1683	Association of Blood Transfusion With Increased Mortality in Myocardial Infarction. <i>JAMA Internal Medicine</i> , 2013, 173, 132.	2.6	196
1684	Gastrointestinal Adverse Events after Dual Antiplatelet Therapy: Clopidogrel Is Safer than Ticagrelor, but Prasugrel Data Are Lacking or Inconclusive. <i>Cardiology</i> , 2013, 126, 35-40.	0.6	21
1685	Using Platelet Function Testing to Guide Antiplatelet Therapy. <i>Drug Development Research</i> , 2013, 74, 517-525.	1.4	4
1686	Risk of Bleeding on Triple Antithrombotic Therapy After Percutaneous Coronary Intervention/Stenting: A Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2013, 29, 204-212.	0.8	55
1687	Safety of Reloading Prasugrel in Addition to Clopidogrel Loading in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2013, 111, 841-845.	0.7	25
1688	Impact of clopidogrel and potent P2Y12-inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention. <i>Thrombosis and Haemostasis</i> , 2013, 109, 93-101.	1.8	45
1689	Low-Dose Anticoagulation for Secondary Prevention in Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2013, 111, 618-626.	0.7	12
1690	Mean Platelet Volume and Long-Term Mortality in Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2013, 111, 185-189.	0.7	43
1691	Current antithrombotic agents for acute coronary syndromes: Focus on bleeding risk. <i>International Journal of Cardiology</i> , 2013, 163, 5-18.	0.8	18
1692	Characterization of aspirin allergies in patients with coronary artery disease. <i>Annals of Allergy, Asthma and Immunology</i> , 2013, 110, 92-95.	0.5	29
1693	Risk factors for upper gastrointestinal bleeding in coronary artery disease patients receiving both aspirin and clopidogrel. <i>Journal of the Chinese Medical Association</i> , 2013, 76, 9-14.	0.6	17
1694	2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non- ST -Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 61, e179-e347.	1.2	370
1695	Novel Antiplatelet and Anticoagulant Agents in the Cardiac Care Unit. <i>Cardiology Clinics</i> , 2013, 31, 533-544.	0.9	6
1696	Nuisance Bleeding With Prolonged Dual Antiplatelet Therapy After Acute Myocardial Infarction and its Impact on Health Status. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2130-2138.	1.2	77
1697	New antiplatelet agents for cardiovascular disease. <i>Cmaj</i> , 2013, 185, 1405-1411.	0.9	10
1698	Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: A meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , 2013, 168, 2579-2587.	0.8	39
1699	Percutaneous revascularization and long term clinical outcomes of diabetic patients randomized in the Occluded Artery Trial (OAT). <i>International Journal of Cardiology</i> , 2013, 168, 2416-2422.	0.8	10

#	ARTICLE	IF	CITATIONS
1700	Antiplatelet Effect of Thienopyridine (Clopidogrel or Prasugrel) Pretreatment in Patients Undergoing Primary Percutaneous Intervention for ST Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2013, 112, 1551-1556.	0.7	16
1701	Clinical Features and Racial/Ethnic Differences Among the 3020 Participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) Trial. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2013, 22, 764-774.	0.7	28
1702	Aspirin, Platelet P2Y12 Receptor Inhibitors, and Other Oral Antiplatelets. <i>Interventional Cardiology Clinics</i> , 2013, 2, 527-535.	0.2	8
1703	Antiplatelet therapy after coronary stenting: for how long?. <i>Lancet, The</i> , 2013, 382, 1684-1685.	6.3	3
1704	Prescribing Patterns of Antiplatelet Agents Are Highly Variable After Lower Extremity Endovascular Procedures. <i>Annals of Vascular Surgery</i> , 2013, 27, 62-67.	0.4	35
1706	The Effect of Antiplatelet and Anticoagulant Therapy on the Clinical Outcome of Patients Undergoing Ureteroscopy. <i>Urology</i> , 2013, 82, 773-779.	0.5	13
1707	Antiagregaci3n oral en el intervencionismo coronario percut3neo: f3rmacos disponibles y duraci3n de la terapia oral. <i>Revista Espanola De Cardiologia Suplementos</i> , 2013, 13, 16-23.	0.2	1
1708	Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes. <i>Journal of Cardiology</i> , 2013, 62, 158-164.	0.8	28
1709	Monitoring and Reversal of Anticoagulation and Antiplatelets. <i>Interventional Cardiology Clinics</i> , 2013, 2, 643-663.	0.2	1
1710	Medical therapy of coronary artery disease after percutaneous intervention. <i>Current Opinion in Pharmacology</i> , 2013, 13, 287-293.	1.7	11
1711	Statements of the <sc>M</sc>alaysian <sc>S</sc>ociety of <sc>G</sc>astroenterology & <sc>H</sc>epatology and the <sc>N</sc>ational <sc>H</sc>eart <sc>A</sc>ssociation of <sc>M</sc>alaysia task force 2012 working party on the use of antiplatelet therapy and proton pump inhibitors in the prevention of gastrointestinal bleeding. <i>Journal of Digestive Diseases</i> , 2013, 14, 1-10.	0.7	2
1712	Therapeutic momentum: a concept opposite to therapeutic inertia. <i>International Journal of Clinical Practice</i> , 2013, 67, 97-98.	0.8	11
1713	Implication of antithrombotic agents on potential bleeding from endoscopically determined peptic ulcers, incidentally detected as surrogate markers for nsaid-associated ulcers complication. <i>Digestive Endoscopy</i> , 2013, 25, 25-31.	1.3	3
1714	Atherothrombosis and Coronary Artery Disease. , 2013, , 653-668.		0
1715	ADP Receptor Antagonists. , 2013, , 1117-1138.		5
1716	Comparative effect of clopidogrel plus aspirin and aspirin monotherapy on hematological parameters using propensity score matching. <i>Vascular Health and Risk Management</i> , 2013, 9, 65.	1.0	8
1717	Dual antiplatelet therapy in patients with diabetes mellitus: special considerations. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 307-317.	0.6	6
1718	Pharmacotherapy for the reduction of stent thrombosis. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 567-576.	0.6	1

#	ARTICLE	IF	CITATIONS
1719	Monitoring Aspirin and Clopidogrel Response: Testing Controversies and Recommendations. Molecular Diagnosis and Therapy, 2013, 17, 123-137.	1.6	5
1720	Platelet Function Monitoring and Clopidogrel. Current Cardiology Reports, 2013, 15, 321.	1.3	9
1721	Antiplatelet agents for chronic kidney disease. , 2013, , CD008834.		61
1722	Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack. New England Journal of Medicine, 2013, 369, 11-19.	13.9	1,384
1723	Stable Angina. , 2013, , 419-438.		0
1724	Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. New England Journal of Medicine, 2013, 368, 1303-1313.	13.9	695
1725	Oral Antithrombotic Therapy in Atrial Fibrillation Associated With Acute or Chronic Coronary Artery Disease. Canadian Journal of Cardiology, 2013, 29, S60-S70.	0.8	11
1726	Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. International Journal of Cardiology, 2013, 167, 2140-2148.	0.8	113
1727	Antiplatelet and Anticoagulant Therapy for Atherothrombotic Disease: The Role of Current and Emerging Agents. American Journal of Cardiovascular Drugs, 2013, 13, 233-250.	1.0	36
1728	Viewpoint: Mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes. Thrombosis and Haemostasis, 2013, 110, 5-10.	1.8	15
1729	Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ, The, 2013, 347, f5307.	3.0	52
1730	Effect of different anticoagulants on multiple electrode platelet aggregometry after clopidogrel and aspirin administration in patients undergoing coronary stent implantation: A comparison between citrate and hirudin. Platelets, 2013, 24, 339-347.	1.1	15
1731	Antiplatelet therapy: new pharmacological agents and changing paradigms. Journal of Thrombosis and Haemostasis, 2013, 11, 316-329.	1.9	61
1732	Impact of Proton Pump Inhibitor Therapy on the Efficacy of Clopidogrel in the CAPRIE and CREDO Trials. Journal of the American Heart Association, 2013, 2, e004564.	1.6	44
1733	Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy. Canadian Journal of Cardiology, 2013, 29, 1334-1345.	0.8	97
1734	Impact of <i>CYP2C19</i> Genetic Testing on Provider Prescribing Patterns for Antiplatelet Therapy After Acute Coronary Syndromes and Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 694-699.	0.9	14
1735	2013 ESC guidelines on the management of stable coronary artery disease. European Heart Journal, 2013, 34, 2949-3003.	1.0	3,915
1736	General Considerations for Neurointerventional Procedures. , 2013, , 153-185.		1

#	ARTICLE	IF	CITATIONS
1737	Mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes. <i>European Heart Journal</i> , 2013, 34, P2510-P2510.	1.0	0
1738	Less use of standard guideline-based treatment of myocardial infarction in patients with chronic kidney disease: a Danish nation-wide cohort study. <i>European Heart Journal</i> , 2013, 34, 2916-2923.	1.0	25
1739	Secondary prevention by stroke subtype: a nationwide follow-up study in 46 108 patients after acute ischaemic stroke. <i>European Heart Journal</i> , 2013, 34, 2760-2767.	1.0	31
1740	Adherence to dual antiplatelet therapy: can we do better?. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1417-1424.	0.6	3
1741	Medical Management and Strategies to Prevent Coronary Artery Disease in Patients with Type 2 Diabetes Mellitus. <i>Postgraduate Medicine</i> , 2013, 125, 17-33.	0.9	11
1742	Antiplatelet Drug Use in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Postgraduate Medicine</i> , 2013, 125, 51-58.	0.9	2
1743	Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey. <i>Journal of Medical Economics</i> , 2013, 16, 510-521.	1.0	15
1744	Cost-effectiveness of ticagrelor in acute coronary syndromes. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 9-18.	0.7	3
1745	Scalable evaluation of platelet aggregation by the degree of blood migration. <i>Applied Physics Letters</i> , 2013, 103, .	1.5	8
1746	2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2013, 127, e663-828.	1.6	219
1747	Pharmacodynamic Effect of Clopidogrel in Patients Undergoing Transcatheter Aortic Valve Implantation. <i>BioMed Research International</i> , 2013, 2013, 1-3.	0.9	14
1748	Cangrelor in patients undergoing cardiac surgery: the BRIDGE study. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 811-816.	0.6	7
1749	Pharmacology of Antithrombotic Drugs. , 2013, , 94-109.		2
1750	Aspirin resistance: Where are we now?. <i>Anatolian Journal of Cardiology</i> , 2013, 13, 370-3.	0.4	6
1751	Combined clopidogrel and aspirin treatment up to surgery increases the risk of postoperative myocardial infarction, blood loss and reoperation for bleeding in patients undergoing coronary artery bypass grafting. <i>European Journal of Cardio-thoracic Surgery</i> , 2013, 43, 722-728.	0.6	40
1752	Historical Lessons in Translational Medicine. <i>Circulation Research</i> , 2013, 112, 174-194.	2.0	38
1753	Rivaroxaban and risk of myocardial infarction. <i>Coronary Artery Disease</i> , 2013, 24, 628-635.	0.3	44
1754	The role of clopidogrel in the management of ischemic heart disease. <i>Current Opinion in Cardiology</i> , 2013, 28, 381-388.	0.8	0

#	ARTICLE	IF	CITATIONS
1755	Efficacy of Cilostazol in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. <i>American Journal of Therapeutics</i> , 2013, 20, 151-153.	0.5	6
1756	Twelve-Month Results of a Randomized Trial Comparing Mono With Dual Antiplatelet Therapy in Endovascularly Treated Patients With Peripheral Artery Disease. <i>Journal of Endovascular Therapy</i> , 2013, 20, 699-706.	0.8	84
1757	Thrombosis. , 2013, , 133-137.		0
1758	Balancing Thrombotic and Bleeding Risks Related to Antiplatelet Therapy in Coronary Bypass Surgery. <i>JAMA Surgery</i> , 2013, 148, 548.	2.2	0
1759	Characteristics of new P2Y12 inhibitors. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, S22-S30.	0.6	4
1760	Intracoronary bivalirudin. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 757-761.	0.5	5
1761	Clopidogrel Use and Short-Term Mortality After Peptic Ulcer Bleeding. <i>American Journal of Therapeutics</i> , 2013, 20, 13-20.	0.5	4
1762	Steroid permeation into the artificial ulcer by combined steroid gel application and balloon dilatation: Prevention of esophageal stricture. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 999-1003.	1.4	35
1763	Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures. <i>Journal of NeuroInterventional Surgery</i> , 2013, 5, 337-343.	2.0	97
1764	Dual Antiplatelet Therapy Can Be Discontinued at Three Months after Implantation of Zotarolimus-Eluting Stent in Patients with Coronary Artery Disease. <i>ISRN Cardiology</i> , 2013, 2013, 1-7.	1.6	4
1765	Failures, Mistakes and Shortcomings of My Stroke Trials. <i>Cerebrovascular Diseases</i> , 2013, 36, 250-256.	0.8	0
1766	The CYP2C19*1/*2 Genotype Does Not Adequately Predict Clopidogrel Response in Healthy Malaysian Volunteers. <i>Cardiology Research and Practice</i> , 2013, 2013, 1-7.	0.5	11
1767	Pharmacologic Options for Treatment of Ischemic Disease. , 2013, , 83-130.		4
1768	Risk of Long-Term Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation in Octogenarians. <i>Journal of Interventional Cardiology</i> , 2013, 26, 114-122.	0.5	4
1769	A Pilot Study of Prasugrel Followed by Post-Procedural Maintenance with Clopidogrel in Patients Receiving Percutaneous Coronary Intervention. <i>Journal of Interventional Cardiology</i> , 2013, 26, 38-42.	0.5	3
1770	Population pharmacokinetic analysis of clopidogrel in healthy Jordanian subjects with emphasis optimal sampling strategy. <i>Biopharmaceutics and Drug Disposition</i> , 2013, 34, 215-226.	1.1	5
1771	Cangrelor: a review on pharmacology and clinical trial development. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1279-1291.	0.6	52
1772	Consideration of Dual Anti-platelet Therapy Duration after Drug-eluting Stent Implantation in a Japanese Population: A Five-year Follow-up after Sirolimus-Eluting Stent Implantation. <i>Internal Medicine</i> , 2013, 52, 703-711.	0.3	3

#	ARTICLE	IF	CITATIONS
1773	Clinical importance of antiplatelet drugs in cardiovascular diseases. <i>Clinical Hemorheology and Microcirculation</i> , 2013, 53, 81-96.	0.9	24
1774	Perioperative Management of Antiplatelet Therapy in Patients With a Coronary Stent Who Need Noncardiac Surgery. <i>Chest</i> , 2013, 144, 1848-1856.	0.4	60
1775	Branded Versus Generic Clopidogrel in Cardiovascular Diseases. <i>Journal of Cardiovascular Pharmacology</i> , 2013, 61, 277-282.	0.8	19
1776	A Multicenter Study of Stent-Assisted Coiling of Cerebral Aneurysms With a Y Configuration. <i>Neurosurgery</i> , 2013, 73, 466-472.	0.6	118
1778	Pharmacokinetics of 600 mg loading dose of clopidogrel in patients undergoing percutaneous coronary intervention. <i>African Journal of Pharmacy and Pharmacology</i> , 2013, 7, 574-584.	0.2	2
1779	Efficacy and Safety of Platelet Inhibitors. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2013, 16, 1.	0.9	10
1780	Polymorphic Cytochrome P450 Enzymes (CYPs) and Their Role in Personalized Therapy. <i>PLoS ONE</i> , 2013, 8, e82562.	1.1	198
1781	Pharmacogenetics in Cardiovascular Diseases. , 2013, , 133-182.		3
1782	Coronary Artery Disease and Myocardial Infarction. , 2013, , 516-529.		0
1783	Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting. <i>Thrombosis and Haemostasis</i> , 2013, 109, 517-254.	1.8	12
1784	Hemostatic Aspects of Cardiovascular Medicine. , 2013, , 342-394.		0
1785	Impact of CYP2C19 Polymorphism on Platelet Function Tests and Coagulation and Inflammatory Biomarkers in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of Atherosclerosis and Thrombosis</i> , 2014, 21, 64-76.	0.9	17
1786	Transfusion Strategy: Impact of Haemodynamics and the Challenge of Haemodilution. <i>Journal of Blood Transfusion</i> , 2014, 2014, 1-12.	3.3	9
1787	Benefits and Harms of Extending the Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stents: A Meta-Analysis. <i>Scientific World Journal</i> , The, 2014, 2014, 1-16.	0.8	10
1788	Dual Antiplatelet Therapy after Noncardioembolic Ischemic Stroke or Transient Ischemic Attack: Pros		

#	ARTICLE	IF	CITATIONS
1792	ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome. European Heart Journal Supplements, 2014, 16, C2-C28.	0.0	2
1793	Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease (SENS-FP trial): study protocol for a randomized controlled trial. Trials, 2014, 15, 355.	0.7	4
1794	A Freeze on Tailored Antiplatelet Therapy?. Circulation, 2014, 129, 2088-2090.	1.6	1
1795	Cangrelor for treatment of arterial thrombosis. Expert Opinion on Pharmacotherapy, 2014, 15, 565-572.	0.9	4
1796	Genetics of Response to Antiplatelet Therapy. Progress in Molecular Biology and Translational Science, 2014, 124, 123-153.	0.9	10
1797	Predictive values of post-clopidogrel platelet reactivity assessed by different platelet function tests on ischemic events in East Asian patients treated with PCI. Platelets, 2014, 25, 292-299.	1.1	25
1798	Diagnostic accuracy of mean platelet volume in prediction of clopidogrel resistance in patients with acute coronary syndrome. Anatolian Journal of Cardiology, 2014, 14, 134-139.	0.4	11
1799	Prevention of Stroke in Patients With Atrial Fibrillation. , 2014, , 1129-1137.		0
1800	Aspirin Allergy Desensitization in Cerebrovascular Disease. Interventional Neuroradiology, 2014, 20, 5-11.	0.7	2
1801	How do we decide the optimal duration of dual antiplatelet therapy after percutaneous coronary intervention?. Interventional Cardiology, 2014, 6, 1-3.	0.0	0
1802	Stent-assisted coil embolization of ruptured wide-necked aneurysms in the acute period: incidence of and risk factors for periprocedural complications. Journal of Neurosurgery, 2014, 121, 4-11.	0.9	94
1803	The impact of smoking on clinical efficacy and pharmacodynamic effects of clopidogrel: a systematic review and meta-analysis. Heart, 2014, 100, 192-199.	1.2	21
1804	Cangrelor for treatment during percutaneous coronary intervention. Future Cardiology, 2014, 10, 201-213.	0.5	3
1805	Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. BMJ, The, 2014, 347, g6269-g6269.	3.0	75
1806	Antithrombotics in atrial fibrillation and coronary disease. Expert Review of Cardiovascular Therapy, 2014, 12, 977-986.	0.6	5
1807	World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nature Reviews Cardiology, 2014, 11, 597-606.	6.1	267
1808	Optimal duration of dual antiplatelet therapy following treatment with the endeavor zotarolimus-eluting stent in real-world Japanese patients with coronary artery disease (OPERA): Study design and rationale. Catheterization and Cardiovascular Interventions, 2014, 84, 368-374.	0.7	3
1809	New Antithrombotics for Secondary Prevention of Acute Coronary Syndrome. Clinical Cardiology, 2014, 37, 178-187.	0.7	20

#	ARTICLE	IF	CITATIONS
1810	A rare complication of arterio-venous fistula following coronary intervention using radial approach. <i>Journal of Indian College of Cardiology</i> , 2014, 4, 266-268.	0.1	0
1811	P2Y ₁₂ Platelet Function Assay for Assessment of Bleeding Risk in Coronary Artery Bypass Grafting. <i>Journal of Cardiac Surgery</i> , 2014, 29, 312-316.	0.3	23
1812	Pretreatment with P2Y ₁₂ Inhibitors in Non-“ST-Segment” Elevation Acute Coronary Syndrome: An Outdated and Harmful Strategy. <i>Circulation</i> , 2014, 130, 1904-1914.	1.6	36
1813	Pretreatment With P2Y ₁₂ Inhibitors in Non-“ST-Segment” Elevation Acute Coronary Syndrome Is Clinically Justified. <i>Circulation</i> , 2014, 130, 1891-1903.	1.6	39
1814	Duraci3n del tratamiento antiagregante en el s3ndrome coronario agudo. <i>Revista Espanola De Cardiologia Suplementos</i> , 2014, 14, 32-37.	0.2	1
1815	Aspirin and clopidogrel resistance using the cone and plate(let) analyser in Indian patients with coronary artery disease. <i>Heart Asia</i> , 2014, 6, 159-162.	1.1	6
1816	2014 AHA/ACC Guideline for the Management of Patients With Non-“ST-Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2014, 130, e344-426.	1.6	928
1817	Gender differences in hemorheological parameters and in in vitro platelet aggregation in acetylsalicylic acid and clopidogrel treated vascular patients. <i>Biorheology</i> , 2014, 51, 197-206.	1.2	6
1818	Comparing coronary artery bypass grafting with drug-eluting stenting in patients with diabetes mellitus and multivessel coronary artery disease: a meta-analysis. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2014, 18, 347-354.	0.5	11
1819	Carotid artery stenting outcomes: do they correlate with antiplatelet response assays?. <i>Journal of NeuroInterventional Surgery</i> , 2014, 6, 373-378.	2.0	29
1820	Recent advances in antithrombotic treatment for acute coronary syndromes. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 507-521.	1.3	5
1821	Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation. <i>Journal of Cardiovascular Pharmacology</i> , 2014, 64, 38-40.	0.8	0
1822	Effects of Clopidogrel Therapy on Oxidative Stress, Inflammation, Vascular Function, and Progenitor Cells in Stable Coronary Artery Disease. <i>Journal of Cardiovascular Pharmacology</i> , 2014, 63, 369-374.	0.8	17
1823	2014 AHA/ACC Guideline for the Management of Patients With Non-“ST-Elevation Acute Coronary Syndromes: Executive Summary. <i>Circulation</i> , 2014, 130, 2354-2394.	1.6	938
1825	Platelet function inhibitors and platelet function testing in neurointerventional procedures: Table1. <i>Journal of NeuroInterventional Surgery</i> , 2014, 6, 567-577.	2.0	37
1826	Antiplatelet Treatment in the Secondary Prevention of Coronary and Cerebrovascular Disease. <i>Angiology</i> , 2014, 65, 473-490.	0.8	3
1827	Biodegradable polymer Biolimus-eluting stent (Nobori®) for the treatment of coronary artery lesions: review of concept and clinical results. <i>Medical Devices: Evidence and Research</i> , 2014, 7, 35.	0.4	9
1828	Timing and nature of in-house postoperative events following uncomplicated elective endovascular aneurysm treatment. <i>Journal of Neurosurgery</i> , 2014, 121, 1063-1070.	0.9	13

#	ARTICLE	IF	CITATIONS
1829	Aspirin Reload Before Elective Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 577-584.	1.4	17
1830	Point-of-care testing of clopidogrel-mediated platelet inhibition and risk for cardiovascular events after coronary angiography with or without percutaneous coronary intervention. <i>Blood Coagulation and Fibrinolysis</i> , 2014, 25, 577-584.	0.5	5
1831	Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus. <i>Platelets</i> , 2014, 25, 348-356.	1.1	17
1832	PPAR β activation rescues mitochondrial function from inhibition of complex I and loss of PINK1. <i>Experimental Neurology</i> , 2014, 253, 16-27.	2.0	56
1833	Antiplatelet Treatment for Prevention of Cerebrovascular Events in Patients With Vascular Diseases. <i>Stroke</i> , 2014, 45, 492-503.	1.0	63
1834	Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: A meta-analysis of randomized trials. <i>Atherosclerosis</i> , 2014, 233, 568-578.	0.4	21
1835	Optimizing Antithrombotic Therapy After Coronary Stent Implantation in Patients on Chronic Oral Anticoagulation. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 64-71.	1.1	2
1837	Management of Antiplatelet and Anticoagulant Therapy in Patients With Atrial Fibrillation in the Setting of Acute Coronary Syndromes or Percutaneous Coronary Interventions. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 113-124.	1.4	67
1838	Clopidogrel High-on-Treatment Platelet Reactivity in Acute Ischemic Stroke Patients. <i>Thrombosis Research</i> , 2014, 133, 396-401.	0.8	26
1839	Cilostazol-based triple antiplatelet therapy in the era of generic clopidogrel and new potent antiplatelet agents. <i>Current Medical Research and Opinion</i> , 2014, 30, 51-54.	0.9	0
1841	Strategia di gestione delle sindromi coronariche acute. <i>EMC - Urgenze</i> , 2014, 18, 1-14.	0.0	0
1843	Impact of Clopidogrel Plus Aspirin Versus Aspirin Alone on the Progression of Native Coronary Artery Disease After Bypass Surgery. <i>Circulation</i> , 2014, 130, S12-8.	1.6	22
1844	Ticagrelor Use in a Patient With a Documented Clopidogrel Hypersensitivity. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1230-1233.	0.9	10
1845	Acute Coronary Syndrome. <i>Hospital Medicine Clinics</i> , 2014, 3, 471-478.	0.2	1
1846	Managing Antithrombotic Therapy in Patients With Both Atrial Fibrillation and Coronary Heart Disease. <i>Clinical Therapeutics</i> , 2014, 36, 1176-1181.	1.1	8
1848	Percutaneous coronary intervention. <i>Medicine</i> , 2014, 42, 520-526.	0.2	2
1849	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2645-2687.	1.2	424
1850	Management of ST-elevation myocardial infarction. <i>Medicine</i> , 2014, 42, 512-519.	0.2	1

#	ARTICLE	IF	CITATIONS
1851	Acute Coronary Syndromes. <i>Cardiology Clinics</i> , 2014, 32, 353-370.	0.9	4
1852	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2014, 35, 2541-2619.	1.0	4,141
1853	Aspirin, Clopidogrel, and the Surgeon. <i>Advances in Surgery</i> , 2014, 48, 211-222.	0.6	15
1854	Antiplatelet therapy for secondary prevention of coronary artery disease. <i>Heart</i> , 2014, 100, 1750-1756.	1.2	33
1855	Temporal Trends in the Occurrence and Outcomes of Atrial Fibrillation in Patients With Acute Myocardial Infarction (from the Atherosclerosis Risk in Communities Surveillance Study). <i>American Journal of Cardiology</i> , 2014, 114, 692-697.	0.7	22
1856	Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 100.	0.7	27
1857	Diagnosis, Nonsurgical Management, and Prevention of LVAD Thrombosis. <i>Journal of Cardiac Surgery</i> , 2014, 29, 83-94.	0.3	33
1859	Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. <i>Stroke</i> , 2014, 45, 2160-2236.	1.0	3,891
1861	Durée de la bithérapie antiplaquettaire après mise en place d'un stent actif. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2014, 2014, 15-18.	0.0	0
1862	2014 AHA/ACC Guideline for the Management of Patients With ST-Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2014, 64, e139-e228.	1.2	2,746
1863	Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1041-1047.	0.8	23
1864	Clopidogrel Plus Aspirin Versus Warfarin in Patients With Stroke and Aortic Arch Plaques. <i>Stroke</i> , 2014, 45, 1248-1257.	1.0	178
1865	Sex differences in stroke: The contribution of coagulation. <i>Experimental Neurology</i> , 2014, 259, 16-27.	2.0	97
1866	Cangrelor: Review of the Drug and the CHAMPION Programme (Including PHOENIX). <i>Current Cardiology Reports</i> , 2014, 16, 493.	1.3	11
1867	Temporary Adjunctive Cilostazol vs Clopidogrel Loading for ST-segment Elevation Acute Myocardial Infarction. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 131-136.	1.0	3
1868	Dyspnea and Reversibility Profile of P2Y12 Antagonists: Systematic Review of New Antiplatelet Drugs. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 303-311.	1.0	10
1869	Duration of dual antiplatelet therapy following percutaneous coronary intervention on re-hospitalization for acute coronary syndrome. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 21.	0.7	2
1870	Genetic and non-genetic factors responsible for antiplatelet effects of clopidogrel in Japanese patients undergoing coronary stent implantation: An algorithm to predict on-clopidogrel platelet reactivity. <i>Thrombosis Research</i> , 2014, 134, 877-883.	0.8	8

#	ARTICLE	IF	CITATIONS
1872	Distribution of ABCB1, CYP3A5, CYP2C19, and P2RY12 gene polymorphisms in a Mexican Mestizos population. <i>Molecular Biology Reports</i> , 2014, 41, 7023-7029.	1.0	20
1873	Antiplatelet effects of clopidogrel dose adjustment (75Åmg/d vs 150Åmg/d) after carotid stenting. <i>Journal of Vascular Surgery</i> , 2014, 60, 428-435.	0.6	12
1875	Impact of Early Versus Late Clopidogrel Discontinuation on Stent Thrombosis Following Percutaneous Coronary Intervention With First- and Second-Generation Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2014, 113, 1968-1976.	0.7	19
1876	Prasugrel loading dose in diabetic patients with acute STEMI - Always sufficiently effective? Observation in two cases and review of current knowledge. <i>Cor Et Vasa</i> , 2014, 56, e388-e395.	0.1	2
1877	Clinical outcomes with 6 months dual antiplatelet therapy after implantation of Biolimus-A9 drug eluting coronary stents. <i>International Journal of Cardiology</i> , 2014, 172, 185-189.	0.8	5
1878	Comparative Effectiveness of Clopidogrel in Medically Managed Patients With Unstable Angina and Non-ÅST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2249-2257.	1.2	27
1879	Pretreatment with P2Y12 inhibitors in non-ÅST-segment elevation acute coronary syndrome: Time to revise the guidelines?. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 1-3.	0.7	1
1880	The effect of doubling the dose of clopidogrel on platelet aggregation in patients with clopidogrel resistance. <i>Egyptian Heart Journal</i> , 2014, 66, 259-262.	0.4	2
1881	Current status of lower-extremity revascularization. <i>Current Problems in Surgery</i> , 2014, 51, 254-290.	0.6	4
1882	Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes. <i>Circulation Research</i> , 2014, 114, 1929-1943.	2.0	79
1883	Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 609-620.	1.5	3
1884	Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 723-734.	1.4	0
1885	Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. <i>European Heart Journal</i> , 2014, 35, 1510-1514.	1.0	70
1886	Hemorrhagic Complications of Thoracentesis and Small-Bore Chest Tube Placement in Patients Taking Clopidogrel. <i>Annals of the American Thoracic Society</i> , 2014, 11, 73-79.	1.5	28
1887	Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans. <i>American Heart Journal</i> , 2014, 167, 413-418.	1.2	13
1888	Cilostazol Eliminates Adverse Smoking Outcome in Patients With Drug-Eluting Stent Implantation. <i>Circulation Journal</i> , 2014, 78, 1420-1427.	0.7	2
1889	Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. <i>Thrombosis and Haemostasis</i> , 2014, 111, 1041-1049.	1.8	16
1890	Fatal Sepsis and Systemic Inflammatory Response Syndrome After Off-Label Prasugrel. <i>American Journal of Therapeutics</i> , 2014, 21, e229-e233.	0.5	5

#	ARTICLE	IF	CITATIONS
1891	Long-term dual antiplatelet treatment and bleeding complications in diabetic patients treated with drug eluting stent implantation. <i>IJC Heart and Vasculature</i> , 2014, 5, 57-62.	0.6	0
1892	Acetylsalicylic acid desensitization in the new era of percutaneous coronary intervention. <i>Medicina Clínica (English Edition)</i> , 2015, 145, 253-257.	0.1	0
1893	Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials. <i>BMC Surgery</i> , 2015, 15, 112.	0.6	63
1894	Outcomes of Percutaneous Coronary Intervention Performed With or Without Preprocedural Dual Antiplatelet Therapy. <i>Circulation Journal</i> , 2015, 79, 2598-2607.	0.7	9
1895	Preprocedural Dual Antiplatelet Therapy for Percutaneous Coronary Intervention in Japanese Current Practice. <i>Circulation Journal</i> , 2015, 79, 2544-2546.	0.7	0
1896	Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. <i>Scientific Reports</i> , 2015, 5, 13789.	1.6	19
1897	Dual Antiplatelet Therapy for Coronary Artery Disease. <i>Circulation Journal</i> , 2015, 79, 255-262.	0.7	16
1898	Antithrombotic Therapy in Patients with Acute Coronary Syndrome in the Intermountain Heart Collaborative Study. <i>Cardiology Research and Practice</i> , 2015, 2015, 1-10.	0.5	3
1899	Personalized Antiplatelet Therapy Following Endovascular Revascularization in Peripheral Artery Occlusive Disease: A Novel Concept. <i>EJVES Short Reports</i> , 2015, 29, 11-17.	0.7	2
1901	2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 1125.	0.4	57
1903	The dogma of aspirin: a critical review of evidence on the best monotherapy after dual antiplatelet therapy. <i>Thrombosis Journal</i> , 2015, 13, 28.	0.9	3
1904	Pre-treatment with dual antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention. <i>Internal Medicine Journal</i> , 2015, 45, 1032-1037.	0.5	2
1905	Effect of P2Y12 inhibitors on inflammation and immunity. <i>Thrombosis and Haemostasis</i> , 2015, 114, 490-497.	1.8	76
1906	The role of antiplatelet therapy in patients with peripheral artery disease and lower extremity peripheral artery revascularization. <i>Current Opinion in Cardiology</i> , 2015, 30, 525-535.	0.8	7
1907	Dual Antiplatelet Therapy of Clopidogrel and Aspirin in Secondary Prevention of Ischemic Stroke: Evidence and Indications. <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 870-876.	1.9	11
1908	Non-antiplatelet effect of clopidogrel: improving endothelial function in Chinese healthy subjects with different CYP2C19 genotype. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2015, 42, 22-26.	0.9	10
1909	ATLANTIC: another reason to investigate the disconnect between stent thrombosis and mortality?. <i>Thrombosis and Haemostasis</i> , 2015, 114, 9-10.	1.8	0
1910	Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1104-1112.	1.8	40

#	ARTICLE	IF	CITATIONS
1911	Current Antiplatelet Treatment Strategy in Patients with Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2015, 39, 95.	1.8	40
1912	Treatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy. <i>World Journal of Critical Care Medicine</i> , 2015, 4, 40.	0.8	30
1913	CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome. <i>Chinese Medical Journal</i> , 2015, 128, 2183-2188.	0.9	11
1914	Impact of Sex and Gender on the Efficacy of Antiplatelet Therapy: The Female Perspective. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015, 22, 109-125.	0.9	16
1915	Baseline Predictors for Good Versus Poor Visual Outcomes in the Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Therapy. , 2015, 56, 5040.		46
1916	Low-Molecular-Weight Heparin or Dual Antiplatelet Therapy Is More Effective Than Aspirin Alone in Preventing Early Neurological Deterioration and Improving the 6-Month Outcome in Ischemic Stroke		

#	ARTICLE	IF	CITATIONS
1929	Comparison of Dual-Antiplatelet Therapy Durations after Endovascular Revascularization of Infringuinal Arteries. <i>Annals of Vascular Surgery</i> , 2015, 29, 1235-1244.	0.4	9
1930	Achieving Safe Femoral Arterial Access. <i>Current Cardiology Reports</i> , 2015, 17, 44.	1.3	3
1931	Effect of a Shortened-Duration Eptifibatide Infusion (75Âmg) as Adjunctive Therapy for Percutaneous Coronary Intervention on Inhospital Cardiovascular Outcomes and Bleeding. <i>American Journal of Cardiology</i> , 2015, 115, 707-710.	0.7	2
1932	Are at Least 12 Months of Dual Antiplatelet Therapy Needed for All Patients With Drug-Eluting Stents?. <i>Circulation</i> , 2015, 131, 2001-2009.	1.6	2
1933	Meta-Analysis of Randomized Controlled Trials Comparing Risk of Major Adverse Cardiac Events and Bleeding in Patients With Prasugrel Versus Clopidogrel. <i>American Journal of Cardiology</i> , 2015, 116, 384-392.	0.7	8
1934	Dual Antiplatelet Therapy in Acute Ischemic Stroke. <i>Current Atherosclerosis Reports</i> , 2015, 17, 37.	2.0	5
1935	Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel. <i>Heart</i> , 2015, 101, 1219-1224.	1.2	15
1936	Coming safely to a stop: a review of platelet activity after cessation of antiplatelet drugs. <i>Therapeutic Advances in Drug Safety</i> , 2015, 6, 141-150.	1.0	19
1937	The future of P2Y₁₂ receptor antagonists. <i>Platelets</i> , 2015, 26, 392-398.	1.1	12
1938	Use and interpretation of cardiac troponin testing. <i>British Journal of Hospital Medicine (London,)</i> Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	0.2	1
1939	Is Extended Duration of Dual Antiplatelet Therapy After Carotid Stenting Beneficial?. <i>Medicine (United)</i> Tj ETQq0 0 0 rgBT /Overlock 10 T	0.4	4
1940	Proteomic signatures of antiplatelet drugs: new approaches to exploring drug effects. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, S323-S331.	1.9	21
1941	Platelet reactivity and antiplatelet management in diabetic patients with coronary artery disease. <i>Interventional Cardiology</i> , 2015, 7, 283-293.	0.0	0
1942	Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development. <i>Future Cardiology</i> , 2015, 11, 547-564.	0.5	17
1943	Antiplatelet Efficacy of Fixed-Dose Aspirinâ€“Clopidogrel Combination in Patients with Stable Coronary Artery Disease Treated with Drug-Eluting Stent Implantation. <i>Clinical Drug Investigation</i> , 2015, 35, 833-842.	1.1	2
1944	Which Should Be the Control Arm in Trials of Antiplatelet Therapies?. <i>American Journal of Cardiology</i> , 2015, 116, 493-494.	0.7	0
1945	Pharmacotherapy for Cardiac Diseases. , 2015, , 457-468.		0
1946	Balancing the risks of bleeding and stent thrombosis: A decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents. <i>American Heart Journal</i> , 2015, 169, 222-233.e5.	1.2	34

#	ARTICLE	IF	CITATIONS
1947	New Approaches to Inhibiting Platelets and Coagulation. Annual Review of Pharmacology and Toxicology, 2015, 55, 373-397.	4.2	44
1948	Comparison of the antiplatelet effect of clopidogrel hydrogenosulfate and clopidogrel besylate in patients with stable coronary artery disease. Journal of Thrombosis and Thrombolysis, 2015, 40, 288-293.	1.0	3
1949	Antiplatelet therapy after drug-eluting stent implantation. Journal of Cardiology, 2015, 65, 98-104.	0.8	7
1950	Secondary Prevention After Coronary Artery Bypass Graft Surgery. Circulation, 2015, 131, 927-964.	1.6	313
1951	Prognostic Impact of Clopidogrel Pretreatment in Patients With Acute Coronary Syndrome Managed Invasively. American Journal of Cardiology, 2015, 115, 1019-1026.	0.7	17
1952	Translation of acute coronary syndrome therapies: From evidence to routine clinical practice. American Heart Journal, 2015, 169, 266-273.	1.2	14
1953	Should Proton Pump Inhibitors Be Withheld From Patients Taking Clopidogrel?. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 6-7.	0.9	8
1954	Dual antiplatelet response during PCI: VerifyNow P2Y12 predicts myocardial necrosis and thromboxane B2 generation confirms wide variation in aspirin response. Thrombosis Research, 2015, 135, 1140-1146.	0.8	3
1955	The effect of clopidogrel on platelet activity in patients with and without type-2 diabetes mellitus: a comparative study. Cardiovascular Diabetology, 2015, 14, 15.	2.7	41
1956	Pretreatment With Antiplatelet Drugs in Invasively Managed Patients With Coronary Artery Disease in the Contemporary Era. Circulation: Cardiovascular Interventions, 2015, 8, e002301.	1.4	58
1957	Novel Anti-platelet Agents in Acute Coronary Syndrome: Mechanisms of Action and Opportunities to Tailor Therapy. Current Atherosclerosis Reports, 2015, 17, 501.	2.0	3
1958	Use of Novel Antiplatelet Agents in Acute Coronary Syndromes. Current Atherosclerosis Reports, 2015, 17, 483.	2.0	1
1959	Dual Antiplatelet Therapy for 6 Months vs 12 Months After New-generation Drug-eluting Stent Implantation: Matched Analysis of ESTROFA-DAPT and ESTROFA-2. Revista Espanola De Cardiologia (English Ed), 2015, 68, 838-845.	0.4	4
1960	Oral dual antiplatelet therapy: what have we learnt from recent trials?. European Heart Journal, 2015, 37, ehv377.	1.0	15
1961	The Impact of Metabolic Syndrome on Clinical Outcomes After Everolimus-Eluting Stent Implantation. American Journal of Cardiology, 2015, 116, 717-724.	0.7	7
1962	Do you still have an appetite for a short DAPT trial?. Cardiovascular Revascularization Medicine, 2015, 16, 133-134.	0.3	0
1963	Pharmacogenetic-guided algorithms to estimate personalized dose or individual responses to anti-thrombotic drugs. Personalized Medicine Universe, 2015, 4, 13-22.	0.1	0
1964	A time course study of high on treatment platelet reactivity in acute coronary syndrome male patients on dual antiplatelet therapy. Thrombosis Research, 2015, 136, 613-619.	0.8	4

#	ARTICLE	IF	CITATIONS
1965	Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. <i>Open Heart</i> , 2015, 2, e000248.	0.9	66
1966	A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI. <i>Indian Heart Journal</i> , 2015, 67, 114-121.	0.2	8
1967	The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1599-1617.	1.5	22
1968	Endovascular Therapy of Cerebral Arterial Occlusions: Intracranial Atherosclerosis versus Embolism. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2015, 24, 2074-2080.	0.7	114
1969	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2015, 36, ehv304.	1.0	175
1970	Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1059-1066.	0.8	14
1971	Antiplatelet Drugs in the Management of Cardiovascular Indications. , 2015, , 953-973.		0
1972	Efficacy and safety of P2Y12 inhibitors according to diabetes, age, gender, body mass index and body weight: Systematic review and meta-analyses of randomized clinical trials. <i>Atherosclerosis</i> , 2015, 240, 439-445.	0.4	28
1973	The Transradial Approach and Antithrombotic Therapy. <i>Interventional Cardiology Clinics</i> , 2015, 4, 213-223.	0.2	0
1974	Is it Time to Repair a Fairly Fast SAAB Convertible? Testing an Evidence-based Mnemonic for the Secondary Prevention of Cardiovascular Disease. <i>Heart Lung and Circulation</i> , 2015, 24, 480-487.	0.2	4
1975	Multicenter trials, guidelines, and uncertainties – Do we know as much as we think we do?. <i>International Journal of Cardiology</i> , 2015, 187, 600-603.	0.8	8
1977	Impact of a high-fat meal on assessment of clopidogrel-induced platelet inhibition in healthy subjects. <i>Thrombosis Journal</i> , 2015, 13, 3.	0.9	1
1978	Impact of prolonged dual antiplatelet therapy after acute myocardial infarction on 5-year mortality in the FAST-MI 2005 registry. <i>International Journal of Cardiology</i> , 2015, 187, 354-360.	0.8	9
1979	Comparison of Ticagrelor Versus Prasugrel to Prevent Periprocedural Myonecrosis in Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2015, 116, 339-343.	0.7	30
1980	Republished: Antiplatelet therapy for secondary prevention of coronary artery disease. <i>Postgraduate Medical Journal</i> , 2015, 91, 284-290.	0.9	1
1981	Prevalence of CYP2C19 alleles, pharmacokinetic and pharmacodynamic variation of clopidogrel and prasugrel in Bangladeshi population. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2015, 42, 451-457.	0.9	16
1982	Actualizaci3n en cardiolog3a intervencionista 2014. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 324-330.	0.6	11
1984	Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 625-637.	1.5	7

#	ARTICLE	IF	CITATIONS
1985	Excessive Long-Term Platelet Inhibition With Prasugrel or Ticagrelor and Risk of Infection. <i>American Journal of Therapeutics</i> , 2015, 22, e22-e27.	0.5	7
1986	Pharmacotherapy in Chronic Kidney Disease Patients Presenting With Acute Coronary Syndrome. <i>Circulation</i> , 2015, 131, 1123-1149.	1.6	61
1987	The Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1311-1313.	1.2	4
1988	Evaluating the bioequivalence of clopidogrel generic formulations. <i>Current Medical Research and Opinion</i> , 2015, 31, 861-864.	0.9	2
1989	Overcoming Aspirin Resistance with Loading Clopidogrel Earlier in Elective Percutaneous Coronary Intervention. <i>International Journal of Angiology</i> , 2015, 24, 19-24.	0.2	2
1990	Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 1623-1629.	0.5	11
1991	Antiplatelet Therapy During PCI for Patients with Stable Angina and Atrial Fibrillation. <i>Current Cardiology Reports</i> , 2015, 17, 64.	1.3	1
1992	Optimal- vs. standard-antiplatelet therapy on platelet function and long-term clinical outcomes in patients with high on-treatment platelet reactivity: 2-year outcomes of the multicentre, randomized Optimal-antiPlatelet Therapy (OPT) trial. <i>European Heart Journal Supplements</i> , 2015, 17, B23-B31.	0.0	4
1993	Optimal Duration of Dual Antiplatelet Therapy After Coronary Stent Implantation. <i>American Journal of Cardiology</i> , 2015, 116, 1631-1636.	0.7	1
1994	Antiplatelet therapy and exodontia. <i>Journal of the American Dental Association</i> , 2015, 146, 851-856.	0.7	14
1995	Duration of Dual Antiplatelet Therapy After Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2015, 66, 832-847.	1.2	105
1996	Dual antiplatelet therapy: optimal timing, management, and duration. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 198-204.	1.4	32
1997	Stopping antiplatelet medication before coronary artery bypass graft surgery: is there an optimal timing to minimize bleeding?. <i>European Journal of Cardio-thoracic Surgery</i> , 2015, 48, e64-e70.	0.6	9
1998	Dual antiplatelet therapy use by Canadian cardiac surgeons. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 150, 1548-1554.e3.	0.4	27
1999	Interventional Management of Unprotected Left Main Coronary Artery Disease: Patient Selection and Technique Optimization. <i>Journal of Interventional Cardiology</i> , 2015, 28, 326-338.	0.5	6
2000	Recommendations for Perioperative Management of Patients on Existing Anticoagulation Therapy. <i>JBJS Reviews</i> , 2015, 3, .	0.8	3
2001	Pharmacogenomics of Hypertension and Heart Disease. <i>Current Hypertension Reports</i> , 2015, 17, 586.	1.5	18
2002	Dual-Antiplatelet Therapy for Diabetic Patients After Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1102-1104.	1.2	4

#	ARTICLE	IF	CITATIONS
2003	Duration of Dual Anti-Platelet Therapy Post-Percutaneous Intervention: Is There A Correct Amount of Time?. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 285-298.	1.6	6
2004	Extended Duration Dual Antiplatelet Therapy and Mortality: A Systematic Review and Meta-Analysis. <i>Journal of Vascular Surgery</i> , 2015, 62, 1369-1370.	0.6	2
2006	Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy after drug-eluting stent implantation in coronary arteries: A meta-analysis of randomized controlled trials. <i>Thrombosis Research</i> , 2015, 136, 870-877.	0.8	8
2007	Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 1333-1344.	0.6	7
2008	Clopidogrel Use in End-stage Kidney Disease. <i>Seminars in Dialysis</i> , 2015, 28, 276-281.	0.7	19
2009	Evaluation of platelet response to different clopidogrel dosing regimens in patients with acute coronary syndrome in clinical practice. <i>Platelets</i> , 2015, 26, 127-131.	1.1	2
2010	Shorter (≤6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: A meta-analysis of randomized clinical trials. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 34-40.	0.7	30
2011	Effect of Addition of Clopidogrel to Aspirin on Subdural Hematoma: Meta-Analysis of Randomized Clinical Trials. <i>International Journal of Stroke</i> , 2015, 10, 501-505.	2.9	26
2012	Effect of Addition of Clopidogrel to Aspirin on Stroke Incidence: Meta-Analysis of Randomized Trials. <i>International Journal of Stroke</i> , 2015, 10, 686-691.	2.9	30
2013	High Clopidogrel Dose in Patients With Chronic Kidney Disease Having Clopidogrel Resistance After Percutaneous Coronary Intervention. <i>Angiology</i> , 2015, 66, 319-325.	0.8	8
2014	Clopidogrel: A multifaceted affair. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1-9.	1.0	7
2015	Long term outcomes in octogenarians undergoing percutaneous coronary intervention: Comparison of bare metal versus drug eluting stent. <i>International Journal of Cardiology</i> , 2015, 179, 385-389.	0.8	10
2016	Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. <i>Lancet, The</i> , 2015, 385, 792-798.	6.3	151
2017	Platelet proteomics in cardiovascular diseases. <i>Translational Proteomics</i> , 2015, 7, 15-29.	1.2	14
2018	Novel antiplatelet agents in acute coronary syndrome. <i>Nature Reviews Cardiology</i> , 2015, 12, 30-47.	6.1	299
2019	Clopidogrel Plus Aspirin Prevents Early Neurologic Deterioration and Improves 6-Month Outcome in Patients With Acute Large Artery Atherosclerosis Stroke. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 453-461.	0.7	34
2020	Lack of association between peri-procedural myocardial damage and CYP2C19 gene variant in elective percutaneous coronary intervention. <i>Heart and Vessels</i> , 2015, 30, 572-579.	0.5	1
2021	Management of Inherited, Acquired, and Iatrogenically Induced Coagulopathies in Oral Surgery. , 0, , .		0

#	ARTICLE	IF	CITATIONS
2022	When is the Best Time for the Second Antiplatelet Agent in Non-St Elevation Acute Coronary Syndrome?. <i>Arquivos Brasileiros De Cardiologia</i> , 2016, 106, 236-46.	0.3	4
2023	Type 2 Diabetes and ADP Receptor Blocker Therapy. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-7.	1.0	8
2024	P2Y12 Inhibitor Pre-Treatment in Non-ST-Elevation Acute Coronary Syndrome: A Decision-Analytic Model. <i>Journal of Clinical Medicine</i> , 2016, 5, 72.	1.0	1
2025	Decision making on timing of surgery for hip fracture patients on clopidogrel. <i>Annals of the Royal College of Surgeons of England</i> , 2016, 98, 91-95.	0.3	14
2026	Comparison of the antiplatelet effect of clopidogrel benzene sulfonate and clopidogrel hydrogen sulfate in stable coronary heart disease. <i>Genetics and Molecular Research</i> , 2016, 15, .	0.3	0
2027	Impact of CYP2C19 Variants on Clinical Efficacy of Clopidogrel and 1-Year Clinical Outcomes in Coronary Heart Patients Undergoing Percutaneous Coronary Intervention. <i>Frontiers in Pharmacology</i> , 2016, 7, 453.	1.6	15
2028	The benefits of drug-eluting stents in the treatment of coronary artery disease. <i>Research Reports in Clinical Cardiology</i> , 2016, , 9.	0.2	2
2029	Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 273-281.	1.9	37
2030	Clinical significance of residual platelet reactivity in patients treated with platelet P2Y12 inhibitors. <i>Vascular Pharmacology</i> , 2016, 84, 25-27.	1.0	18
2031	Exome sequencing of extreme clopidogrel response phenotypes identifies <i>C4GALT2</i> as a determinant of on-treatment platelet reactivity. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 287-294.	2.3	22
2036	Ultrasound-guided Femoral Artery Access for Minimally Invasive Neuro-intervention and Risk Factors for Access Site Hematoma. <i>Neurologia Medico-Chirurgica</i> , 2016, 56, 745-752.	1.0	8
2037	Secondary prevention after coronary artery bypass graft surgery. <i>Current Opinion in Cardiology</i> , 2016, 31, 635-643.	0.8	27
2038	Bleeding Events Before Coronary Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2608-2618.	1.2	10
2039	The effect of alprostadil on preventing contrast-induced nephropathy for percutaneous coronary intervention in diabetic patients. <i>Medicine (United States)</i> , 2016, 95, e5306.	0.4	13
2040	Intraprocedural abciximab bolus versus pretreatment oral dual antiplatelet medication for endovascular stenting of unruptured intracranial aneurysms. <i>Journal of NeuroInterventional Surgery</i> , 2016, 8, 909-912.	2.0	11
2041	2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1082-1115.	1.2	1,232
2042	Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease. <i>Drug Safety</i> , 2016, 39, 715-727.	1.4	12
2043	Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2016, 134, e156-78.	1.6	105

#	ARTICLE	IF	CITATIONS
2044	Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1116-1139.	1.2	154
2045	Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2016, 133, 2094-2098.	1.6	19
2046	Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial. <i>American Heart Journal</i> , 2016, 178, 37-44.	1.2	20
2047	Spray-dried Eudragit® L100 microparticles containing ferulic acid: Formulation, in vitro cytoprotection and in vivo anti-platelet effect. <i>Materials Science and Engineering C</i> , 2016, 64, 318-328.	3.8	22
2048	Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2016, 216, 190-193.	0.8	6
2049	Spray-dried solid dispersions containing ferulic acid: comparative analysis of three carriers, <i>in vitro</i> dissolution, antioxidant potential and <i>in vivo</i> anti-platelet effect. <i>Drug Development and Industrial Pharmacy</i> , 2016, 42, 1813-1824.	0.9	27
2050	Continued Antiplatelet Therapy and Risk of Bleeding in Gastrointestinal Procedures: A Systematic Review. <i>Journal of the American College of Surgeons</i> , 2016, 222, 890-905e11.	0.2	25
2051	One-year incidence and clinical impact of bleeding events in patients treated with prasugrel or clopidogrel after ST-segment elevation myocardial infarction. <i>Archives of Cardiovascular Diseases</i> , 2016, 109, 337-347.	0.7	7
2052	Antiplatelet Management for Coronary Heart Disease: Advances and Challenges. <i>Current Atherosclerosis Reports</i> , 2016, 18, 35.	2.0	12
2053	Do we need P2Y12 inhibitor pretreatment in non-ST elevation acute coronary syndrome?. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2016, 35, 319-321.	0.2	0
2054	2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 152, 1243-1275.	0.4	249
2055	Clinical practice guideline on thromboprophylaxis and management of anticoagulant and antiplatelet drugs in neurosurgical and neurocritical patients. <i>Revista Española De Anestesiología Y Reanimación (English Edition)</i> , 2016, 63, 406-418.	0.1	0
2056	Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1413-1447.	1.4	10
2057	Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions. <i>Circulation</i> , 2016, 134, 723-733.	1.6	31
2058	Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease. <i>Nature Reviews Cardiology</i> , 2016, 13, 609-622.	6.1	24
2059	The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease. <i>Current Cardiology Reports</i> , 2016, 18, 81.	1.3	54
2060	Platelet function testing in cardiac surgery. <i>Transfusion Medicine</i> , 2016, 26, 319-329.	0.5	10
2061	Pharmacodynamic Assessment of Platelet Reactivity After a Loading Dose of Prasugrel or Clopidogrel in Patients With ST-Segment Elevation Myocardial Infarction. <i>Circulation Journal</i> , 2016, 80, 2520-2527.	0.7	7

#	ARTICLE	IF	CITATIONS
2062	Postdischarge Bleeding After Percutaneous Coronary Intervention and Subsequent Mortality and Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	42
2063	Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1905-1913.	1.1	38
2064	Clinical outcomes of various continued antiplatelet therapies in patients who were administered DAPT following the implantation of drug-eluting stents and developed gastrointestinal hemorrhage. <i>Experimental and Therapeutic Medicine</i> , 2016, 12, 1125-1129.	0.8	6
2065	Significant variation in P2Y12 inhibitor use after peripheral vascular intervention in Medicare beneficiaries. <i>American Heart Journal</i> , 2016, 179, 10-18.	1.2	14
2066	Variation in Practice Regarding Pretreatment With Dual Antiplatelet Therapy for Patients With Non-STEMI Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	4
2067	Adapting DAPT to Improve Outcomes After Coronary Stenting. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1458-1460.	1.1	0
2069	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	83
2070	Genotype Frequencies of CYP2C19, P2Y ₁₂ and GP1IIa Polymorphisms in Coronary Heart Disease Patients of Han Ethnicity, and Their Impact on Clopidogrel Responsiveness. <i>International Heart Journal</i> , 2016, 57, 586-592.	0.5	19
2071	Risks and Benefits of Dual Antiplatelet Therapy Beyond 12 Months After Coronary Stenting. <i>Medicine (United States)</i> , 2016, 95, e3663.	0.4	6
2072	Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: A meta-analysis of observational studies. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, E12-22.	0.7	22
2073	2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Dis. <i>Circulation</i> , 2016, 134, e123-55.	1.6	1,069
2074	Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 779-791.	0.6	3
2075	Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study. <i>European Heart Journal</i> , 2017, 38, ehw203.	1.0	57
2076	Dual antiplatelet therapy after coronary stenting. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1775-1787.	0.9	11
2077	Why we need intravenous antiplatelet agents. <i>Future Cardiology</i> , 2016, 12, 553-561.	0.5	4
2079	Platelet reactivity in patients undergoing transcatheter aortic valve implantation. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 11-18.	1.0	18
2080	Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2016, 21, 516-525.	1.0	6
2081	Efficacy and safety of prolonged dual antiplatelet therapy: a meta-analysis of 15 randomized trials enrolling 85 265 patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 218-228.	1.4	18

#	ARTICLE	IF	CITATIONS
2082	Do we need P2Y12 inhibitor pretreatment in non-ST elevation acute coronary syndrome?. Revista Portuguesa De Cardiologia, 2016, 35, 319-321.	0.2	1
2083	Dual antiplatelet therapy, drug-eluting stents and bioresorbable vascular scaffolds: Evolutionary perspectives. Catheterization and Cardiovascular Interventions, 2016, 87, 909-919.	0.7	5
2084	Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes. Journal of Pharmacy Practice, 2016, 29, 239-249.	0.5	10
2085	Dual Antiplatelet Therapy in Patients with Stable Ischemic Heart Disease. Current Atherosclerosis Reports, 2016, 18, 5.	2.0	4
2086	Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: conceptual evolution based on emerging evidence. European Heart Journal, 2016, 37, 353-364.	1.0	64
2087	The Tradeoff Between Shorter and Longer Courses of Dual Antiplatelet Therapy After Implantation of Newer Generation Drug-Eluting Stents. Current Cardiology Reports, 2016, 18, 8.	1.3	4
2088	Acute Coronary Syndromes. Heart Failure Clinics, 2016, 12, 31-48.	1.0	14
2089	Comparative effect on platelet function of a fixed-dose aspirin and clopidogrel combination versus separate formulations in patients with coronary artery disease: A phase IV, multicenter, prospective, 4-week non-inferiority trial. International Journal of Cardiology, 2016, 202, 331-335.	0.8	3
2090	Antithrombotic therapy in peripheral artery disease. Vascular Medicine, 2016, 21, 156-169.	0.8	14
2091	Impact of renal impairment on platelet reactivity and clinical outcomes during chronic dual antiplatelet therapy following coronary stenting. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 145-151.	1.4	23
2092	Protease receptor antagonism to target blood platelet therapies. Clinical Pharmacology and Therapeutics, 2016, 99, 72-81.	2.3	10
2093	P2Y ₁₂ receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation. British Journal of Clinical Pharmacology, 2016, 81, 621-633.	1.1	27
2094	Dual Antiplatelet Therapy Duration: A Review of Current Available Evidence. Clinical Therapeutics, 2016, 38, 961-973.	1.1	1
2095	Antiplatelet Therapy in Percutaneous Coronary Intervention. Interventional Cardiology Clinics, 2016, 5, 221-237.	0.2	5
2096	Current status of data on cangrelor. , 2016, 159, 102-109.		39
2097	Secondary Prevention After Symptomatic Large Artery Extracranial Disease. , 2016, , 147-160.		0
2098	Pivotal Bioequivalence Study of ClopacinÂ®, a Generic Formulation of Clopidogrel 75Âmg Film-Coated Tablets. Advances in Therapy, 2016, 33, 186-198.	1.3	5
2099	Reviewing the controversy surrounding pre-treatment with P2Y12inhibitors in acute coronary syndrome patients. Expert Review of Cardiovascular Therapy, 2016, 14, 811-820.	0.6	13

#	ARTICLE	IF	CITATIONS
2100	Guía de práctica clínica sobre tromboprofilaxis y manejo de los fármacos anticoagulantes y antiagregantes en pacientes neuroquirúrgicos y neurocríticos. Revista Española De Anestesiología Y Reanimación, 2016, 63, 406-418.	0.1	2
2101	Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial. American Heart Journal, 2016, 173, 134-142.	1.2	17
2102	Purinergic receptor P2RY12-dependent microglial closure of the injured blood-brain barrier. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1074-1079.	3.3	306
2103	Antiplatelet Therapy in Carotid Artery Stenting and Carotid Endarterectomy in the Asymptomatic Carotid Surgery Trial-2. European Journal of Vascular and Endovascular Surgery, 2016, 51, 336-342.	0.8	36
2104	Pre-treatment with P2Y ₁₂ inhibitors in ACS patients: who, when, why, and which agent?. European Heart Journal, 2016, 37, 1284-1295.	1.0	52
2105	Randomized Comparison of Different Thienopyridine Loading Strategies in Patients Undergoing Elective Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 219-227.	1.1	23
2106	Esomeprazole and rabeprazole did not reduce antiplatelet effects of aspirin/clopidogrel dual therapy in patients undergoing percutaneous coronary intervention: a prospective, randomized, case-control study. Expert Opinion on Pharmacotherapy, 2016, 17, 7-16.	0.9	11
2107	Temporal trends in the utilisation of preventive medicines by older people: A 9-year population-based study. Archives of Gerontology and Geriatrics, 2016, 62, 103-111.	1.4	14
2108	In-hospital switching from clopidogrel to prasugrel following thrombolysis for ST-elevation myocardial infarction: a 3-year single center experience. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 271-276.	0.4	1
2109	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2016, 37, 267-315.	1.0	5,890
2110	Influence of dual antiplatelet therapy on mean platelet volume in patients with coronary artery disease undergoing percutaneous coronary intervention. Heart and Vessels, 2016, 31, 269-274.	0.5	9
2111	Influence of Different β -Blockers on Platelet Aggregation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy. Journal of Cardiovascular Pharmacology and Therapeutics, 2016, 21, 44-52.	1.0	11
2112	Impact of preoperative dual antiplatelet therapy on bleeding complications in patients with acute coronary syndromes who undergo urgent coronary artery bypass grafting. Journal of Cardiology, 2017, 69, 156-161.	0.8	12
2113	Utility of the HAS-BLED Score in Risk Stratifying Patients on Dual Antiplatelet Therapy Post 12 Months After Drug-Eluting Stent Placement. Catheterization and Cardiovascular Interventions, 2017, 89, E99-E103.	0.7	10
2114	Oral Antiplatelet Therapy in Coronary Disease. American Journal of Therapeutics, 2017, 24, e744-e750.	0.5	2
2115	Adding CABG to the Dual Antiplatelet Salad. Journal of the American College of Cardiology, 2017, 69, 128-130.	1.2	5
2117	Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nature Reviews Cardiology, 2017, 14, 361-379.	6.1	76
2118	Gender differences in cardiovascular prophylaxis: Focus on antiplatelet treatment. Pharmacological Research, 2017, 119, 36-47.	3.1	48

#	ARTICLE	IF	CITATIONS
2119	Comparison of P2Y12 inhibitors for mortality and stent thrombosis in patients with acute coronary syndromes: Single center study of 10 793 consecutive "real-world"™ patients. <i>Platelets</i> , 2017, 28, 767-773.	1.1	16
2120	Pharmacology: Inhibitors of P2Y12. , 2017, , 1253-1267.		1
2121	Defining optimal activated clotting time for percutaneous coronary intervention: A systematic review and Bayesian meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 351-366.	0.7	19
2122	A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the "DAPT-STEMI trial". <i>American Heart Journal</i> , 2017, 188, 11-17.	1.2	13
2123	Bleeding associated with the management of acute coronary syndromes. <i>Heart</i> , 2017, 103, 546-562.	1.2	5
2124	Optimal duration of dual antiplatelet therapy after acute coronary syndromes and coronary stenting. <i>Heart</i> , 2017, 103, 871-884.	1.2	4
2125	Single or dual antiplatelet therapy after PCI. <i>Nature Reviews Cardiology</i> , 2017, 14, 294-303.	6.1	35
2126	Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials. <i>European Heart Journal</i> , 2017, 38, 2559-2566.	1.0	42
2127	Systemically administered collagen-targeted gold nanoparticles bind to arterial injury following vascular interventions. <i>Physiological Reports</i> , 2017, 5, e13128.	0.7	12
2128	Antithrombotic Therapy to Reduce Ischemic Events in Acute Coronary Syndromes Patients Undergoing Percutaneous Coronary Intervention. <i>Interventional Cardiology Clinics</i> , 2017, 6, 131-140.	0.2	5
2129	Complications of Proton Pump Inhibitor Therapy. <i>Gastroenterology</i> , 2017, 153, 35-48.	0.6	353
2130	Preoperative Low-Dose Aspirin Exposure and Outcomes After Emergency Neurosurgery for Traumatic Intracranial Hemorrhage in Elderly Patients. <i>Anesthesia and Analgesia</i> , 2017, 125, 514-520.	1.1	24
2131	Meta-analysis of Comparison of the Newer P2Y12 Inhibitors (Oral Preparation or Intravenous) to Clopidogrel in Patients With Acute Coronary Syndrome. <i>Journal of Cardiovascular Pharmacology</i> , 2017, 69, 147-155.	0.8	10
2133	Antiplatelet therapy in acute coronary syndrome. <i>Continuing Cardiology Education</i> , 2017, 3, 11-21.	0.4	1
2134	Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2017, 22, 347-355.	1.0	13
2135	The optimal discontinuation of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention with drug-eluting stents: A meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , 2017, 235, 73-86.	0.8	6
2136	The use of intravenous tPA for the treatment of severe frostbite. <i>Burns</i> , 2017, 43, 1088-1096.	1.1	28
2137	Prognostic Factors in Patients With Stemi Undergoing Primary PCI in the Clopidogrel Era: Role of Dual Antiplatelet Therapy at Admission and the Smoking Paradox on Long-term Outcome. <i>Journal of Interventional Cardiology</i> , 2017, 30, 5-15.	0.5	8

#	ARTICLE	IF	CITATIONS
2138	Antithrombotic Therapy. <i>Frontiers of Neurology and Neuroscience</i> , 2017, 40, 141-151.	3.0	2
2139	Dual antiplatelet therapy for secondary prevention of coronary artery disease. <i>Open Heart</i> , 2017, 4, e000651.	0.9	49
2140	Management of acute coronary syndromes: special considerations in women. <i>Heart</i> , 2017, 103, 1638-1646.	1.2	14
2141	Caesarean delivery during dual antiplatelet therapy after acute myocardial infarction and stenting. <i>Case Reports in Perinatal Medicine</i> , 2017, 6, .	0.1	1
2142	Precatheterization Use of P2Y ₁₂ Inhibitors in Non-ST-Elevation Myocardial Infarction Patients Undergoing Early Cardiac Catheterization and In-Hospital Coronary Artery Bypass Grafting: Insights From the National Cardiovascular Data Registry. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	9
2143	Renal Dysfunction: How to Think About That in Acute Coronary Syndromes. <i>Current Cardiology Reports</i> , 2017, 19, 91.	1.3	1
2144	Benefits and risks of P2Y ₁₂ inhibitor preloading in patients with acute coronary syndrome and stable angina. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 303-315.	1.0	5
2145	Association of CYP2C19*2 polymorphism with clopidogrel response and 1-year major adverse cardiovascular events in a multiethnic population with drug-eluting stents. <i>Pharmacogenomics</i> , 2017, 18, 1225-1239.	0.6	5
2146	Individualizing dual antiplatelet therapy duration after percutaneous coronary intervention: from randomized control trials to personalized medicine. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 681-693.	0.6	4
2147	P2Y ₁₂ Receptor Function and Response to Cangrelor in Neonates With Cyanotic Congenital Heart Disease. <i>JACC Basic To Translational Science</i> , 2017, 2, 465-476.	1.9	9
2148	Head-to-head comparison of prasugrel versus ticagrelor in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. <i>Journal of Interventional Cardiology</i> , 2017, 30, 457-464.	0.5	8
2149	Update on antithrombotic therapy after percutaneous coronary revascularisation. <i>Lancet, The</i> , 2017, 390, 810-820.	6.3	25
2150	Optimization of Antiplatelet Therapy in STEMI. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2017, 19, 65.	0.4	2
2151	Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	7
2153	P2Y ₁₂ receptor inhibitor resistance and coronary artery disease. <i>Current Opinion in Cardiology</i> , 2017, 32, 617-626.	0.8	1
2154	Drug Hepatotoxicity. <i>Clinics in Liver Disease</i> , 2017, 21, 115-134.	1.0	58
2155	Meta-analysis of clopidogrel pretreatment in acute coronary syndrome patients undergoing invasive strategy. <i>International Journal of Cardiology</i> , 2017, 229, 82-89.	0.8	12
2156	Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 1176-1184.	0.7	5

#	ARTICLE	IF	CITATIONS
2157	Acute myocardial infarction. <i>Lancet, The</i> , 2017, 389, 197-210.	6.3	869
2158	Changes in P2Y12 reaction units after switching treatments from prasugrel to clopidogrel in Japanese patients with acute coronary syndrome followed by elective coronary stenting. <i>Cardiovascular Intervention and Therapeutics</i> , 2017, 32, 341-350.	1.2	14
2159	Quality indicators for acute myocardial infarction: A position paper of the Acute Cardiovascular Care Association. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 34-59.	0.4	109
2160	Optimizing the Use of Cangrelor in the Real World. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 5-16.	1.0	7
2161	Pretreatment with Antiplatelet Agents in the Setting of Percutaneous Coronary Intervention. <i>Interventional Cardiology Clinics</i> , 2017, 6, 13-24.	0.2	6
2162	Optimal Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Interventional Cardiology Clinics</i> , 2017, 6, 25-37.	0.2	8
2163	Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. <i>The Cochrane Library</i> , 2017, 2017, CD005158.	1.5	50
2164	Antithrombotic therapy for acute coronary syndrome: Past, present and future. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1240-1248.	1.8	41
2165	On-clopidogrel platelet reactivity as predictor for long-term clinical outcome in patients after planned discontinuation of clopidogrel. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1644-1650.	1.8	6
2166	Clinical pathways and management of antithrombotic therapy in patients with acute coronary syndrome (ACS): a Consensus Document from the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Society of Emergency Medicine (SIMEU) and Italian Society of Interventional Cardiology (SICI-GISE). <i>European Heart Journal Supplements</i> , 2017, 19, D130-D150.	0.0	4
2167	Add-on Antiplatelet Effects of Eicosapentaenoic Acid With Tailored Dose Setting in Patients on Dual Antiplatelet Therapy. <i>International Heart Journal</i> , 2017, 58, 481-485.	0.5	7
2168	Medical Treatment of Intracranial Atherosclerosis: An Update. <i>Journal of Stroke</i> , 2017, 19, 261-270.	1.4	30
2169	Dual antiplatelet therapy and non-cardiac surgery: evolving issues and anesthetic implications. <i>Korean Journal of Anesthesiology</i> , 2017, 70, 13.	0.9	17
2170	General Considerations for Neurointerventional Procedures. , 2018, , 167-246.		1
2171	Contemporary Antiplatelet Pharmacotherapy in the Management of Acute Coronary Syndromes. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 17.	0.4	1
2173	<i>Cardiovascular Drugs and Hemostasis</i> . , 2018, , 561-589.		0
2174	Etiology of gastrointestinal bleeding in patients on dual antiplatelet therapy. <i>Journal of Digestive Diseases</i> , 2018, 19, 66-73.	0.7	7
2175	The Timing of P2Y 12 Inhibitor Initiation in the Treatment of ACS? Does the Evidence Exist in This Era?. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 471-477.	1.6	6

#	ARTICLE	IF	CITATIONS
2176	Dual antiplatelet therapy after percutaneous coronary intervention for stable CAD or ACS. <i>Herz</i> , 2018, 43, 11-19.	0.4	2
2177	Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e005795.	1.4	25
2178	Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 478-490.	1.6	61
2179	Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel. <i>Thrombosis Journal</i> , 2018, 16, 5.	0.9	2
2180	In-Hospital Bleeding and Utility of a Maintenance Dose of Prasugrel 2.5 mg in High Bleeding Risk Patients With Acute Coronary Syndrome. <i>Circulation Journal</i> , 2018, 82, 1874-1883.	0.7	13
2181	Pretreatment with P2Y12 inhibitors and outcome in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 234-239.	0.6	2
2182	First 24h in the management of non-ST segment elevation myocardial infarction. <i>European Heart Journal Supplements</i> , 2018, 20, B29-B38.	0.0	1
2183	Dual antiplatelet therapy in patients with an acute coronary syndrome: up to 12 months and beyond. <i>European Heart Journal Supplements</i> , 2018, 20, B21-B28.	0.0	2
2184	Impact of ticagrelor versus aspirin on graft patency after CABG: Rationale and design of the TARGET (ticagrelor antiplatelet therapy to reduce graft events and thrombosis) randomized controlled trial (NCT02053909). <i>Contemporary Clinical Trials</i> , 2018, 68, 45-51.	0.8	9
2185	Platelet inhibition after loading dose of prasugrel in patients with ST-elevation and non-ST-elevation acute coronary syndrome. <i>Cardiovascular Intervention and Therapeutics</i> , 2018, 33, 239-246.	1.2	14
2186	Dual-antiplatelet Therapy Guidelines and Implications for Perioperative Management. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2018, 32, 1072-1080.	0.6	8
2187	Role of genetic testing in patients undergoing percutaneous coronary intervention. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 151-164.	1.3	57
2188	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Heart Journal</i> , 2018, 39, 213-260.	1.0	2,246
2189	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 34-78.	0.6	261
2190	Heart-type fatty acid-binding protein (H-FABP) and highly sensitive troponin T (hsTnT) as markers of myocardial injury and cardiovascular events in elective percutaneous coronary intervention (PCI). <i>QJM - Monthly Journal of the Association of Physicians</i> , 2018, 111, 33-38.	0.2	2
2191	The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts. <i>Expert Review of Hematology</i> , 2018, 11, 5-12.	1.0	17
2192	The safety and effectiveness of adenosine diphosphate receptor inhibitor pretreatment among acute myocardial infarction patients treated with percutaneous coronary intervention in community practice: insights from the TRANSLATE-ACS study. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 242-250.	0.7	4
2193	Cangrelor compared with clopidogrel in patients with prior myocardial infarction – Insights from the CHAMPION trials. <i>International Journal of Cardiology</i> , 2018, 250, 49-55.	0.8	5

#	ARTICLE	IF	CITATIONS
2194	Prevention of Stroke in Atrial Fibrillation. , 2018, , 1092-1100.		0
2195	Self-expandable metal stents for the extraction of common bile duct stones in patients receiving dual antiplatelet agents: a pilot study. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 1077-1081.	1.3	6
2196	Thrombus Pharmacotherapy. , 2018, , 587-603.		2
2197	Diabetes and antiplatelet therapy: from bench to bedside. Cardiovascular Diagnosis and Therapy, 2018, 8, 594-609.	0.7	45
2198	Percutaneous pleural drainage in patients taking clopidogrel: real danger or phantom fear?. Journal of Thoracic Disease, 2018, 10, 5162-5169.	0.6	3
2199	Continuum of Care for Acute Coronary Syndrome. Critical Pathways in Cardiology, 2018, 17, 114-138.	0.2	5
2200	A polyhedral oligomeric silsesquioxane/molecular sieve codoped molecularly imprinted polymer for gastroretentive drug-controlled release <i>in vivo</i>. Biomaterials Science, 2018, 6, 3170-3177.	2.6	20
2201	Individualized Antiplatelet Therapy. Chinese Medical Journal, 2018, 131, 1387-1389.	0.9	1
2202	Evaluation of the Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Bleeding Score for Predicting the Long-term Out-of-hospital Bleeding Risk in Chinese Patients after Percutaneous Coronary Intervention. Chinese Medical Journal, 2018, 131, 1406-1411.	0.9	4
2203	Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome. Journal of the American College of Cardiology, 2018, 72, 2886-2903.	1.2	68
2204	Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease. Expert Opinion on Drug Safety, 2018, 17, 1041-1052.	1.0	20
2205	The impact of in-hospital P2Y12 inhibitor switch in patients with acute coronary syndrome. Cardiovascular Revascularization Medicine, 2018, 19, 912-916.	0.3	5
2206	Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ: British Medical Journal, 2018, 363, k3793.	2.4	125
2208	Pharmacogenetics of Stroke. Stroke, 2018, 49, 2541-2548.	1.0	7
2209	Parameter Estimation of Platelets Deposition: Approximate Bayesian Computation With High Performance Computing. Frontiers in Physiology, 2018, 9, 1128.	1.3	5
2210	Use of Antiplatelet Agents in the Neurosurgical Patient. Neurosurgery Clinics of North America, 2018, 29, 517-527.	0.8	4
2211	The Evolving Concept of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: Focus on Unique Feature of East Asian and "Asian Paradox". Korean Circulation Journal, 2018, 48, 537.	0.7	52
2212	Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10,854 patients from the CHAMPION PHOENIX trial. European Heart Journal, 2018, 39, 4112-4121.	1.0	49

#	ARTICLE	IF	CITATIONS
2213	Modern Antiplatelet Therapy: When Is Clopidogrel the Right Choice?. <i>Cardiovascular Innovations and Applications</i> , 2018, 3, .	0.1	0
2214	Evaluation of CRUSADE and ACUITY-HORIZONS Scores for Predicting Long-term Out-of-Hospital Bleeding after Percutaneous Coronary Interventions. <i>Chinese Medical Journal</i> , 2018, 131, 262-267.	0.9	3
2215	Delayed presentation of penetrating carotid injury: Two cases and a review of the literature. <i>Trauma</i> , 2018, 20, 151-155.	0.2	0
2216	Carotid Stenting With Antithrombotic Agents and Intracranial Thrombectomy Leads to the Highest Recanalization Rate in Patients With Acute Stroke With Tandem Lesions. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1290-1299.	1.1	129
2217	Efficacy of 2.5-mg Prasugrel in Elderly or Low-Body-Weight Patients. <i>Circulation Journal</i> , 2018, 82, 2326-2331.	0.7	12
2218	Triple Therapy: When, if Ever?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 61.	0.4	1
2219	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. <i>Nature Reviews Cardiology</i> , 2018, 15, 480-496.	6.1	180
2220	Antiplatelet Agents in Secondary Stroke Prevention: Selection, Timing, and Dose. <i>Current Treatment Options in Neurology</i> , 2018, 20, 32.	0.7	4
2221	Thromboembolism prophylaxis in orthopaedics: an update. <i>EFORT Open Reviews</i> , 2018, 3, 136-148.	1.8	142
2222	Dual versus single antiplatelet therapy after coronary artery bypass graft surgery: An updated meta-analysis. <i>International Journal of Cardiology</i> , 2018, 269, 80-88.	0.8	28
2223	Quality of health economic evaluations for the ACC/AHA stable ischemic heart disease practice guideline: A systematic review. <i>American Heart Journal</i> , 2018, 204, 17-33.	1.2	7
2224	Aspirin hypersensitivity in patients with coronary artery disease: linking pathophysiology to clinical practice. <i>American Heart Journal</i> , 2018, 203, 74-81.	1.2	2
2225	Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma. <i>Journal of Clinical Medicine</i> , 2018, 7, 74.	1.0	5
2226	Prevention of Coronary Microvascular Obstruction by Addressing Ischemia Reperfusion Injury Part A. , 2018, , 255-276.		0
2227	Oral Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 457-472.	1.0	13
2228	Impact of Clopidogrel on Mortality in Patients With Acute Heart Failure Stratified by Coronary Artery Disease: Findings From the Arabian Gulf Acute Heart Failure Registry (Gulf CARE). <i>Angiology</i> , 2018, 69, 884-891.	0.8	0
2229	Strategies in Acute Coronary Syndrome. , 2018, , 921-938.		2
2230	Potent effect of prasugrel on acute phase resolution of intra-stent athero-thrombotic burden after percutaneous intervention to acute coronary syndrome. <i>Journal of Cardiology</i> , 2018, 72, 403-410.	0.8	1

#	ARTICLE	IF	CITATIONS
2231	Carotid and Intracranial Stent Placement. , 2018, , 345-355.		2
2232	Effects of clopidogrel with or without aspirin on the generation of extracellular vesicles in the microcirculation and in venous blood: A randomized placebo controlled trial. <i>Thrombosis Research</i> , 2018, 167, 149-155.	0.8	4
2233	Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. <i>European Heart Journal Supplements</i> , 2018, 20, F1-F74.	0.0	25
2234	Panax quinquefolius saponins combined with dual antiplatelet drug therapy alleviate gastric mucosal injury and thrombogenesis through the COX/PG pathway in a rat model of acute myocardial infarction. <i>PLoS ONE</i> , 2018, 13, e0194082.	1.1	10
2235	Validation of DAPT score for prolonged dual antiplatelet therapy in patients with acute myocardial infarction. <i>Hellenic Journal of Cardiology</i> , 2019, 60, 296-302.	0.4	8
2236	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2019, 40, 87-165.	1.0	4,537
2237	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 4-90.	0.6	402
2238	Clopidogrel-associated genetic variants on inhibition of platelet activity and clinical outcome for acute coronary syndrome patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 124, 84-93.	1.2	21
2239	Myocardial salvage after ST-segment-elevation myocardial infarction: comparison between prasugrel and clopidogrel in the presence or absence of high-residual platelet reactivity. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 1422-1434.	1.4	4
2240	Gender and Outcomes following Guided De-Escalation of Antiplatelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Gender Substudy. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1527-1538.	1.8	7
2241	Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention. <i>Open Heart</i> , 2019, 6, e000951.	0.9	16
2242	<p>Pharmacogenomics In Pharmacy Practice: Current Perspectives</p>. <i>Integrated Pharmacy Research & Practice</i> , 2019, Volume 8, 97-104.	0.9	19
2244	A randomized trial of endovascular versus surgical management of ruptured intracranial aneurysms: Interim results from ISAT2. <i>Neurochirurgie</i> , 2019, 65, 370-376.	0.6	16
2245	Antiplatelet Agents for Cancer Prevention: Current Evidences and Continuing Controversies. <i>Cancers</i> , 2019, 11, 1639.	1.7	9
2246	The Effect of CYP2C19 and Nongenetic Factors on Clopidogrel Responsiveness in the MENA Region: A Systematic Review. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961987552.	0.7	3
2247	Perioperative ST-elevation myocardial infarction: with time of the essence, is there a case for guidelines?. <i>British Journal of Anaesthesia</i> , 2019, 123, 548-554.	1.5	4
2248	Pharmacogenetics in Cardiovascular Diseases. , 2019, , 133-179.		3
2250	The clinical effects of CYP2C19 *2 allele frequency on Palestinian patients receiving clopidogrel after percutaneous coronary intervention. <i>International Journal of Clinical Pharmacy</i> , 2019, 41, 96-103.	1.0	6

#	ARTICLE	IF	CITATIONS
2251	Aspirin plus clopidogrel <i>versus</i> aspirin mono-therapy for ischemic stroke: a meta-analysis. Scandinavian Cardiovascular Journal, 2019, 53, 169-175.	0.4	10
2252	Global vascular guidelines on the management of chronic limb-threatening ischemia. Journal of Vascular Surgery, 2019, 69, 3S-125S.e40.	0.6	841
2253	Role of Gender in Dual Antiplatelet Therapy After Acute Coronary Syndrome. Current Atherosclerosis Reports, 2019, 21, 34.	2.0	6
2254	Why maximum tolerated dose?. British Journal of Clinical Pharmacology, 2019, 85, 2213-2217.	1.1	15
2255	Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. European Journal of Vascular and Endovascular Surgery, 2019, 58, S1-S109.e33.	0.8	741
2256	Dual antiplatelet therapy in non-ST elevation acute coronary syndromes at Veterans Affairs Hospitals. Heart, 2019, 105, 1575-1582.	1.2	3
2257	Antithrombotic dose: Some observations from published clinical trials. British Journal of Clinical Pharmacology, 2019, 85, 2194-2197.	1.1	1
2258	Mean Platelet Volume (MPV): New Perspectives for an Old Marker in the Course and Prognosis of Inflammatory Conditions. Mediators of Inflammation, 2019, 2019, 1-14.	1.4	288
2259	The Two-way Relationship Between Cancer and Atherosclerosis. Revista Espanola De Cardiologia (English Ed), 2019, 72, 487-494.	0.4	14
2260	The effects of secondary prevention after coronary revascularization in Taiwan. PLoS ONE, 2019, 14, e0215811.	1.1	4
2261	The safety of morphine use in acute coronary syndrome: a meta-analysis. Heart Asia, 2019, 11, e011142.	1.1	5
2262	Outcomes of patients on dual antiplatelet therapy post-coronary stenting following emergency noncardiac surgery. Acta Anaesthesiologica Scandinavica, 2019, 63, 982-992.	0.7	2
2263	Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y12 Inhibitor Pretreatment. Circulation: Cardiovascular Interventions, 2019, 12, e007445.	1.4	0
2264	Pretreatment with P2Y12 receptor antagonists in ST-elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry. European Heart Journal, 2019, 40, 1202-1210.	1.0	34
2265	Genetic and Nongenetic Implications of Racial Variation in Response to Antiplatelet Therapy. American Journal of Cardiology, 2019, 123, 1878-1883.	0.7	4
2266	The Role of Platelets in Diabetes Mellitus. , 2019, , 469-503.		9
2267	P2Y12 Antagonists. , 2019, , 937-956.		1
2268	Antiplatelet Drugs in the Management of Coronary Artery Disease. , 2019, , 1017-1029.		0

#	ARTICLE	IF	CITATIONS
2269	Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI: A Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1000-1020.	1.8	15
2270	Endovascular Treatment of Intracranial Atherosclerotic Stenosis. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2019, 191, 643-652.	0.7	10
2271	Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non-ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 906-914.	1.2	14
2272	La relación bidireccional entre el cáncer y la aterosclerosis. <i>Revista Espanola De Cardiología</i> , 2019, 72, 487-494.	0.6	15
2273	Short- and long-term follow-up of antithrombotic management patterns in patients hospitalized with acute coronary syndrome: Indian subgroup of EPICOR Asia study. <i>Indian Heart Journal</i> , 2019, 71, 25-31.	0.2	4
2274	Initiation And Persistence With Antiplatelet Agents Among The Patients With Acute Coronary Syndromes: A Retrospective, Observational Database Study In China. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 2159-2169.	0.8	7
2275	Clinical trials in long-term antiplatelet therapies. <i>Current Opinion in Cardiology</i> , 2019, 34, 315-322.	0.8	2
2276	The Case of Crossover Design for Drug-Drug Interactions. <i>Epidemiology</i> , 2019, 30, 204-211.	1.2	11
2277	La DAPT chez le patient diabétique coronarien. <i>Archives of Cardiovascular Diseases Supplements</i> , 2019, 11, S3-S7.	0.0	0
2278	Antithrombotic Management After Intracranial Hemorrhage. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 88.	0.4	2
2279	Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 210-215.	1.4	7
2280	Anti-platelet and anti-coagulant therapy in peripheral arterial disease prior to surgical intervention. <i>Vascular</i> , 2019, 27, 299-311.	0.4	9
2281	Clopidogrel Hypersensitivity: Overview of the Problem. <i>Current Vascular Pharmacology</i> , 2019, 17, 108-109.	0.8	0
2282	Are we ready for a gender-specific approach in interventional cardiology?. <i>International Journal of Cardiology</i> , 2019, 286, 226-233.	0.8	28
2283	Impact of platelet reactivity on long-term prognosis in Korean patients receiving percutaneous coronary intervention. <i>Platelets</i> , 2019, 30, 1030-1035.	1.1	4
2284	Perioperative Bridging With Glycoprotein IIb/IIIa Inhibitors Versus Cangrelor: Balancing Efficacy and Safety. <i>Annals of Pharmacotherapy</i> , 2019, 53, 726-737.	0.9	17
2285	Effectiveness and Safety of Clopidogrel Co-administered With Statins and Proton Pump Inhibitors: A Korean National Health Insurance Database Study. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 182-194.	2.3	4
2286	The association between a three-day ticagrelor discontinuation and perioperative bleeding complications. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 714-720.	0.6	15

#	ARTICLE	IF	CITATIONS
2287	Meta-Analysis Design and Results in Real Life: Problem Solvers or Detour to Maze. A Critical Review of Meta-Analysis of DAPT Randomized Controlled Trials. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 897-906.	0.3	1
2288	Long-lasting anti-platelet activity of cilostazol from poly(ϵ -caprolactone)-poly(ethylene glycol) blend nanocapsules. <i>Materials Science and Engineering C</i> , 2019, 94, 694-702.	3.8	29
2289	Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. <i>Nature Reviews Cardiology</i> , 2019, 16, 113-130.	6.1	73
2290	Effects of Cilostazol-Based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy After Coronary Drug-Eluting Stent Implantation: An Updated Meta-Analysis of the Randomized Controlled Trials. <i>Clinical Drug Investigation</i> , 2019, 39, 1-13.	1.1	8
2291	Antiplatelet Therapy in Cardiovascular Medicine. , 2019, , 396-414.		0
2292	Dual Antiplatelet Therapy Combining Aspirin and Ticagrelor for Intracranial Stenting Procedures: A Retrospective Single Center Study of 154 Consecutive Patients With Unruptured Aneurysms. <i>Neurosurgery</i> , 2019, 84, 77-83.	0.6	41
2293	Modern Management of ST-Segment Elevation Myocardial Infarction. <i>Current Problems in Cardiology</i> , 2020, 45, 100393.	1.1	26
2294	The effect of smoking on residual platelet reactivity to clopidogrel: a systematic review and meta-analysis. <i>Platelets</i> , 2020, 31, 3-14.	1.1	6
2295	Are We Optimizing the Use of Dual Antiplatelet Therapy in Patients Hospitalized with Acute Myocardial Infarction?. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 182-188.	0.3	0
2296	Comorbidity and low use of new antiplatelets in acute coronary syndrome. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 1525-1531.	1.4	5
2297	Impact of Dual versus Single Antiplatelet Therapy on Major Cardiovascular Outcomes in Patients with Acute Coronary Syndrome in the Arabian Gulf. <i>Medical Principles and Practice</i> , 2020, 29, 181-187.	1.1	0
2298	Endovascular Revascularization Incorporating Infrapopliteal Coronary Drug-Eluting Stents Improves Clinical Outcomes in Patients with Critical Limb Ischemia and Tissue Loss. <i>Annals of Vascular Surgery</i> , 2020, 63, 234-240.	0.4	2
2299	Identification of patients at higher risk for myocardial injury following elective coronary artery intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 578-585.	0.7	4
2300	Update on Antithrombotic Therapy after Percutaneous Coronary Intervention. <i>Internal Medicine</i> , 2020, 59, 311-321.	0.3	25
2301	Differential Effects of Ticagrelor With or Without Aspirin on Platelet Reactivity and Coagulation Activation: A Randomized Trial in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 415-422.	2.3	8
2302	Impact of high on-treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPT-DES substudy. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 793-801.	0.7	6
2303	Antithrombotic therapy after percutaneous coronary intervention from the Japanese perspective. <i>Cardiovascular Intervention and Therapeutics</i> , 2020, 35, 19-29.	1.2	37
2304	When is the optimal time to discontinue clopidogrel before in-hospital coronary bypass surgery? A closer look at the current literature. <i>Journal of Cardiac Surgery</i> , 2020, 35, 413-421.	0.3	0

#	ARTICLE	IF	CITATIONS
2305	HAuCl ₄ , Putative General Aquaporins Blocker, Reduces Platelet Spreading, Filopodia Formation, Procoagulant Response, and Thrombus Formation Under Flow. <i>Frontiers in Physiology</i> , 2020, 11, 1025.	1.3	4
2306	Evolving Concepts in Post-PCI Antiplatelets Therapy. <i>Indian Journal of Clinical Cardiology</i> , 2020, 1, 186-194.	0.3	0
2307	Timing of Oral P2Y ₁₂ Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2450-2459.	1.2	64
2308	Association of Pretreatment With P2Y ₁₂ Receptor Antagonists Preceding Percutaneous Coronary Intervention in Non-ST-Segment Elevation Acute Coronary Syndromes With Outcomes. <i>JAMA Network Open</i> , 2020, 3, e2018735.	2.8	48
2309	Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. <i>Lancet</i> , The, 2020, 396, 1737-1744.	6.3	75
2310	Trends of prescribing adherence of antiplatelet agents in Hong Kong patients with acute coronary syndrome: a 10-year retrospective observational cohort study. <i>BMJ Open</i> , 2020, 10, e042229.	0.8	4
2311	<i>CYP2C19</i> genotype-guided antiplatelet therapy: promises and pitfalls. <i>Pharmacogenomics</i> , 2020, 21, 889-897.	0.6	13
2312	Genetic Polymorphisms and Perioperative Bleeding in Off-Pump Coronary Artery Bypass Grafting Surgery. <i>Annals of Thoracic Surgery</i> , 2020, 112, 116-123.	0.7	1
2313	Letter by Alfaddagh Regarding Article, "Healed Plaques in Patients With Stable Angina Pectoris: Arteriosclerosis, Thrombosis, and Vascular Biology", 2020, 40, e256-e257.	1.1	0
2314	Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2460-2462.	1.2	3
2315	Optimizing Monotherapy Selection, Aspirin Versus P2Y ₁₂ Inhibitors, Following Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2020, 135, 154-165.	0.7	7
2316	Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug-eluting stent implantation: a network meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 56-64.	1.4	17
2317	Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators. <i>Drug Metabolism and Disposition</i> , 2020, 48, 230-244.	1.7	62
2318	Periprocedural Myocardial Injury: Pathophysiology, Prognosis, and Prevention. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1041-1052.	0.3	7
2319	JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease. <i>Circulation Journal</i> , 2020, 84, 831-865.	0.7	197
2320	Antiplatelet therapies in diabetes. <i>Diabetic Medicine</i> , 2020, 37, 726-734.	1.2	2
2321	Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1095-1106.	1.2	25
2322	Efficacy and Safety of Long-Term and Short-Term Dual Antiplatelet Therapy: A Meta-Analysis of Comparison between Asians and Non-Asians. <i>Journal of Clinical Medicine</i> , 2020, 9, 652.	1.0	10

#	ARTICLE	IF	CITATIONS
2323	Evaluation of a Novel Antiplatelet Therapy Strategy in Patients Undergoing Elective Percutaneous Coronary Intervention. <i>Journal of Pharmacy Practice</i> , 2020, 34, 089719002093346.	0.5	0
2325	Cangrelor in clinical use. <i>Future Cardiology</i> , 2020, 16, 89-102.	0.5	5
2326	Stability and bioactivity of pepCD47 attachment on stainless steel surfaces. <i>Acta Biomaterialia</i> , 2020, 104, 231-240.	4.1	7
2327	Treatment selection and medication adherence for stable angina: The role of area-based health literacy. <i>Journal of Evaluation in Clinical Practice</i> , 2020, 26, 1711-1721.	0.9	4
2328	Impact of genetic variants of selected cytochrome P450 isoenzymes on pharmacokinetics and pharmacodynamics of clopidogrel in patients co-treated with atorvastatin or rosuvastatin. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 419-430.	0.8	4
2329	Ischemic Versus Bleeding Outcomes After Percutaneous Coronary Interventions in Patients With High Bleeding Risk. <i>American Journal of Cardiology</i> , 2020, 125, 1631-1637.	0.7	9
2330	Combination of cyclic nucleotide modulators with P2Y ₁₂ receptor antagonists as antiplatelet therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1705-1713.	1.9	3
2331	Combined aspirin and clopidogrel therapy in phacoemulsification cataract surgery: a risk factor for ocular hemorrhage?. <i>International Ophthalmology</i> , 2020, 40, 2023-2029.	0.6	5
2332	World Heart Federation Expert Consensus Statement on Antiplatelet Therapy in East Asian Patients with ACS or Undergoing PCI. <i>Global Heart</i> , 2020, 9, 457.	0.9	34
2333	Efficacy and safety of short-term 3 months versus standard 12 months dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials. <i>Platelets</i> , 2021, 32, 582-590.	1.1	3
2334	Pharmacology before, during and after percutaneous coronary intervention. <i>Heart</i> , 2021, 107, 585-592.	1.2	4
2335	Impact of Delay in Surgery on Outcome in Patients Undergoing Cardiac Revascularisation Surgery. <i>Heart Lung and Circulation</i> , 2021, 30, 888-895.	0.2	3
2336	Differential Effects of Clopidogrel With or Without Aspirin on Platelet Reactivity and Coagulation Activation: A Randomized Trial in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1546-1554.	2.3	1
2337	Impact of antiplatelet therapy on tissue prolapse at super acute phase after stenting: serial OCT study in acute coronary syndrome patients. <i>Heart and Vessels</i> , 2021, 36, 200-210.	0.5	1
2338	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2021, 42, 1289-1367.	1.0	3,048
2339	Efficacy and safety outcomes of short duration antiplatelet therapy with early cessation of aspirin post percutaneous coronary intervention: a systematic review and meta-analysis. <i>Current Cardiology Reviews</i> , 2021, 17, .	0.6	1
2340	Cardiovascular Medications. , 2021, , 597-642.		1
2341	Clinical risk scores: a tool to understand bleeding and thrombotic risk. , 2021, , 145-166.		0

#	ARTICLE	IF	CITATIONS
2342	Drugs in Myocardial Infarction. , 2021, , 115-124.		0
2343	Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI). <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00738.	1.1	6
2344	Antiplatelet and anticoagulation therapy after revascularization for lower extremity artery disease: a national survey and literature overview. <i>Journal of Cardiovascular Surgery</i> , 2021, 62, 59-70.	0.3	3
2345	Platelet-fibrin clot strength measured by thromboelastography could predict hypercoagulability and antiplatelet effects in patients after percutaneous coronary intervention. <i>Annals of Palliative Medicine</i> , 2021, 10, 2448-2457.	0.5	2
2346	Antithrombotic Therapy in Patients with Coronary Artery Disease and Prior Stroke. <i>Journal of Clinical Medicine</i> , 2021, 10, 1923.	1.0	3
2347	Oral Antiplatelet Therapy After Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1545.	3.8	62
2348	Serum Free Triiodothyronine and the Responsiveness to Clopidogrel in Patients Undergoing Elective Percutaneous Coronary Intervention. <i>Advances in Therapy</i> , 2021, 38, 3077-3088.	1.3	0
2350	Primary repair of femoral pseudoaneurysm secondary to interventional procedure. <i>Van SagittlÄ±k Bilimleri Dergisi</i> , 0, , 93-97.	0.6	0
2351	Antiplatelet Therapy And Percutaneous Coronary Interventions. <i>Current Cardiology Reviews</i> , 2021, 17, 232-243.	0.6	0
2352	Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 963-978.	1.3	27
2353	Dual antiplatelet therapy after percutaneous coronary intervention: Personalize the duration. <i>Cleveland Clinic Journal of Medicine</i> , 2021, 88, 325-332.	0.6	2
2355	Biomarkers for Antiplatelet Therapies in Acute Ischemic Stroke: A Clinical Review. <i>Frontiers in Neurology</i> , 2021, 12, 667234.	1.1	8
2356	Percutaneous Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 2021, 78, 384-407.	1.2	16
2357	Translational Pharmacogenomics: Discovery, Evidence Synthesis and Delivery of Raceâ€Conscious Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 909-925.	2.3	19
2358	Duration of dual antiplatelet therapy and stability of coronary heart disease: a 60 000-patient meta-analysis of randomised controlled trials. <i>Open Heart</i> , 2021, 8, e001707.	0.9	4
2359	Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina InstÃ¡vel e Infarto Agudo do MiocÃ¡rdio sem SupradesnÃ¡vel do Segmento ST â€“ 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 117, 181-264.	0.3	45
2360	Treatment Outcomes of Clopidogrel in Patients With ACS and Diabetes Undergoing PCI-Analysis of Beijing Municipal Medical Insurance Database. <i>Frontiers in Endocrinology</i> , 2021, 12, 713849.	1.5	2
2361	Platelet Function Testing and Genotyping for Tailoring Treatment in Complex PCI Patients. <i>US Cardiology Review</i> , 0, 15, .	0.5	1

#	ARTICLE	IF	CITATIONS
2362	Efficacy and Safety of Very Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation for Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 660360.	1.1	3
2363	Antiplatelet Therapy After Percutaneous Coronary Intervention—Past, Current and Future Perspectives. <i>Circulation Journal</i> , 2021, , .	0.7	1
2364	STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, 35, 2569-2591.	0.6	56
2365	STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management. <i>Annals of Thoracic Surgery</i> , 2021, 112, 981-1004.	0.7	88
2366	Role of diabetes in stroke: Recent advances in pathophysiology and clinical management. <i>Diabetes/Metabolism Research and Reviews</i> , 2022, 38, e3495.	1.7	10
2367	Pretreatment With P2Y12 Inhibitors in Patients With Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the Swedish Coronary Angiography and Angioplasty Registry. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010849.	1.4	5
2368	Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke. <i>Stroke</i> , 2021, 52, 3258-3265.	1.0	5
2369	Cardiovascular Drugs and Hemostasis. , 2022, , 701-729.		1
2370	Impact of acetylsalicylic acid in patients undergoing cerebral aneurysm surgery — should the neurosurgeon really worry about it?. <i>Neurosurgical Review</i> , 2021, 44, 2889-2898.	1.2	1
2371	Platelet physiology and pharmacology—relevant considerations for patient care. , 2021, , 15-45.		0
2372	Diabetes mellitus und das Gerinnungssystem. , 2005, , 40-55.		1
2374	Antiplatelet Agents. , 2005, , 335-367.		1
2375	Antithrombotic Treatment and Cardioversion of Patients with Atrial Fibrillation. , 2008, , 169-183.		1
2376	The Challenge for Stem Cell Therapy. , 2007, , 1-6.		1
2377	Resistance to Antiplatelet Drugs. , 2010, , 449-464.		1
2378	Antiplatelet Therapies: Drug Interactions in the Management of Vascular Disorders. <i>Methods in Molecular Biology</i> , 2010, 663, 203-219.	0.4	2
2379	Pharmacology of Platelet Adhesion and Aggregation. <i>Handbook of Experimental Pharmacology</i> , 2004, , 437-471.	0.9	5
2380	Gender Differences in Anticoagulation and Antithrombotic Therapy. <i>Handbook of Experimental Pharmacology</i> , 2013, , 523-542.	0.9	11

#	ARTICLE	IF	CITATIONS
2381	Stable Ischemic Heart Disease Stable Ischemic Heart Disease. , 2015, , 2109-2172.		1
2382	Stable Ischemic Heart Disease. , 2014, , 1-70.		1
2383	Experimental Antiplatelet Therapy. , 2007, , 1193-1208.		1
2384	Platelet Inhibitor Agents. , 2012, , 97-112.		2
2385	Meta-analysis Comparing Outcomes of Type 2 Myocardial Infarction and Type 1 Myocardial Infarction With a Focus on Dual Antiplatelet Therapy. CJC Open, 2020, 2, 118-128.	0.7	9
2386	Acute coronary syndromes: diagnosis and management, part I. Mayo Clinic Proceedings, 2009, 84, 917-38.	1.4	147
2387	Antithrombotic treatment in peripheral artery disease. Vasa - European Journal of Vascular Medicine, 2018, 47, 99-108.	0.6	25
2388	Oral antiplatelet agents in cardiovascular disease. Vasa - European Journal of Vascular Medicine, 2019, 48, 291-302.	0.6	14
2390	Safety and Efficacy of the Drug-Eluting Stent: A Double-Edged Sword?. Southern Medical Journal, 2008, 101, 174-178.	0.3	8
2391	Role of Antiplatelet Agents in the Primary and Secondary Prevention of Atherothrombotic Events in High Risk-Patients. Southern Medical Journal, 2008, 101, 273-283.	0.3	5
2392	Clopidogrel in acute coronary syndromes. BMJ: British Medical Journal, 2009, 338, b1180-b1180.	2.4	13
2394	Improving outcomes with antiplatelet therapies in percutaneous coronary intervention and stenting. Thrombosis and Haemostasis, 2009, 101, 23-30.	1.8	5
2395	P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. Journal of Clinical Investigation, 2003, 112, 398-406.	3.9	296
2396	Clopidogrel resistance response in patients with coronary artery disease and metabolic syndrome: the role of hyperglycemia and obesity. Journal of Geriatric Cardiology, 2015, 12, 378-82.	0.2	13
2397	Aspirin desensitisation for Chinese patients with coronary artery disease. Hong Kong Medical Journal, 2013, 19, 207-13.	0.1	12
2398	Anti-Platelet Therapy with Clopidogrel Prevents Endothelial Dysfunction and Vascular Remodeling in Aortas from Hypertensive Rats. PLoS ONE, 2014, 9, e91890.	1.1	17
2399	Antiplatelet Resistanceâ€”Fact or Myth?. The American Heart Hospital Journal, 2009, 7, 50.	0.2	1
2400	Antithrombotic Treatment After Coronary Intervention: Agreement and Controversy. European Cardiology Review, 2020, 15, 1-8.	0.7	9

#	ARTICLE	IF	CITATIONS
2401	Current Concepts in the Clinical Utility of Platelet Reactivity Testing. <i>Interventional Cardiology Review</i> , 2013, 8, 100.	0.7	4
2402	Platelet function monitoring in patients on clopidogrel. <i>Interventional Medicine & Applied Science</i> , 2011, 3, 32-38.	0.2	1
2403	Brain Injury Secondary to Carotid Intervention. <i>Journal of Endovascular Therapy</i> , 2007, 14, 219-231.	0.8	8
2404	Platelets and Arterial Thrombosis: Evolving Role of Platelet Gpvi as an Antithrombotic Drug Target. <i>Proceedings of the Indian National Science Academy</i> , 2014, 80, 289.	0.5	1
2406	Developments in Secondary Stroke Prevention. <i>European Neurological Review</i> , 2008, 3, 50.	0.5	1
2407	Antiplatelet therapy after coronary occlusion. <i>Australian Prescriber</i> , 2007, 30, 92-96.	0.5	6
2408	Genetic Polymorphisms of CYP2C19 and Resistance to Clopidogrel Therapy among Iranian Patients Suffering from Ischemic Heart Disease. <i>Research in Molecular Medicine</i> , 2016, 4, 41-46.	0.1	1
2409	Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI). <i>Vascular Health and Risk Management</i> , 2006, 2, 379-387.	1.0	3
2410	Clopidogrel. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 361-374.	1.0	7
2411	Clopidogrel Resistance in Lower Extremity Arterial Endovascular Interventions. <i>Current Pharmaceutical Design</i> , 2019, 24, 4554-4557.	0.9	3
2412	Antithrombotic Treatment in Diabetes Mellitus: A Review of the Literature about Antiplatelet and Anticoagulation Strategies Used for Diabetic Patients in Primary and Secondary Prevention. <i>Current Pharmaceutical Design</i> , 2020, 26, 2780-2788.	0.9	14
2413	Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting. <i>Current Clinical Pharmacology</i> , 2017, 12, 11-17.	0.2	16
2414	Antiplatelet Drug's Resistance. <i>The Open Atherosclerosis & Thrombosis Journal</i> , 2009, 2, 24-28.	0.4	4
2415	Everolimus-eluting bioresorbable vascular scaffolds: learning from the past to improve the future. <i>Minerva Cardioangiologica</i> , 2019, 67, 288-305.	1.2	1
2416	Ferulic Acid, A Potential Antithrombotic Drug. <i>Journal of Lung Health and Diseases</i> , 2018, 2, 25-28.	0.1	6
2417	Stent thrombosis after Cypher and Taxus stent implantation. , 2005, , 187-198.		1
2419	Pharmacology and Clot. , 2008, , 103-122.		1
2420	Diabetes Mellitus and Cardiovascular Disease in the Elderly. <i>Fundamental and Clinical Cardiology</i> , 2008, , 179-214.	0.0	4

#	ARTICLE	IF	CITATIONS
2421	The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis. Health Technology Assessment, 2009, 13, iii-iv, ix-xi, 1-77.	1.3	11
2422	Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT. Health Technology Assessment, 2018, 22, 1-76.	1.3	8
2423	Anti-Platelet Drug Resistance in the Prediction of Thromboembolic Complications after Neurointervention. Journal of Korean Neurosurgical Society, 2010, 48, 319.	0.5	30
2424	The Impact of Generic Clopidogrel Bisulfate on Platelet Inhibition in Patients with Coronary Artery Stents: Results of the ACCEL-GENERIC Study. Korean Journal of Internal Medicine, 2010, 25, 154.	0.7	22
2425	Prasugrel for acute coronary syndromes: Faster, more potent, but higher bleeding risk. Cleveland Clinic Journal of Medicine, 2009, 76, 707-714.	0.6	10
2426	Dual antiplatelet therapy for acute coronary syndromes: How long to continue?. Cleveland Clinic Journal of Medicine, 2016, 83, 675-688.	0.6	2
2427	Clopidogrel-induced hepatotoxicity. Journal of Postgraduate Medicine, 2008, 54, 152.	0.2	15
2428	Rationale and Role of High Loading Dose Clopidogrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Pharmacology & Pharmacy, 2012, 03, 481-484.	0.2	1
2429	Mean Platelet Volume and Prognosis of Unstable Angina. World Journal of Cardiovascular Diseases, 2015, 05, 32-41.	0.0	3
2430	State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation – past, present and future perspectives. EuroIntervention, 2017, 13, 717-733.	1.4	37
2431	Incidence of stent thrombosis in patients with drug eluting stents and short-term dual antiplatelet therapy. EuroIntervention, 2009, 4, 593-599.	1.4	3
2432	A novel strategy for managing clopidogrel-induced adverse skin reactions. EuroIntervention, 2009, 5, 470-474.	1.4	4
2433	Coronary angioscopic findings eight months after sirolimus-eluting stent implantation: a comparison between ST-elevation myocardial infarction and stable angina pectoris. EuroIntervention, 2010, 6, 251-256.	1.4	10
2434	Patent coronary artery and myocardial infarction in the era of primary angioplasty: assessment of an old problem in a new setting with data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). EuroIntervention, 2010, 6, 590-595.	1.4	3
2435	Cangrelor versus clopidogrel in percutaneous coronary intervention: a systematic review and meta-analysis. EuroIntervention, 2014, 9, 1350-1358.	1.4	10
2436	2014 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention, 2015, 10, 1024-1094.	1.4	251
2437	2018 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention, 2019, 14, 1435-1534.	1.4	367
2438	Endovascular treatment of extracranial vertebral artery stenosis. World Journal of Radiology, 2012, 4, 391.	0.5	31

#	ARTICLE	IF	CITATIONS
2440	Intracranial hemorrhage and platelet transfusion after administration of anti-platelets agents: Fukushima Prefecture. Fukushima Journal of Medical Sciences, 2016, 62, 51-56.	0.1	1
2441	Atopaxar. Hamostaseologie, 2012, 32, 228-233.	0.9	2
2442	Platelet Function Measured Using a Whole Blood Aggregometer Can Predict Bleeding Events. Journal of Atherosclerosis and Thrombosis, 2011, 18, 16-23.	0.9	3
2443	Aspirin desensitization in patients undergoing percutaneous coronary intervention: A survey of current practice. Cardiology Journal, 2013, 20, 134-8.	0.5	8
2445	Economic Impact Associated with Pharmaceutical Interventions in Cardiovascular Disease. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2017, 43, 680-690.	0.0	2
2446	A Meta-Analysis of Randomized Clinical Trials Comparing Shorter (Less or Equal Than 6 Months) and Longer (More or Equal Than 12 Months) Dual Anti-Platelet Therapy Following Drug-Eluting Coronary Stents. Iranian Red Crescent Medical Journal, 2015, 17, e26904.	0.5	4
2447	Diagnostic and Therapeutic Strategies for Acute Intracranial Atherosclerosis-related Occlusions. Journal of Stroke, 2017, 19, 143-151.	1.4	84
2448	Statement on Antiplatelet Agents and Anticoagulants in Cardiology - 2019. Arquivos Brasileiros De Cardiologia, 2019, 113, 111-134.	0.3	4
2449	MEDICATION BELIEFS IN PATIENTS FOLLOWING PERCUTANEOUS CORONARY INTERVENTION: A CROSS-SECTIONAL STUDY. Jurnal Keperawatan Indonesia, 2019, 22, 161-168.	0.2	1
2450	Clopidogrel improves aspirin response after off-pump coronary artery bypass surgery. Journal of Biomedical Research, 2014, 28, 108-13.	0.7	13
2451	An Idiosyncratic Reaction to Clopidogrel. , 2015, 19, 74-76.		5
2452	Physician-pharmacist collaborative management in patients after percutaneous coronary intervention: a retrospective propensity score matching cohort study. International Journal of Clinical Pharmacy, 2022, 44, 90-99.	1.0	3
2453	Comparative Safety and Effectiveness of Loading Doses of P2Y12 Inhibitors in Patients Undergoing Elective PCI: a Network Meta-analysis. Cardiovascular Drugs and Therapy, 2023, 37, 291-298.	1.3	3
2454	Formation of a Rectus Sheath Hematoma Secondary to COPD Exacerbation While Taking Dual Antiplatelet Therapy. Cureus, 2021, 13, e18821.	0.2	0
2455	Management of Unstable Angina and Non-ST Elevation Myocardial Infarction. , 2003, , 109-125.		0
2456	Long-Term Medical Management of Ischemic Stroke and Transient Ischemic Attack Due to Arterial Disease. , 2004, , 1129-1150.		0
2457	Aggregationshemmertherapie bei Koronarerkrankungen. , 2004, , 897-910.		1
2458	Perkutane koronare Intervention. , 2004, , 971-995.		0

#	ARTICLE	IF	CITATIONS
2459	Klinik der koronaren Herzerkrankung II: Akute Koronarsyndrome. , 2004, , 497-529.		0
2460	Carotid Stenting. , 2004, , 1151-1169.		0
2462	Inflammatory Markers in Acute Coronary Syndromes. , 2004, , 339-364.		0
2464	Treatment of Vulnerable Plaques. , 2004, , 164-202.		0
2465	Complications of the Medications. , 2005, , 6-16.		0
2466	Early versus Late Complications. , 2005, , 92-112.		0
2468	Traitement Antithrombotique des Syndromes Coronariens aigus sans Sus-d'Alcalage de ST. Bulletin De L'Academie Nationale De Medecine, 2005, 189, 217-226.	0.0	0
2469	Optimal antiplatelet and anticoagulation therapy for drug-eluting stents. , 2005, , 126-135.		0
2470	Anti-platelet treatment in reperfusion therapy for acute myocardial infarction. , 2006, , 77-96.		0
2471	Antiplatelet Agents. , 2006, , 79-83.		0
2472	Heart Attacks. , 2006, , 397-431.		0
2473	Antiplatelet therapy. Japanese Journal of Thrombosis and Hemostasis, 2006, 17, 649-663.	0.1	0
2474	In welke gevallen is de combinatie van clopidogrel en acetylsalicylzuur geïndiceerd?. , 2006, , 33-34.		0
2475	TRANSMUTATION OF METAL AT LOW ENERGY IN A CONFINED PLASMA IN WATER. , 2006, , .		1
2476	Anticoagulation and Antiplatelet Agents. Fundamental and Clinical Cardiology, 2006, , 501-524.	0.0	0
2477	Optimal antiplatelet and anticoagulation therapy, prevention and management of thrombotic complications. , 2006, , 39-52.		0
2478	Specific concerns to improve the safety of drug-eluting stents. , 2006, , 219-228.		0
2479	Optimal patient preparation and selection to avoid complications. , 2006, , 17-37.		0

#	ARTICLE	IF	CITATIONS
2480	Mechanical Approaches to Percutaneous Coronary Intervention. , 2007, , 121-134.		0
2483	Part II. Specific Complications by Vessel Area or Specific Scenarios. , 2007, , 61-62.		0
2484	Cardiovascular interventional pharmacology in the diabetic patient. , 2007, , 473-482.		0
2485	Pharmacotherapy peri-percutaneous coronary intervention. , 2007, , 525-536.		0
2486	Anti-platelet therapies. , 2008, , 35-44.		0
2487	Hemostasis and Coagulation. , 2008, , 149-165.		2
2488	Current major trials in interventional cardiology. , 2008, , 527-552.		0
2489	Infarktbedingter kardiogener Schock " Diagnose, Monitoring und Therapie. , 2008, , 93-106.		0
2490	Traitement de l'angor stable et des syndromes coronariens aigus sans sus-d'calage du segment ST. , 2008, , 73-100.		0
2491	Cardiovascular and Other Noninfectious Complications after Renal Transplantation in Adults. , 2008, , 1009-1033.		1
2492	Anti-platelet treatment for acute coronary syndrome in Japan. Japanese Journal of Thrombosis and Hemostasis, 2008, 19, 504-509.	0.1	0
2494	Antiplatelet Agents. Fundamental and Clinical Cardiology, 2008, , 176-194.	0.0	0
2495	Anti-platelet therapies. , 2009, , 37-48.		0
2496	ACC/AHA Non-ST Elevation Myocardial Infarction Guidelines' Revision 2007:Implications for Nursing Practice. Progress in Cardiovascular Nursing, 2008, 23, 53-56.	0.5	0
2498	Intensity of antiplatelet therapy and percutaneous coronary intervention. F1000 Medicine Reports, 2009, 1, .	2.9	0
2499	Case 24. Coronary Artery Disease. , 2009, , .		0
2500	Very late stent thrombosis of DES implanted patient during noncardiac surgery - A case report -. Korean Journal of Anesthesiology, 2009, 57, 800.	0.9	0
2503	Antithrombotic Agents: Platelet Inhibitors, Anticoagulants, and Fibrinolytics. , 2009, , 293-340.		2

#	ARTICLE	IF	CITATIONS
2504	Variability of the antiplatelet effect of clopidogrel in Japanese. Japanese Journal of Thrombosis and Hemostasis, 2009, 20, 589-593.	0.1	0
2505	Determinants of thrombin generation, fibrinolytic activity and endothelial dysfunction in dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad. Japanese Journal of Thrombosis and Hemostasis, 2009, 20, 48-55.	0.1	0
2506	Antithrombotic therapy after acute myocardial infarction. Cor Et Vasa, 2009, 51, 112-117.	0.1	0
2507	Three Generations of Thienopyridines: Ticlopidine, Clopidogrel, and Prasugrel. Fundamental and Clinical Cardiology, 2009, , 471-484.	0.0	0
2508	Overview of Antiplatelet Therapy. Fundamental and Clinical Cardiology, 2009, , 399-408.	0.0	0
2509	Antiplatelet therapy in coronary artery disease after surgical revascularization. Arterial Hypertension (Russian Federation), 2009, 15, 256-261.	0.1	0
2510	Platelet Glycoprotein IIb/IIIa Inhibitors. , 2009, , 67-76.		0
2511	Thienopyridines in Stable Coronary Disease. , 2010, , 131-141.		0
2512	Antiplatelet Therapies: Aspirin, Clopidogrel and Thienopyridines, and Glycoprotein IIb/IIIa Inhibitors for the Management of ST-Segment Elevation Myocardial Infarction. , 2010, , 219-233.		0
2513	Antiplatelet Therapies in Unstable Angina and Non-ST Segment Elevation Myocardial Infarction. , 2010, , 145-163.		0
2514	Antithrombotic Therapy in Percutaneous Coronary Intervention. , 2010, , 261-282.		0
2516	Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes. Yearbook of Critical Care Medicine, 2010, 2010, 82-84.	0.2	0
2517	[Treatment] Platelet inhibitors of the P2Y12 receptor. Japanese Journal of Thrombosis and Hemostasis, 2010, 21, 457-461.	0.1	0
2518	Thrombosen und GefÄÄverschlÄÄsse trotz antithrombotischer Therapie. , 2010, , 681-688.		0
2519	Special Management of Diabetic Patients with STEMI. , 2010, , 183-196.		0
2520	Adjunctive Pharmacologic Therapies. , 2010, , 54-64.		0
2522	Clopidogrel and Salicylates. , 2011, , 139-153.		0
2523	Oral antiplatelet therapy. , 2011, , 311-319.		0

#	ARTICLE	IF	CITATIONS
2525	Management of the postcoronary patient. , 2011, , 650-659.		0
2526	Diabetes in the coronary care unit. , 2011, , 606-610.		0
2528	Antiplatelet Therapy. , 2011, , 201-221.		0
2529	Percutaneous Coronary Intervention and Concomitant Antithrombotic Therapy. , 2011, , 313-321.		0
2531	3. Risk of Upper Gastrointestinal Bleeding during Clopidogrel Therapy with or without a PPI. Japanese Journal of Clinical Pharmacology and Therapeutics, 2011, 42, 369-373.	0.1	0
2532	The effect of the duration of clopidogrel use on hsCRP levels after stenting the target vessel in patients with acute coronary syndrome. Clinical and Investigative Medicine, 2011, 34, 211.	0.3	1
2533	Can a rash cause stent thrombosis?. , 2011, , 15-32.		0
2534	Secondary Prevention Strategies. , 2012, , 169-182.		0
2536	Coronary Plaque Rupture in Patients with Acute. , 2011, , 49-67.		0
2542	Clopidogrel Within Few Hours of Coronary Artery Bypass Grafting Does Significantly Increase the Risk of Bleeding. Cardiology Research, 2012, 3, 209-213.	0.5	2
2546	Antiplatelet Drugs in Coronary Artery Disease. , 0, , .		0
2547	Current Status of Pharmacogenetics in Antithrombotic Drug Therapy. , 0, , .		0
2549	Pharmacotherapy During Percutaneous Coronary Interventions. , 0, , .		0
2550	Dramatic effect of early clopidogrel administration in reducing mortality and MACE rates in ACS patients. Swiss Medical Weekly, 2012, 142, w13573.	0.8	7
2555	Antiplatelet drug resistance in patients with coronary heart disease. Cardiovascular Therapy and Prevention (Russian Federation), 2012, 11, 71-77.	0.4	2
2556	Management of thrombotic risk in old patients. Japanese Journal of Thrombosis and Hemostasis, 2013, 24, 45-52.	0.1	0
2557	Left main pci, still a main issue. Research in Cardiovascular Medicine, 2013, 2, 185.	0.2	0
2558	Insufficient Efficiency of Prasugrel in Diabetic Patients with Acute STEMI Undergoing Ppci of Culprit Coronary Lesion – Review of Current Knowledge. Journal of Hematology & Thromboembolic Diseases, 2013, 01, .	0.1	0

#	ARTICLE	IF	CITATIONS
2559	Outcomes in Traumatic Brain Injury Patients on Preinjury Anticoagulation and Antiplatelet Agents. JHN Journal, 2013, 8, .	0.0	0
2560	Evaluation of percutaneous coronary intervention and stenting of left main coronary artery stenosis in tehran's rajaie and lavasani hospitals from 2010 to 2011. Research in Cardiovascular Medicine, 2013, 2, 181.	0.2	3
2561	Clopidogrel in ischemic heart disease: A critical appraisal. Health, 2013, 05, 465-468.	0.1	0
2562	Effects of Antiplatelet Drugs in Cardiovascular Prevention. Korean Journal of Medicine, 2013, 85, 15.	0.1	1
2563	Pharmacogenomics and Personalized Medicine of the Antiplatelet Drugs. , 2013, , 469-506.		0
2564	Management of the Urological Patient Taking Anticoagulant or Antiplatelet Medication. , 2014, , 271-289.		0
2565	American Versus European Guidelines: Critical Appraisal. , 2014, , 139-184.		0
2567	PCI Considerations in Women: Gender-Specific Outcomes and Challenges. , 2014, , 227-241.		0
2568	Antithrombotic Issues in Women. , 2014, , 321-357.		0
2569	Antiplatelet Agent-Related Peptic Ulcer Disease. Korean Journal of Medicine, 2014, 86, 673.	0.1	0
2570	Optimizing Intensity and Duration of Oral Antithrombotic Therapy after Primary Percutaneous Coronary Intervention. , 2014, , 569-581.		0
2571	Antiplatelet Drugs in the Management of Cardiovascular Indications. , 2014, , 1-24.		0
2573	Comparison of the efficiency of antiaggregative therapy in patients with first arisen and progressive angina pectoris to influence the fatty acid spectrum of platelet membrane phospholipids. Reports National Academy of Science of Ukraine, 2014, , 138-143.	0.0	0
2575	DAPT After Stenting in Stable and Acute Coronary Syndromes- Does the Drug Combination Really Matter?. , 2015, , 255-269.		0
2576	Antithrombotic therapy in the anticoagulated patient undergoing percutaneous coronary intervention with coronary stenting. Current Opinion in Cardiology, 2015, 30, 319-324.	0.8	0
2577	Evaluation of the Relative Efficacy and Safety of Prasugrel and Clopidogrel in Medically Managed High Risk UA/NSTEMI ACS Population. International Journal of Medical and Dental Sciences, 2015, 4, 809.	0.1	0
2578	Stable Ischemic Heart Disease. , 2016, , 1-70.		5
2579	Overview of Antiplatelet Therapy. , 2016, , 421-430.		0

#	ARTICLE	IF	CITATIONS
2580	Peri- and Post-procedural Antithrombotic Therapy in Women. , 2017, , 73-100.		1
2581	Optimal medical therapy to improve saphenous vein graft patency. Journal of the Japanese Coronary Association, 2017, 23, 196-203.	0.0	0
2583	Revascularization Strategies in CKD: Antiplatelet Therapy, Stent Type, Timing, and Complications of PCI. , 2017, , 329-335.		0
2584	Possibility of active management of the target P2Y12 reaction unit range in patients undergoing aneurysmal neurointerventional procedures. No Junkan Taisha = Cerebral Blood Flow and Metabolism, 2017, 28, 241-247.	0.1	1
2585	Stratifying Thromboembolic Risk: Why Is Your Patient on Antithrombotic Medications?. , 2018, , 73-89.		0
2587	Antiplatelet Therapy in Cardiovascular Disease. , 2019, , 195-207.		0
2588	EARLY PRESCRIPTION OF PLATELET P2Y12 RECEPTOR INHIBITORS TO PATIENTS WITH ACUTE CORONARY SYNDROME: A BENEFIT OR A HARM?. Atherothrombosis, 2018, , 76-86.	0.1	0
2589	Intervenci3n coronaria en pacientes con fibrilaci3n auricular. Revista Espanola De Cardiologia Suplementos, 2019, 18, 15-20.	0.2	0
2590	Benefits of a combination of clopidogrel and aspirin in patients with high cardiovascular risk. Kardiologiya I Serdechno-Sosudistaya Khirurgiya, 2019, 12, 504.	0.1	0
2591	Patient with diabetes after acute coronary event. How to improve forecast?. Medical Alphabet, 2019, 1, 6-11.	0.0	0
2592	Clinical Markers of Clopidogrel Resistance in Percutaneous Coronary-Treated Patients. Konuralp Tip Dergisi, 0, , 55-61.	0.1	0
2593	Clopidogrel as a part of double disaggregant therapy in ACS: a reasonable choice in complex clinical situations. Meditsinskiy Sovet, 2019, , 20-29.	0.1	0
2594	Infarto del miocardio: diagnosi, gestione e complicate. EMC - AKOS - Trattato Di Medicina, 2019, 21, 1-14.	0.0	0
2595	Infarto de miocardio: diagn3stico, tratamiento y complicaciones. EMC - Tratado De Medicina, 2019, 23, 1-14.	0.0	0
2596	Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study. Marshall Journal of Medicine, 2019, 5, 30.	0.1	0
2597	Patient-Clinician Decision Making for Stable Angina: The4Role of Health Literacy. EGEMS (Washington,) Tj ETQq1 1,0,784314,rgBT /Ove 2,0		0
2599	TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary Intervention. US Cardiology Review, 0, 14, .	0.5	0
2600	Retrospective Analysis of 120 Cases of Iatrogenic and Traumatic Peripheral Arterial Pseudoaneurysms. Eurasian Journal of Medicine, 2020, 52, 180-184.	0.2	9

#	ARTICLE	IF	CITATIONS
2601	Secondary prevention after acute coronary syndrome. <i>Vnitřni Lekarství</i> , 2020, 66, 236-241.	0.1	1
2602	Antiplatelet Therapy. <i>Contemporary Cardiology</i> , 2021, , 249-288.	0.0	0
2603	Antiplatelet therapy in secondary prevention of non-embolic ischaemic stroke. <i>Vnitřni Lekarství</i> , 2020, 66, 501-506.	0.1	0
2604	Benefits of clopidogrel in clinical practice: current data. <i>Kardiologiya I Serdechno-Sosudistaya Khirurgiya</i> , 2020, 13, 322.	0.1	0
2605	ASSOCIATION BETWEEN SMOKING AND THE ANTIPLATELET EFFECT OF CLOPIDOGREL. <i>Juvenis Scientia</i> , 2020, 6, 14-24.	0.1	0
2606	Drug-coated Balloons or Drug-eluting Stents – Determining an Optimum Strategy for Patients with High Bleeding Risk. <i>Heart International</i> , 2020, 14, 100.	0.4	0
2607	Does Extended Use of Clopidogrel-Based Dual Anti-Platelet Therapy Increase the Risk of Gastrointestinal Bleeding?. <i>Gastroenterology Research</i> , 2020, 13, 146-149.	0.4	1
2608	Allele and Genotype Frequencies of CYP2C19 in Patients with Drug-Eluting Stents Following Percutaneous Coronary Intervention in Southwest of Iran. <i>Jundishapur Journal of Chronic Disease Care</i> , 2020, 9, .	0.1	0
2609	Long-term effect of clopidogrel in patients with and without diabetes: A systematic review and meta-analysis of randomized controlled trials. <i>World Journal of Diabetes</i> , 2020, 11, 137-149.	1.3	3
2610	Aspirin and nonsteroidal anti-inflammatory drug hypersensitivity. <i>Clinical Reviews in Allergy and Immunology</i> , 2007, 32, 97-109.	2.9	3
2611	Koronarinsuffizienz und Herzinfarkt. , 2005, , 3-33.		0
2612	Interventionelle Kardiologie. , 2005, , 272-295.		0
2613	Koronare Herzkrankheit – akute Verlaufsformen. , 2006, , 169-201.		0
2614	Stable Angina. , 2005, , 451-470.		0
2615	Unstable Angina and Non-ST Segment Elevation Myocardial Infarction (Acute Coronary Syndromes). , 2005, , 471-487.		0
2616	Complications of Carotid Artery Stenting. , 2007, , 175-188.		0
2617	The Approach to Intracranial and Extracranial Vertebral Artery Stenting. , 2007, , 211-228.		1
2618	Aspirin and Antiplatelet Agents in the Prevention of Complications of Coronary Artery Disease. , 2006, , 285-307.		0

#	ARTICLE	IF	CITATIONS
2619	Antiplatelet Agents, Anticoagulants, and Specific Thrombin Inhibitors. , 2007, , 331-348.		0
2620	Pharmacotherapy in Prevention and Rehabilitation. , 2007, , 439-453.		1
2621	Clopidogrel: an updated and comprehensive review. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 621-631.	1.5	7
2622	Platelets and new antiplatelet drugs. Therapy: Open Access in Clinical Medicine, 2005, 2, 465-502.	0.2	0
2624	Dual antiplatelet therapy duration after percutaneous coronary intervention with drug-eluting stents: how short can we go?. Minerva Cardioangiologica, 2020, 68, 436-450.	1.2	3
2626	Cardiology. British Journal of General Practice, 2004, 54, 695-702.	0.7	2
2627	Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction. Heart, 2004, 90, e37.	1.2	4
2628	Antiplatelet therapy in patients undergoing coronary stenting: The risk of late stent thrombosis. Netherlands Heart Journal, 2006, 14, 297-300.	0.3	1
2629	Antiplatelet therapy in populations at high risk of atherothrombosis. Journal of the National Medical Association, 2006, 98, 711-21.	0.6	10
2630	Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care. Mayo Clinic Proceedings, 2009, 84, 149-60.	1.4	5
2631	Late stent thrombosis associated with heavy exercise. Texas Heart Institute Journal, 2009, 36, 154-7.	0.1	0
2632	Stroke Best Practices: a team approach to evidence-based care. Journal of the National Medical Association, 2004, 96, 5S-20S.	0.6	2
2633	Balancing potency of platelet inhibition with bleeding risk in the early treatment of acute coronary syndrome. Western Journal of Emergency Medicine, 2009, 10, 163-75.	0.6	3
2635	Patient with recent coronary artery stent requiring major non cardiac surgery. Indian Journal of Anaesthesia, 2009, 53, 582-91.	0.3	4
2636	The impact of generic form of Clopidogrel on cardiovascular events in patients with coronary artery stent: results of the OPCES study. Journal of Research in Medical Sciences, 2011, 16, 640-50.	0.4	15
2637	Secondary prevention of ischaemic cardiac events. Clinical Evidence, 2011, 2011, .	0.2	2
2638	Can doubling the maintenance dose of clopidogrel prevent from early stent thrombosis after the primary percutaneous coronary intervention?. ARYA Atherosclerosis, 2011, 7, 18-23.	0.4	3
2639	Clopidogrel compared with other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention: clinical and cost-effectiveness analyses. CADTH Technology Overviews, 2012, 2, e2103.	0.5	0

#	ARTICLE	IF	CITATIONS
2640	Prophylactic Add-on Antiplatelet Therapy in Chronic Kidney Disease With Type 2 Diabetes Mellitus: Comparison Between Clopidogrel and Low-dose Aspirin. <i>International Journal of Preventive Medicine</i> , 2013, 4, 902-10.	0.2	4
2641	Is the Combination of Aspirin and Clopidogrel always Better than Aspirin Alone? Or will it be too much of a good thing?. <i>Malaysian Family Physician</i> , 2008, 3, 94-5.	0.2	0
2642	Efficacy and safety of individually tailored antiplatelet therapy in patients with acute coronary syndrome after coronary stenting: a single center, randomized, feasibility study. <i>Journal of Geriatric Cardiology</i> , 2015, 12, 23-9.	0.2	5
2643	Antithrombotic Utilization Trends after Noncardioembolic Ischemic Stroke or TIA in the Setting of Large Antithrombotic Trials (2002-2009). <i>Journal of Vascular and Interventional Neurology</i> , 2015, 8, 20-6.	1.1	3
2644	Mean Platelet Volume as a Predictor of One-Year Major Adverse Cardiac Events following Elective Percutaneous Coronary Interventions. <i>The Journal of Tehran Heart Center</i> , 2014, 9, 64-9.	0.3	1
2645	How long should dual antiplatelet therapy be continued following implantation of drug eluting stents?. <i>Annals of Translational Medicine</i> , 2015, 3, S10.	0.7	0
2646	Contemporary use of dual antiplatelet therapy for preventing cardiovascular events. <i>American Journal of Managed Care</i> , 2014, 20, 659-65.	0.8	1
2647	Use of a thrombelastograph platelet mapping assay for diagnosis of clopidogrel resistance: a case report. <i>Journal of Extra-Corporeal Technology</i> , 2009, 41, 32-6.	0.2	3
2648	Comparison of Clinical Outcomes in Patients Undergoing Coronary Intervention with Drug-Eluting Stents or Bare-Metal Stents: A Nationwide Population Study. <i>Acta Cardiologica Sinica</i> , 2017, 33, 10-19.	0.1	30
2649	Comparison of ticagrelor and high-dose clopidogrel on the platelet functions in patients with inadequate response to clopidogrel. <i>American Journal of Cardiovascular Disease</i> , 2017, 7, 1-8.	0.5	5
2650	ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathy. <i>European Heart Journal Supplements</i> , 2017, 19, D163-D189.	0.0	0
2651	A comparative study of different methods for automatic identification of clopidogrel-induced bleedings in electronic health records. <i>AMIA Summits on Translational Science Proceedings</i> , 2017, 2017, 185-192.	0.4	2
2652	Contemporary Trends and Outcomes Associated With the Preprocedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). <i>Journal of Invasive Cardiology</i> , 2017, 29, 340-351.	0.4	2
2653	The Role of Proton Pump Inhibitors in the Management of Upper Gastrointestinal Disorders. <i>Gastroenterology and Hepatology</i> , 2018, 14, 169-175.	0.2	4
2654	P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: Is It Safe to Abandon Aspirin?. <i>Acta Cardiologica Sinica</i> , 2021, 37, 1-8.	0.1	9
2655	STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management. <i>Journal of Extra-Corporeal Technology</i> , 2021, 53, 97-124.	0.2	3
2656	Efficacy and safety of short-term dual antiplatelet therapy in East Asians. <i>Journal of Cardiovascular Pharmacology</i> , 2021, Publish Ahead of Print, .	0.8	0
2657	Assessment of Pretreatment With Oral P2Y12 Inhibitors and Cardiovascular and Bleeding Outcomes in Patients With Non-ST Elevation Acute Coronary Syndromes. <i>JAMA Network Open</i> , 2021, 4, e2134322.	2.8	12

#	ARTICLE	IF	CITATIONS
2658	Stroke of antiplatelet and anticoagulant therapy in patients with coronary artery disease: a meta-analysis of randomized controlled trials. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 574.	0.7	0
2659	Periprocedural Myocardial Injury in High-Risk Patients With NSTEMI Pretreated With Ticagrelor for Less or More Than 6 Hours Before PCI. <i>Journal of Clinical Pharmacology</i> , 2021, , .	1.0	1
2660	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. <i>Journal of the American College of Cardiology</i> , 2022, 79, e21-e129.	1.2	561
2661	Antithrombotic therapy in acute coronary syndromes setting: new clinical guidelines, controversial issues and the role of prehospital stage. <i>Emergency Medical Care</i> , 2022, 22, 4-11.	0.1	0
2662	JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease. <i>Circulation Journal</i> , 2022, 86, 477-588.	0.7	38
2663	Commentary: Prevention of saphenous vein graft disease remains elusive. <i>Journal of Cardiac Surgery</i> , 2022, 37, 571-573.	0.3	0
2664	Quality care in ST-segment elevation myocardial infarction. <i>Journal of the Chinese Medical Association</i> , 2022, Publish Ahead of Print, .	0.6	1
2666	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2022, 145, CIR0000000000001038.	1.6	177
2667	Triple Antithrombotic Therapy (Triple Therapy) After Percutaneous Coronary Intervention in Chronic Anticoagulation: A Literature Review. <i>Cureus</i> , 2022, 14, e21810.	0.2	5
2668	Duration and clinical outcome of dual antiplatelet therapy after percutaneous coronary intervention: a retrospective cohort study using a medical information database from Japanese hospitals. <i>Cardiovascular Intervention and Therapeutics</i> , 2022, 37, 465-474.	1.2	6
2670	Prevalence of High Bleeding Risk among Hospitalized Suspected NSTEMI Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 1324.	1.0	3
2671	Antiplatelet agents for chronic kidney disease. <i>The Cochrane Library</i> , 2022, 2022, CD008834.	1.5	6
2672	The Evolution of Antiplatelet Therapy After Percutaneous Coronary Interventions: A 40-Year Journey. <i>Canadian Journal of Cardiology</i> , 2022, 38, S79-S88.	0.8	6
2673	Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention. <i>Current Cardiology Reports</i> , 2022, 24, 277-293.	1.3	3
2674	Clopidogrel Bolus is Inferior to Sustained Clopidogrel Pretreatment in Patients Undergoing Carotid Artery Stent Placement. <i>Neurosurgery</i> , 2022, Publish Ahead of Print, .	0.6	0
2675	Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation. <i>Pharmacogenetics and Genomics</i> , 2022, 32, 183-191.	0.7	5
2676	Antiplatelet therapy after percutaneous coronary intervention. <i>EuroIntervention</i> , 2022, 17, e1371-e1396.	1.4	94
2677	Periprocedural Antithrombotic Treatment in Complex Percutaneous Coronary Intervention. <i>Journal of Cardiovascular Pharmacology</i> , 2022, 79, 407-419.	0.8	3

#	ARTICLE	IF	CITATIONS
2678	Clopidogrel versus ticagrelor in the treatment of Chinese patients undergoing percutaneous coronary intervention: effects on platelet function assessed by platelet function tests and mean platelet volume. <i>Thrombosis Journal</i> , 2021, 19, 97.	0.9	0
2681	Effect of anti-platelet therapy on peri-operative blood loss in patients undergoing off-pump coronary artery bypass grafting. <i>Annals of Cardiac Anaesthesia</i> , 2022, 25, 182.	0.3	0
2683	Use of Antiplatelet Drugs in Secondary Prevention in Patients With Atherothrombotic Disease. <i>Comprehensive Therapy</i> , 2006, 32, 182-188.	0.2	0
2686	Optimal Antithrombotic Therapy. , 0, , 1-9.		0
2692	Synopsis of Adult Cardiac Surgical Disease. , 0, , 1-58.		1
2695	Does dual antiplatelet therapy affect blood loss and transfusion requirements in robotic-assisted coronary artery surgery?. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2012, 7, 399-402.	0.4	2
2699	Long-term outcomes following drug-eluting balloon or thin-strut drug-eluting stents for treatment of in-stent restenosis stratified by duration of dual antiplatelet therapy (DEB-Dragon Registry). <i>Postepy W Kardiologii Interwencyjnej</i> , 0, , .	0.1	1
2700	Mono or Dual Antiplatelet Therapy for Treating Patients with Peripheral Artery Disease after Lower Extremity Revascularization: A Systematic Review and Meta-Analysis. <i>Pharmaceuticals</i> , 2022, 15, 596.	1.7	2
2703	Part 5: Acute Coronary Syndromes. <i>Circulation</i> , 2005, 112, .	1.6	4
2704	Antithrombotic agents: Platelet inhibitors, acute anticoagulants, fibrinolytics, and chronic anticoagulants. , 2013, , 332-397.		1
2705	Pharmacogenetics in clinical practice: Challenges and opportunities. , 2015, 49, 26-32.		0
2708	Antacid Therapy in Coronary Artery Disease and Heart Failure: Proton Pump Inhibitors vs. H2 Receptor Blockers. <i>Cardiovascular Drugs and Therapy</i> , 2024, 38, 181-189.	1.3	5
2709	Optimal cardiovascular medical therapy: current guidelines and new developments. <i>Baylor University Medical Center Proceedings</i> , 0, , 1-7.	0.2	3
2710	Comparison of hybrid coronary revascularization versus coronary artery bypass grafting in patients with multivessel coronary artery disease: a meta-analysis. <i>Journal of Cardiothoracic Surgery</i> , 2022, 17, .	0.4	6
2711	Panax Notoginseng Saponins Combined with Dual Antiplatelet Drugs Potentiates Anti-Thrombotic Effect with Alleviated Gastric Injury in A Carotid Artery Thrombosis Rat Model. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2022, 31, 106597.	0.7	2
2712	P2Y12 inhibitor pretreatment in patients with nonST-segment elevation acute coronary syndrome: A meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e29824.	0.4	0
2713	Ideal P2Y12 Inhibitor in Acute Coronary Syndrome: A Review and Current Status. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8977.	1.2	7
2714	Safety of Transcarotid Revascularization in Patients with a Contraindication to Dual Antiplatelets. <i>Vascular and Endovascular Surgery</i> , 2022, 56, 746-753.	0.3	3

#	ARTICLE	IF	CITATIONS
2715	A comparison of the effects of ticagrelor and clopidogrel on development of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. Mersin Üniversitesi Saġlık Bilimleri Dergisi, 0, , 178-187.	0.2	0
2716	Impact of ticagrelor versus clopidogrel on bleeding outcomes of isolated coronary artery bypass grafting. Cardiovascular Revascularization Medicine, 2022, , .	0.3	0
2717	Things We Do for No Reasonâ„¢: Routine pretreatment with a P2Y12 receptor inhibitor before invasive coronary angiography for patients with a nonâ€”ST elevation acute coronary syndrome. Journal of Hospital Medicine, 2023, 18, 177-180.	0.7	0
2718	CYP2C19 loss-of-function alleles predicts clinical outcomes in East Asian patients with acute myocardial infarction undergoing percutaneous coronary intervention and stenting receiving clopidogrel. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
2719	Comparison of Prognosis between Patients with Acute Myocardial Infarction Treated with Ticagrelor and Clopidogrel in the Emergency Department: A Propensity Score Matched Retrospective Cohort Study. SSRN Electronic Journal, 0, , .	0.4	0
2720	The Updated ACC/AHA Coronary Revascularization Guidelines with Implications for Cardiovascular Anesthesiologists and Intensivists. Journal of Cardiothoracic and Vascular Anesthesia, 2022, , .	0.6	0
2721	Current and Future Insights for Optimizing Antithrombotic Therapy to Reduce the Burden of Cardiovascular Ischemic Events in Patients with Acute Coronary Syndrome. Journal of Clinical Medicine, 2022, 11, 5605.	1.0	1
2722	The factors influencing the efficiency of drug-coated balloons. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	10
2723	Gender-differences in antithrombotic therapy across the spectrum of ischemic heart disease: Time to tackle the Yentl syndrome?. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	7
2724	EFFECTIVENESS AND SAFETY COMPARISON OF P2Y12 RECEPTOR INHIBITORS IN PATIENTS WITH INVASIVE STRATEGY FOR ACUTE CORONARY SYNDROME. Tavriġskij Mediko-biologiġskij Vestnik, 2022, 23, 108-116.	0.1	0
2725	Dual Antiplatelet Alternatives are Associated With Increased Stroke and Death After Transcarotid Revascularization. Annals of Surgery, 2023, 278, e620-e625.	2.1	1
2726	Pharmacogenomics in Stroke and Cardiovascular Disease: State of the Art. Stroke, 2023, 54, 270-278.	1.0	7
2727	Stroke, coronary and peripheral artery disease survey on antithrombotic treatment (START IT). Swiss Medical Weekly, 0, , .	0.8	0
2730	Antiplatelet Therapy in Coronary Artery Disease: Now and Then. Seminars in Thrombosis and Hemostasis, 0, , .	1.5	2
2731	Management of Antiplatelet Therapy During Acute Percutaneous Coronary Intervention: New Strategies and Therapeutics. Annals of the Academy of Medicine, Singapore, 2010, 39, 221-229.	0.2	2
2732	Percutaneous Coronary Intervention and Bleeding Complications. European Medical Journal Interventional Cardiology, 0, , 100-109.	0.0	0
2733	Antithrombotic therapy in patients with diabetes mellitus. Vestnik of Russian Military Medical Academy, 2023, 24, 737-750.	0.1	1
2734	Perspective: Collagen induced platelet activation via the GPVI receptor as a primary target of colchicine in cardiovascular disease. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1

#	ARTICLE	IF	CITATIONS
2735	Shortening and De-Escalation of Dual Antiplatelet Therapy After PCI. Current Treatment Options in Cardiovascular Medicine, 0, , .	0.4	0
2736	Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Expert Opinion on Pharmacotherapy, 2023, 24, 453-471.	0.9	5
2738	Differential prognosis of patients that are candidates for standard, short or prolonged dual antiplatelet treatment discharged after an acute coronary syndrome. Thrombosis Research, 2023, 224, 46-51.	0.8	0
2739	Propensity-score-matched analysis of dual antiplatelet treatment and alternative antiplatelet regimens after transcatheter revascularizations. Journal of Vascular Surgery, 2023, 78, 142-149.	0.6	0
2740	Antiplatelet Strategies Following PCI: A Review of Trials Informing Current and Future Therapies. , 2023, 2, 100607.		1
2741	Pretreatment with P2Y12 Receptor Inhibitors in Acute Coronary Syndromesâ€”Is the Current Standpoint of ESC Experts Sufficiently Supported?. Journal of Clinical Medicine, 2023, 12, 2374.	1.0	0
2742	Novel Aspects Targeting Platelets in Atherosclerotic Cardiovascular Diseaseâ€”A Translational Perspective. International Journal of Molecular Sciences, 2023, 24, 6280.	1.8	1
2743	Are P2Y12 inhibitors superior to aspirin for long-term secondary prevention of cardiovascular disease?. Expert Review of Cardiovascular Therapy, 2023, 21, 305-309.	0.6	1
2744	Current concepts and novel targets for antiplatelet therapy. Nature Reviews Cardiology, 2023, 20, 583-599.	6.1	7
2745	Percutaneous Myocardial Revascularization. , 2023, , 369-382.		0
2746	Antiplatelet therapy for coronary artery disease in 2023: current status and future prospects. Expert Review of Cardiovascular Therapy, 2023, 21, 311-328.	0.6	2
2774	Thrombozytenaggregationshemmer. Springer Reference Medizin, 2023, , 1-9.	0.0	0
2782	Pharmacogenomics in Cardiovascular Diseases. , 2023, , 201-237.		0
2783	General Considerations for Neurointerventional Procedures. Contemporary Medical Imaging, 2023, , 173-262.	0.3	0